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Abstract  
 
Introduction 
Stress hyperglycaemia (SH), defined as transient hyperglycaemia during illness, is seen in up 
to 50% of inpatients and may progress to glucose intolerance in a significant proportion. SH 
is also associated with increased mortality. Despite this, there is no consensus on definition 
and management. Existing work focuses on single disease groups, frequently reporting 
adverse outcomes and variable success with therapies.  There is, however, a scarcity of work 
profiling individuals with SH in detail. It is hoped that this approach may contribute to 
individualised management and improved outcomes for people with the condition. 
 
Methods 
The central hypotheses of this work focus on metabolic profiling and were examined through 
a prospective observational study. Participants were allocated into study groups based on 
glucose levels. A 30-day follow-up was organised for people with SH. Novel biomarkers, 
tools and a diabetes risk calculator were employed to provide the most detailed profile 
currently available of individuals with stress hyperglycaemia. Finally, results from the first 
multicentre trial to bear on the effect of metformin in SH are presented.  
 
Results 
The prevalence of SH was 34% and 31% in prospective (n=62) and metformin (n=52) studies 
respectively. People with SH had lower fasting insulin levels and insulin resistance. 
Otherwise, few differences were found. Metabolic profile, glycaemic variability, and HbA1c 
values were similar in both groups. Metabolic abnormalities and marked glycaemic 
excursions were also seen in both groups. Metformin was well tolerated but did not result in 
significantly reduced glucose variability or levels during the study period.  
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Conclusions  
People with SH do not appear to be phenotypically different from people without the 
condition. Marked hyper- and hypoglycaemia are common in hospital patients despite 
apparent normal glucose levels. Increased vigilance as well as timely and appropriate 
interventions could significantly improve outcomes for these individuals.  
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Chapter	  1:	  Introduction	  
1.1 The History of Stress Hyperglycaemia 
(Section 1.1 reproduced with kind permission from the Journal of the Royal College of Physicians Edinburgh, 
Article in Press) 
 
Stress hyperglycaemia, defined as ‘transient hyperglycaemia during illness’ (Dungan, 
Braithwaite, & Preiser, 2009), is a common condition (Umpierrez et al., 2002). 
Hyperglycaemia typically resolves as the illness dissipates, although in a proportion of 
people, it may indicate unrecognised diabetes mellitus (Husband, Alberti, & Julian, 1983). 
A number of studies have shown that stress hyperglycaemia is associated with poor outcomes 
across a wide range of conditions. (Baker et al., 2006; Capes, Hunt, Malmberg, & Gerstein, 
2000; Umpierrez et al., 2002) Despite this, best management of the condition is unclear and 
remains the subject of active research.  
This article explores views on hyperglycaemia, stress and disease as they emerge in antiquity 
and evolve through to the current day. The story incorporates aspects from the modern fields 
of biochemistry, mechanics, physiology and medicine. 
A glimpse into the history of this intriguing condition provides insights into the evolution of 
major themes in medicine such as homeostasis, as well as the challenges involved in 
converting research, even conducted by the world’s most eminent thinkers, into direct patient 
benefit. The staggered accumulation of knowledge described is perhaps not surprising given 
the diversity of research conducted and the substantial clinical concepts involved. 
The first written descriptions relating to the symptoms of hyperglycaemia appear to have 
been found in the Ebers Papyrus, an ancient Egyptian text relating to the practice of 
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medicine, written about 1550BCE. In ancient Greece, Hippocrates, ‘the father of medicine’ 
described polyuria and wasting of the body. His disciple Aretaeus of Cappadocia, a Greek 
physician, was the first to use the term ‘diabetes’, derived from the Greek word for ‘siphon’ 
in relation to these symptoms (Sanders, 2002; Tattersall, 2009). 
In parallel, concepts relating to homeostasis, stress and disease were beginning to emerge. 
Ancient Greeks such as Heraclitus (540-480BC) and Empedocles (495-435 BC) used terms 
such as balance and equilibrium to define the basic characteristics of life; the emerging view 
being that the ability to change or react to threatening forces was pivotal in restoring harmony 
and enabling survival of the organism. Hippocrates elaborated further by describing  health as 
harmony and disease as disharmony (Le Moal, 2007). 
It took until the 17th century for the clinical features of diabetes and glycosuria to be well 
documented. A variety of clinicians across the globe had described the urine of polyuric 
patients as sweet, honey-tasting and attractive to flies and ants. (MacFarlane, 1990; Tattersall, 
2009). Despite this, it was some time before hyperglycaemia was identified.  
In Europe, Thomas Willis (1621-75), who studied medicine at Oxford, referred to diabetes as 
the ‘pissing evil’(Feudtner, 2003) but also went a step further to suggest that the condition 
was primarily a disease of the blood (Sanders, 2002). 
Matthew Dobson (1734-1784) advanced understanding further by experimenting on the urine 
and blood of Peter Dickonson, a 33 year old man with symptoms of uncontrolled diabetes 
(Tattersall, 2009). As well as confirming that his urine contained a substance 
indistinguishable from sugar, (Sanders, 2002) he also identified that the blood serum was 
sweet to taste. Following further experimentation, he concluded that diabetic urine always 
contains sugar which is not formed in the kidney as previously thought but, ‘existed in the 
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serum of the blood’ (Tattersall, 2009). This important observation, obvious as it may seem 
now, paved the way for the modern understanding of diabetes and hyperglycaemia.  
Particularly important here, as is typical of this narrative and many others in medicine, the 
flow of knowledge was staggered. Dobson published his research in the journal of a London 
medical society with a handful of members who ‘met on alternate Monday evenings at the 
Mitre Tavern in Fleet street’ and the findings were debated for some time (MacFarlane, 
1990). Despite this, Dobson’s discovery was, amongst many things, pivotal in the progress of 
diagnostics for hyperglycaemia. 
	  
1.1.1	  The	  19th	  Century	  
Major developments in the concept of stress hyperglycaemia occurred during the 19th century 
with the beginning of the experimental period in diabetes and work defining modern medical 
views of stress conducted by Claude BernardFIG1 (1813-1878) and Walter Cannon (1871-
1945). 
Bernard is often described as the greatest physiologist of his time and founder of 
experimental medicine. He was born in 1813 in the village of Saint-Julien in France (Wilson, 
1914) and originally pursued a career in literature. Having been dissuaded from this course 
by a literary critic (Gross, 1998), he eventually trained in medicine instead. When he died, his 
distinguished contribution to the field accorded him a public funeral – an honour that France 
had never before bestowed on a man of science (Wilson, 1914). 
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Figure	  1:	  ‘The	  investigator	  should	  have	  a	  robust	  faith	  -­‐	  and	  yet	  not	  believe’,	  Claude	  Bernard	  (PD-­‐1923)-­‐	  published	  before	  
1923	  and	  public	  domain	  in	  the	  US 	  
	  
Early in his career as a medical student, Bernard developed respect for clinicians such as 
François Magendie, (Gross, 1998; Wilson, 1914) who cultivated his interest in nutrition, and 
Pierre Rayer (Theodorides, 1968) who had a particular expertise in diabetes. It is perhaps 
these influences, which encouraged Bernard closely to scrutinise glucose metabolism. His 
discovery, that gastric juices were capable of digesting cane sugar and starch into glucose, 
was eventually to form part of his thesis (Young, 1957).  
Some 5 years later in 1848 he expanded his research into this field, developing a particular 
interest in the distribution of glucose through the body. He was intrigued to detect glucose in 
the blood of fasting humans and concluded, through rigorous experimentation and careful 
deduction that the liver was capable of synthesising glucose, even in fasting humans 
(Tattersall, 2009). He named the substance responsible for this ‘glycogene’ (Wilson, 1914; 
Young, 1957). 
That the liver was capable of synthesising glucose was a controversial observation, in direct 
opposition to two commonly held beliefs: the inability of animals to synthesise nutrients 
(Tattersall, 2009) and ‘one-organ one-function’. In disproving both these theories, Bernard 
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set the scene for a new way of thinking which ultimately led to the discovery of further 
‘glands of internal secretion’ and the definition of the modern endocrine system (Heilbron, 
2003).  
Bernard also contributed significantly to modern medical views on stress by appreciating 
that, whilst organisms are closely responsive to their external environment, they also strive to 
maintain a stable and independent internal environment or ‘Milieu Interieur’ (Gross, 1998). 
This was encapsulated in his statement, ‘constancy and stability of the internal environment 
is the condition that life should be free and independent’ (M. Jackson, 2013; Le Moal, 2007). 
Applying these principles to medicine, Bernard was the first to report data relating to 
hyperglycaemia in critically ill patients in 1855 (Bernard, 1855). 
The other great 19th century master of this field was Walter Bradford CannonFIG2 who was 
born in Wisconsin in 1871 (Benison, Barger, & Wolfe, 1987), towards the end of Bernard’s 
life.  As Claude Bernard before him, he was credited with an open, enquiring mind and his 
lifetime achievements eventually led to him being recognised as one of the America’s leading 
physiologists.  
                                                    
Figure	  2:	  Walter	  Bradford	  Canon,	  circa	  1908,	  Image	  in	  public	  domain.	  Courtesy	  of	  the	  National	  Library	  of	  Medicine	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From an early age, Cannon displayed an interest in the biological sciences and absorbed 
himself in debates between traditionalists and Darwinists. He struggled with a conflict 
between his religious and scientific beliefs, eventually leading him to reject the ideals of his 
family’s faith. He reports being challenged by the church following this decision; ‘he wanted 
to know what right I had, as a mere youth, to set up my opinion against the opinion of great 
scholars’ (Bhattacharyya, 2011). 
Despite this early discouragement, Cannon went on to distinguish himself academically, and 
was accepted into Harvard medical school in 1896 (Brown & Fee, 2002).  Here, he sought out 
opportunities for research and was enrolled by the professor of physiology to use x-rays, a 
new discovery, to explore the mechanism of swallowing (Brown & Fee, 2002; B. Cannon, 
1994; Cooper, 2008). During the course of this research, an astute observation, that anxiety 
led to a change in stomach motility, piqued an interest in the relationship between emotion 
and physiology (M. Jackson, 2013). This culminated in the discovery that major emotions 
involve the excitation of the sympathetic nervous system, increased secretion of adrenaline 
and a collection of physiological changes, now recognised as the ‘stress response’ (Brown & 
Fee, 2002). Cannon coined the term ‘fight or flight’ in a 1915 publication (W. Cannon, 1920) 
to describe these changes.  
 
1.1.2	  The	  20th	  Century	  
Some 20 years later, and with the benefit of a significant body of work measuring blood 
variables, Cannon expanded Bernard’s concept of the milieu interieur to ‘homeostasis’ 
(Goldstein & Kopin, 2007; M. Jackson, 2013; Le Moal, 2007), a maintenance of 
physiological variables within acceptable, narrow ranges, rather than more precise fixed 
values (Cooper, 2008).  Laying the foundations for modern understanding of stress 
hyperglycaemia, a section of Canon’s successful 1932 publication, ‘The Wisdom of the 
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Body’ (W. Cannon, 1932) describes how a state of ‘pseudo or sham rage’ was induced 
through the abrupt cessation of anaesthesia in decorticate animals.  In addition to the signs of 
sympathetic innervation associated with this stressful event, an increase in blood glucose to 
five times the normal percentage was observed. 
During this period, Cannon’s research programme grew considerably and by the end of his 
36-year professorship at Harvard Medical School, he would work with over 400 graduate 
students and colleagues. He died 3 years after retirement, a major public and political figure, 
described by Ralph W Gerard, a fellow former president of the American Physiological 
Association, as ‘the greatest American physiologist’ (Brooks, Koizumi, & Pinkston, 1975). 
The next important development originates from the world-renowned endocrinologist Hans 
Seyle who was born in Vienna in 1907. Seyle trained in medicine at the German University 
of Prague where he graduated first in his class. As a medical student, he noted a constellation 
of signs and symptoms common to sick patients, regardless of the disease and subsequently 
popularised the term ‘stress’ within this context, using it to describe the response of the body 
to a wide range of stressors (Goldstein & Kopin, 2007).  
Following extensive research, he refined his observations to propose the ‘General Adaptation 
Syndrome’ (GAS), a description of three stages in the response to a stressor: 
• The alarm reaction  
• Stage of resistance  
• Stage of exhaustion 
As highlighted by the ‘stage of exhaustion’, Seyle concluded that, ‘the ability of living 
organisms to adapt themselves to changes in their surroundings is a finite quality’ (Seyle, 
1951).   
	  	  	  	  	  	  	  33	  
	  
During this period, the term ‘adaptation’ was widely used in physiological, psychological and 
sociological literature. The English biologist Herbert Spencer (1820-1903) claimed that all 
‘evil results from the non-adaptation of constitution to conditions’. Seyle himself appeared to 
shift his vocabulary around 1950 to ‘reconceptualise stress, referring to it not merely as an 
external trigger of internal processes but also as a physiological or pathological process 
itself’. It is thought that this shift in language from adaptation to stress may have been 
preferred by Seyle for various reasons, including that it positioned his work more closely to 
that of Walter Cannon, as well as those studying anxiety and illness in occupational settings 
where the term ‘stress’ was already popularised (M. Jackson, 2013). 
A large amount of Seyle’s work is relevant to modern understanding of stress 
hyperglycaemia. Aside from popularising the term ‘stress’ within the medical vocabulary, he 
also described how physiological features of ‘defense’ to and ‘damage’ from stress may 
coexist, noting that ‘some of the hormones produced during stress have definitely toxic 
effects’. The key role of the hypothalamic-pituitary-adrenal (HPA) axis in orchestrating 
responses was also highlighted (Seyle, 1951). 
Seyle dedicated most of his life to researching stress in medicine and by the time of his death 
in 1982, had left an incredible legacy of over 1700 papers and 39 books.  His two major 
books The Stress of Life (1956) and Stress Without Distress (1974) sold millions of copies 
worldwide.  
The early 20th century also saw an increasing number of reports reporting hyperglycaemia to 
extreme stressors such as asphyxia (Kellaway, 1919) and pontine decerebration (Forster, 
1933).  Amongst other things, these early experiments highlighted the importance of counter-
regulatory hormones such as epinephrine and hepatic gluconeogenesis in such scenarios.   
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Eight years later, it was observed that ‘coronary artery disease produces by itself a glycosuria 
that need not be indicative of diabetes’ (Levine, 1922). This was followed by a number of 
publications reporting ‘transient glycosuria’ in association with coronary thrombosis 
(Cruickshank, 1931; Eckerstrom, 1951; Levine, 1922; Raab, 1936). In one case, 12 patients 
were followed up 10 years after their coronary event and found to have normal glucose 
tolerance curves (Eckerstrom, 1951). 
Although the distinction was clearly made between this apparent ‘transient glycosuria’ 
syndrome and diabetes, it was another 25 years before the term ‘stress hyperglycaemia’ 
appeared in the title of a (PubMed) medical publication (Gitelson, 1956).  In this paper, 26 
patients with stress hyperglycaemia are described and a number of important observations, 
illustrative of 20th century knowledge into this condition, are made.  
Firstly, a variety of acute illnesses including myocardial infarction and cerebral haemorrhage 
are mentioned in association with stress hyperglycaemia. Secondly, ‘hyperglycaemia and 
glycosuria disappeared with clinical improvement’, in all but 3 of these patients, within a few 
days of the acute episode. This statement is closely aligned to modern definitions of stress 
hyperglycaemia. Follow-up studies of this nature are now an established investigative tool in 
this condition.  Thirdly, the 3 patients in whom hyperglycaemia did not resolve were 
described as ‘latent diabetes that became manifest following the acute disorder’. This was 
also reported by other authors during this period (Datey & Nanda, 1967; Eckerstrom, 1951; 
Raab, 1936), and is now a well-recognised outcome.  Finally, having previously reported 
raised pyruvic acid levels in association with emotional stress (Gitelson & Tiberin, 1952), the 
authors noted that levels are ‘markedly elevated’ in people with stress hyperglycaemia 
compared to those with diabetes.  
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Since this publication, other biomarkers have been examined in stress hyperglycaemia and 
reported for their ability to demonstrate a stress response or predict development of future 
diabetes (Carmen Wong et al., 2010). 
Another important paper to emerge during this period (1951) was co-authored by Max 
Ellenburg, a former president of the American Diabetes Association. In this paper, ‘75 
consecutive autopsied cases of coronary thromboses were studied and associations between 
hyperglycaemia, clinical course and histological findings were reported. Of note, people with 
stress hyperglycaemia (reported as ‘nondiabetic cases with hyperglycaemia’) suffered more 
profound shock and a ‘stormier’ clinical course (Ellenberg, Osserman, & Pollack, 1952). 
Although it is now well recognised, this was one of the first papers to highlight links between 
stress hyperglycaemia and adverse clinical outcomes, reporting a higher incidence of 
conduction pathway defects and arrhythmias and an average survival of 6.3 days as compared 
to 20.3 days for those with normoglycaemia. Histological findings also indicated more 
extensive areas of infarct in the hyperglycaemic group as well as central liver cell necrosis.  
Based on contemporary knowledge, largely gained through animal experimentation, the 
authors presented their ‘crude picture’ of the mechanisms leading to stress hyperglycaemia 
highlighting adrenaline-driven hepatic glycogenolysis and gluconeogenesis. In fact, 
gluconeogenesis was later recognised as one of the most important contributing factors to 
stress hyperglycaemia (Dungan et al., 2009). 
Of interest, the authors also drew parallels between deteriorating diabetes and stress 
hyperglycaemia: ‘the mechanism of increased severity of the diabetes in cases with coronary 
thrombosis is identical with the mechanism of hyperglycaemia in non-diabetics with coronary 
thrombosis’. Deteriorating glycaemic control in acutely unwell people with established 
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diabetes, now considered by some as a version of stress hyperglycaemia, is often under-
recognised. 
During this period, the term ‘latent diabetes’ began to emerge to describe individuals in 
whom evidence of impaired glucose tolerance only appeared with the administration of 
cortisone (Camerini-Dávalos & Cole, 2013; Fajans & Conn 1954). In addition to such 
provocation, a publication in 1970 suggested that ‘stress situations’ such as infection, 
pregnancy and obesity may also unmask latent diabetes (Camerini-Dávalos & Cole, 2013). In 
this context, it is suggested that ‘stress’ acts as a catalyst toward the development of ‘overt 
diabetes’. Whilst the modern definition of stress hyperglycaemia refers to a ‘transient’ 
phenomenon, some research suggests that a proportion of those with SH go on to develop 
overt diabetes during follow-up  (Dave et al., 2010; C. S. Gray, Scott, French, Alberti, & 
O&apos;Connell, 2004). 
Another important condition that came to light in parallel with SH was gestational diabetes 
(GDM). A transient diabetes, associated with pregnancy, was described as far back as 1882 
(Duncan, 1882). Subsequent work demonstrated various similarities between GDM and SH: 
i) a clear association with adverse outcomes (Coustan, 2013; W. Jackson, 1952); ii) a 
propensity to develop diabetes in the years following pregnancy/period of stress (Damm, 
2009; Sutherland & Stowers, 1984). SH and GDM differ, however, in that the latter has 
recognised definitions, endorsed by speciality societies, established screening procedures and 
well-rehearsed modes of treatment (Coustan, 2013). In addition, unlike SH, the 
pathophysiology of GDM was examined as far back as 1898 with dedicated experimentation 
(McCance, Maresh, & Sacks, 2013; J. W. Williams, 1909). 
By the early 1970s, more information relating to the pathogenesis of SH had emerged. A 
paper investigating the metabolic response to myocardial infarction, described as a ‘severe 
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trauma…an acute emotional stress’ drew parallels between the hormonal changes found in 
this condition and other ‘medical and surgical diseases’ outlining: 
• Increased plasma concentrations of ACTH and cortisol 
• High levels of urinary adrenaline and noradrenaline  
• Failure of response of plasma immunoreactive insulin to intravenous glucose 
• Failure of rise in plasma insulin level in spite of stress hyperglycaemia (Opie, 1971) 
Over the years, it has become recognised that this picture is considerably more complex 
(Dungan et al., 2009). 
Other key articles of the 20th century examined clinical outcomes (Sewdarsen, Jialal, 
Vythilingum, Govender, & Rajput, 1987), prediction tools (Greci et al., 2003) and factors 
involved in the aetiology of stress hyperglycaemia (Yudkin & Oswald, 1987).  Myocardial 
infarction was a major area of interest up to this point and a paper published in 2000 (Capes 
et al., 2000) identified 15 studies (1966-1998) suitable for inclusion into a meta-analysis. The 
findings consolidated earlier suspicions: people without diabetes and stress hyperglycaemia 
on admission for acute myocardial infarction are at increased risk of in-hospital mortality and 
congestive heart failure or cardiogenic shock. A number of mechanisms were proposed to 
explain this including: 
• Relative insulin deficiency, increased lipolysis and excess circulating free fatty acids, 
toxic to ischaemic myocardium 
• Osmotic diuresis leading to interference with normal compensatory mechanisms for 
failing left ventricle (increased end-diastolic volume leading to increased stroke 
volume) 
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Stress hyperglycaemia was also associated with an increased risk of mortality in people with 
diabetes although the effect was smaller than in those without diabetes.  
Within this period, interest also grew in stress hyperglycaemia and stroke. From the mid 
1970s, studies began to emerge reporting poor neurological outcomes and increased mortality 
in the context of hyperglycaemia (Melamed, 1976; Pulsinelli, Levy, Sigsbee, Scherer, & 
Plum, 1983; E. Woo, Chan, Yu, & Huang, 1988). Similar reports were published in the 90s 
(Kiers et al., 1992; O’Neill, Davies, Fullerton, & Bennett, 1991; Weir, Murray, Dyker, & 
Lees, 1997; J. Woo et al., 1990) and biomarker studies suggested a vital role for 'stress 
hormones' notably cortisol, in the intensity of hyperglycaemia as well as the overall outcome 
post-stroke (Murros, Fogelholm, Kettunen, & Vuorela, 1993). Other studies demonstrated 
elevated plasma catecholamine levels although no clear link with outcomes was reported 
(Myers, Norris, Hachniski, & Sole, 1981). 
A high prevalence of hyperglycaemia, recognised and unrecognised in the period preceding 
stroke was also reported (Riddle & Hart, 1982). Finally, towards the end of the century, a 
small randomised controlled trial concluded that glucose-lowering therapy for mild to 
moderate hyperglycaemia (plasma glucose 7.0-17.0mmol/L) was a safe intervention in the 
acute phase of stroke (Scott et al., 1999). 
	  
1.1.3	  The	  21st	  Century	  	  
More recently, stress hyperglycaemia has been studied in a wide range of conditions 
including COPD (Baker et al., 2006), pneumonia (McAlister et al., 2005), stroke (Capes, 
Hunt, Malmberg, Pathak, & Gerstein, 2001), heart failure (Mebazaa et al., 2013) and sepsis 
(Leonidou et al., 2007). In almost all cases, adverse outcomes have been identified in 
association with stress hyperglycaemia. In response, further work has aimed to improve 
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outcomes through risk stratification and proactive management (G van den Berghe et al., 
2001). 
 
1.1.4	  Hyperglycaemia	  in	  Intensive	  Care	  
Several studies suggest that people with stress hyperglycaemia have worse outcomes at a 
given degree of hyperglycaemia than people with diabetes (Dungan et al., 2009; Moritoki Egi 
et al., 2008; Rady, Johnson, Patel, Larson, & Helmers, 2005). 
A landmark interventional study in 2001 randomly assigned 1548 patients on a surgical 
intensive care unit to either intensive insulin therapy (maintaining blood glucose 4.4-
6.1mmol/L) or conventional treatment (maintaining blood glucose 10-11.1 mmol/L with 
infusion of insulin only if blood glucose rose to >11.9mmol/L).  It was concluded that 
intensive insulin therapy reduced mortality (G van den Berghe et al., 2001). 
Various studies following failed to reproduce this finding (Arabi et al., 2008; Greet Van den 
Berghe et al., 2006) and several meta-analyses (Griesdale et al., 2009; Wiener, Wiener, & 
Larson, 2008) concluded that tight glycaemic control was not associated with significantly 
reduced hospital mortality (Preiser, 2009). Included in the analysis was a large, international 
trial of 6104 intensive care patients which concluded that intensive glucose control actually 
increased mortality (Finfer et al., 2009).  
A few studies specifically aimed to identify patients with stress hyperglycaemia in the 
intensive care setting. Of these, one found that a target glucose of 6.9mmol/L led to a 
significantly reduced mortality in patients with stress hyperglycaemia but not diabetes. In 
concordance with this, mortality began to rise when mean glucose was greater than 
7.8mmol/L in patients without diabetes, compared to a higher threshold of 10mmol/L in 
people with diabetes (Krinsley, 2006).  
	  	  	  	  	  	  	  41	  
	  
Similar findings have been reported in other settings and disease states and various 
hypotheses have been suggested to explain this (Capes, Hunt, Malmberg, & Gerstein, 2000). 
In 2002 an American group studied a mixed population of general medical patients and 
grouped them according to blood glucose levels and medical history (normoglycaemia, new 
hyperglycaemia or pre-existing diabetes). When compared to those with normoglycaemia, 
mortality was significantly higher in those with ‘new hyperglycaemia’ compared to those 
with diabetes (Umpierrez et al., 2002). 
	  
1.1.5	  Hyperglycaemia	  in	  Acute	  Myocardial	  Infarction	  
Recent work in cardiovascular disease supports findings of the earlier mentioned meta-
analysis. In a large sample of elderly patients with acute myocardial infarction (AMI) it was 
found that higher glucose levels were associated with a greater risk of 30-day mortality in 
patients without diabetes compared to patients with diabetes (Kosiborod et al., 2005). Longer 
follow-up periods have, however, resulted in variable results (Ishihara et al., 2007; Petursson 
et al., 2007; Schiele et al., 2006). 
In addition to previous hypotheses on mechanisms of harm, recent studies have concluded 
that stress hyperglycaemia is an independent predictor of left ventricular remodelling after 
anterior MI (Bauters et al., 2007) and may also contribute to arrhythmias (Sanjuán et al., 
2011). 
There has also been a recent focus on biomarkers and tools to predict the risk of stress 
hyperglycaemia, future diabetes and outcomes from intervention. For example, higher 
cortisol levels have been found to be predictive of the onset of stress hyperglycaemia 
(Bronisz et al., 2012) as well as of subsequent normalisation of blood glucose levels(Carmen 
Wong et al., 2010). In the case of the latter, it was suggested that higher cortisol levels reflect 
stress-precipitated hyperglycaemia whereas lower cortisol levels suggest ‘underlying glucose 
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intolerance’ as the most likely explanation for hyperglycaemia. Glycated haemoglobin 
(HbA1c) has also been studied with varying results. One study found that hyperglycaemia 
and non-elevated HbA1c was associated with a poor prognosis following AMI whereas 
another study did not find any association between mortality and HbA1c (Hadjadj et al., 
2004). 
A number of recent studies examine the role of insulin intervention in MI. This was first 
suggested as a treatment for AMI in the early 60s (Sodi-Pallares et al., 1962) and subsequent 
trials have examined effects on mortality (Malmberg et al., 1995). More recently, DIGAMI-2 
(Malmberg et al., 2005), HI-5 (Cheung et al., 2006) and CREATE-ECLA (S. R. Mehta et al., 
2005) studies did not find a benefit to this approach.  
Future work may focus on the role of Glucagon-like peptide 1 (GLP-1) in the setting of AMI 
(Egom, 2012) as well as the role of percutaneous coronary intervention in the treatment and 
risk reduction of patients with stress hyperglycaemia and AMI (McGregor, Leech, Purcell, & 
Edwards, 2012). 
 
1.1.6	  Hyperglycaemia	  in	  Respiratory	  Disease	  
Another recent field of interest has been pulmonary disease. Stress hyperglycaemia is seen in 
up to 50% of patients hospitalised with exacerbations of chronic obstructive pulmonary 
disease (COPD) and each 1mmol/L increase in blood glucose has been shown to increase the 
absolute risk of death or prolonged hospital stay by 15% (Baker et al., 2006).  Prospective 
studies are currently underway to determine whether blood glucose control can improve 
COPD exacerbation outcomes (see Chapter 5). 
A similar picture has been identified with pneumonia. A study of 6891 adults (2003-9) 
reported hyperglycaemia in 40% of patients presenting with community acquired pneumonia 
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(CAP). Hyperglycaemia was found to be an independent predictor of 28-, 90- and 180- day 
mortality with increasing glucose levels corresponding to increased risk (Lepper et al., 2012). 
Of interest, a separate study identified an association between hyperglycaemia (in ‘non-
diabetic CAP patients’), a more pronounced inflammatory response and adverse clinical 
outcomes (Schuetz et al., 2014). 
 
1.1.7	  Hyperglycaemia	  in	  Stroke	  
More evidence is now available to demonstrate how hyperglycaemia and insulin resistance 
exacerbate brain injury and induce cell lysis (Lindsberg & Roine, 2004; Parsons et al., 2002; 
Shao & Bayraktutan, 2013). 
The glucose profile of patients with post-stroke hyperglycaemia has also been investigated in 
more detail using continuous glucose monitoring. ‘Early’ hyperglycaemia (≥7.0mmol/L, 8 
hours post-stroke) was reported in 50% of people without diabetes followed by a later 
hyperglycaemic phase in 27% at between 48-88 hours post-stroke (Allport et al., 2006). 
Longer term outcomes were studied in a retrospective analysis of 433 patients and it was 
concluded that hyperglycaemia (>10.0 mmol/L) but not diabetes per se is an independent 
predictor of dependency 1 year post-stroke (Vibo, Kõrv, & Roose, 2007).  As with myocardial 
infarction, further evidence accumulates to suggest that hyperglycaemia is associated with 
worse outcomes in people without diabetes compared to those with the condition (Capes et 
al., 2000, 2001; Farrokhnia, Björk, Lindbäck, & Terent, 2005; Fogelholm, Murros, Rissanen, 
& Avikainen, 2005; Samiullah, Qasim, Imran, & Mukhtair, 2010). Interestingly, in lacunar 
stroke, studies have reported that hyperglycaemia may have a protective effect (Bruno et al., 
1999, 2002; Uyttenboogaart et al., 2007) and is not associated with functional outcome, 
irrespective of diabetic status  (Fang, Zhang, Wu, & Liu, 2012). 
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As with other conditions, controversy exists over whether acute hyperglycaemia directly 
leads to worsening pathology or whether it is, in fact an epiphenomenon. Some question why, 
‘glucose, the main energy substrate for the brain, causes demise of brain tissue at the time of 
cerebral ischaemia’ (McCormick, Muir, Gray, & Walters, 2008). Recent magnetic resonance 
imaging studies, however, seem to support a causative role for hyperglycaemia in 
neurological deterioration (Parsons et al., 2002).  
Another area of contention in stroke is whether stress hyperglycaemia is a separate entity or, 
in fact, unmasked glucose intolerance. It has been reported that two thirds of those with post-
stroke hyperglycaemia (but not diabetes) are diagnosed with impaired glucose tolerance or 
diabetes at 12 weeks (C. S. Gray et al., 2004) whilst another study reports that 
hyperglycaemia in the setting of an acute stroke is transient in the majority of patients (Dave 
et al., 2010). 
	  
1.1.8	  Hyperglycaemia	  in	  Heart	  Failure	  
Although links between diabetes and heart failure have been recognised for some time 
(Kannel, Hjortland, & Castelli, 1974) and there are many studies linking SH to mortality in 
AMI, the heart failure story is not as clear.  Blood glucose values have been shown to be 
predictive of short-term mortality in a number of studies (Barsheshet et al., 2006; Helfand et 
al., 2015; Mebazaa et al., 2013; Sud et al., 2015) but a large (n=50 532) study did not find 
associations between admission glucose and mortality (Kosiborod et al., 2009). 
The result of a study examining the effect of insulin on outcomes is awaited 
(ClinicalTrials.gov identifier: NCT00812487).  
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1.1.9	  Conclusions	  on	  the	  History	  of	  Stress	  Hyperglycaemia	  
The history of stress hyperglycaemia is complex and fascinating. The body of knowledge 
accumulates over centuries and across continents, incorporating major themes such as 
homeostasis and ‘fight or flight’. Despite the involvement of a large number of eminent 
thinkers, the spread and acceptance of valuable clinical knowledge was often suboptimal. 
This problem continues today.  
Enquiring minds opened up the possibility of a new disease entity, separate to diabetes. It is 
now established to be a common condition with studies reporting 16-79% affected depending 
on the disease group and population examined (O’Sullivan, Duignan, O’Shea, Griffin, & 
Dinneen, 2013).  
It was initially believed that hyperglycaemia during stress was a benign response or 
epiphenomenon. As more evidence has been presented, thinking has largely (but not entirely) 
shifted towards viewing stress hyperglycaemia as a mediator of harm and a marker of poor 
outcomes. It is notable that Hans Seyle, observed that ‘some of the hormones produced 
during stress have definitely toxic effects’ as far back as the early 20th century. Knowledge of 
the underlying mechanisms of pathogenesis and harm has evolved greatly since then. 
(Dungan et al., 2009; Van Cromphaut, 2009).  
The medical definition of ‘stress’ has also evolved considerably. It is now recognised that 
there is no ‘stereotyped response pattern’ to a stressor and an ‘understanding of the health 
consequences of stress requires an integrative approach’(Goldstein & Kopin, 2007). 
Despite this, all these years later, basic gaps in knowledge remain. In particular, there is no 
consensus definition for stress hyperglycaemia, and best management in the acute care setting 
remains unclear. Understandably, there has been a focus on outcomes but a lack of detailed 
profiling of individuals with the condition. Future researchers may be inspired by Claude 
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Bernard’s quote from so many years ago, ‘The investigator should have a robust faith - and 
yet not believe’. 
 
1.2 Modern Views on the Pathophysiology of Stress Hyperglycaemia 
Figure	  4 illustrates the current understanding of glucose metabolism in stress hyperglycaemia. 
Gluconeogenesis is thought to be the most important contributing factor (Jeevanandam, 
Young, & Schiller, 1990; Lang, Bagby, Blakesley, & Spitzer, 1989) although the aetiology 
also involves various other counter-regulatory hormones, cytokines and hospital related 
factors (e.g. exogenous glucocorticoids). An individual’s pancreatic reserve and degree of 
insulin resistance also play an important role in the development of stress hyperglycaemia 
(although the latter, to our knowledge, has not been measured in all-comers with stress 
hyperglycaemia in the acute care setting, see section 4.2.3).  A vicious cycle then develops 
with hyperglycaemia exacerbating metabolic disturbance and contributing to further 
hyperglycaemia (Dungan et al., 2009).  
 
Figure	  4:	  Glucose	  metabolism	  in	  stress	  hyperglycaemia.	  Reprinted	  from	  the	  Lancet,	  volume	  373,	  KM	  Dungan,	  SS	  
Braithwaite,	  JC	  Preiser.	  ‘Stress	  Hyperglycaemia’,	  Figure	  3,	  page	  6,	  Copyright	  2009,	  with	  permission	  from	  Elsevier	  
(Appendix	  7)	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Once developed, it is clear that stress hyperglycaemia is related to poor outcomes across a 
range of conditions (section 1.1). Figure 5 illustrates the mechanisms by which both acute 
and chronic hyperglycaemia may cause harm to an individual. This poses a few questions: 
• Why do people with Stress Hyperglycaemia often have worse outcomes compared to 
similar people with diabetes? (Kosiborod et al., 2005) 
• How does harm develop so rapidly in Stress Hyperglycaemia whereas complications 
in people with diabetes may take years to develop? (Dungan et al., 2009) 
Various theories and evidence have been presented in response to these questions. Glycaemic 
variability or acute glucose fluctuations is one such example. This is covered in more detail 
in section 4.3. 
 
Figure	  5:	  Overlapping	  mechanisms	  of	  harm	  in	  hyperglycaemia.	  Reprinted	  from	  the	  Lancet,	  volume	  373,	  KM	  Dungan,	  SS	  
Braithwaite,	  JC	  Preiser.	  ‘Stress	  Hyperglycaemia’,	  Figure	  4,	  page	  7,	  Copyright	  2009,	  with	  permission	  from	  Elsevier	  
(Appendix	  7)	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1.3 Modern Views on Management of Stress Hyperglycaemia 
	  
Large randomised-controlled trials, predominantly in the MI (Malmberg et al., 2005) and 
critically unwell populations (Finfer et al., 2009) have sought to clarify the best management 
for stress hyperglycaemia. Some studies have noted that in striving for tight glycaemic 
control (TGC) or normoglycaemia with insulin therapy, damaging episodes of 
hypoglycaemia have occurred (Finfer et al., 2009). Recent guidelines propose that less 
intensive glycaemic targets be implemented (Dellinger et al., 2013; Moghissi et al., 2009) and 
most UK (ITU) units now aim for a blood glucose of between 6-10mmol/L.  
Outside of the intensive care setting, various aspects have complicated the picture, making 
management decisions difficult for a practising clinician on the shop floor. 
• Lack of a consensus clinical/biochemical definition for SH 
• Lack of detailed profiling of people with SH, particularly unselected AMU patients 
• Lack of evidence-base for management decisions 
A number of organisations have, however, issued disease-specific guidelines for the 
management of hyperglycaemia in the acute setting. These frequently relate to individuals 
with pre-existing DM, a scenario which many would consider to fall under the umbrella of 
SH (Dungan et al., 2009). 
The UK National Institute for Health and Clinical Excellence (NICE) recommends initiating 
treatment with a dose-adjusted insulin infusion to manage hyperglycaemia in patients 
admitted with Acute Coronary Syndrome (ACS). Hyperglycaemia requiring treatment is 
defined as a blood glucose level >11.0mmol/L noted within 48 hours of admission (NICE, 
2011). Of interest, a recent study suggests that an intravenous insulin infusion may only be of 
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benefit to patients with STEMI, and associated with poor outcomes in patients with NSTEMI 
(Birkhead, Weston, Timmis, & Chen, 2014). 
International guidelines for the management of hyperglycaemia in stroke vary. NICE in the 
UK recommend that ‘people with acute stroke should be treated to maintain a blood glucose 
concentration between 4 and 11 mmol/L’(NICE, 2008). The European Stroke Organization 
recommends treating levels >10mmol/L (European Stroke Organisation, 2008) whereas 
American associations (AHA/ASA) suggest treatment to maintain serum glucose 
concentrations between 7.8 and 10.0 mmol/L  (Jauch et al., 2013).  
Aside from acute management, the NICE ACS guideline (NICE, 2011) also addresses follow-
up. As with the maternal condition, Gestational Diabetes Mellitus (GDM), it is probably 
prudent to follow up all hyperglycaemic patients to establish/exclude underlying glucose 
intolerance. As described previously, it has been shown that a certain proportion of patients 
with SH will go on to develop Diabetes Mellitus (C. S. Gray et al., 2004). 
	  
1.4 Gaps in Knowledge and Dilemmas 
Despite the body of work described, there remain significant gaps in knowledge/areas of 
controversy with regards stress hyperglycaemia. To summarise: 
1. Why do people with Stress Hyperglycaemia often have worse outcomes compared to 
similar people with diabetes? (Kosiborod et al., 2005) 
2. How does harm develop so rapidly in Stress Hyperglycaemia whereas complications 
in people with diabetes may take years to develop? (Dungan et al., 2009) 
3. Do people with Stress Hyperglycaemia actually have underlying glucose intolerance, 
unmasked during acute illness, rather than a genuinely transient disorder? 
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1.5 Research Objectives 
	  
The research in this thesis aims to address questions 3 and 5 through the detailed study of 
individuals with Stress Hyperglycaemia. Various metabolic parameters (including BMI, waist 
circumference, BP, Epworth score for obstructive sleep apnoea and copeptin values) were 
considered to be of most interest given established aetiological links with Type 2 Diabetes 
(question 3) as well as their relevance to an individualised treatment approach for SH 
(question 5). These selected parameters are summarised as the ‘metabolic profile’ for the 
purposes of this study and are described in more detail in section 3.1.1.  
The main research objective, addressed through a prospective observational study, 
investigates whether there is a difference between the metabolic profile of people with and 
without Stress Hyperglycaemia (section 3.3). Five separate null hypotheses related to this 
objective are described below: 
NULL HYPOTHESIS 1: There is no statistically significant difference between the mean 
Body Mass Index (BMI) values of people with and without stress hyperglycaemia 
NULL HYPOTHESIS 2: There is no statistically significant difference between the mean 
waist circumference values of people with and without stress hyperglycaemia 
NULL HYPOTHESIS 3: There is no statistically significant difference between the mean 
(systolic and diastolic) blood pressure values of people with and without stress 
hyperglycaemia 
NULL HYPOTHESIS 4: There is no statistically significant difference between the mean 
Epworth score of people with and without stress hyperglycaemia 
	  	  	  	  	  	  	  52	  
	  
NULL HYPOTHESIS 5: There is no statistically significant difference between the mean 
Copeptin values of people with and without stress hyperglycaemia 
In addition to the main research question and hypotheses, a number of other novel measures 
will be described for interest only (see sections 3.1.1 and 4.1.1). Additionally, relevant data 
from a separate randomised controlled study is included in this thesis to compliment the main 
body of work and provide insight into a sub-population with SH (see section 2.2.1 for study 
objectives and Chapter 5 for results).  
 It is hoped that these comparisons will provide new insights into the differences between 
people with and without the condition, ultimately, and with subsequent work, enabling 
practising clinicians to make decisions on how best to manage patients with stress 
hyperglycaemia in the acute care setting.  
For the purposes of this study, Stress Hyperglycaemia has been defined as a random plasma 
glucose 7.1-11.0 mmol/L in an individual without diabetes. Expert opinion and relevant 
clinical trials have informed this definition. (Baker et al., 2006) 
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Chapter	  2:	  Materials	  and	  Methods	  
2.1 Prospective Observational Study 
	  
2.1.1	  Ethical	  Approval	  
Application was made through the Integrated Research Application System (IRAS) and 
approved by the National Research Ethics Service (NRES) Committee-South East Coast, 
Surrey on the 11th July 2011 (now Surrey Borders NRES). Local approvals to conduct the 
research at Chelsea and Westminster Hospital NHS Foundation Trust were granted on the 
30th August 2011. A substantial amendment requesting the addition of biomarkers copeptin 
and proADM as well as BIVA assessment was approved on the 4th January 2012.  
 
2.1.2	  Overall	  Trial	  Design	  
This project was designed as a prospective observational study with a baseline visit and 
follow-up visits at 90 and 180 days. Early on in the recruitment process, it became clear that 
many participants found the proposed follow-up schedule challenging and so a single follow-
up visit at 30 days was proposed.  We do not believe that the scientific aspects of this study 
were compromised by a shortened follow-up period. These challenges are discussed in more 
detail in section 6.12.2. 
	  
2.1.3	  Study	  population	  	  
Participants were recruited from a population of patients admitted to the Acute Assessment 
Unit (AAU) at Chelsea and Westminster Hospital, London who were able to enter the study 
within 72 hours of admission. Nationally, the term AMU is more commonly used. In this 
thesis, the terms AAU, AMU and ‘acute care setting’ are used interchangeably.  
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2.1.4	  Inclusion	  and	  exclusion	  criteria	  
	  
Inclusion criteria: 
1. All patients >18 years admitted to AAU  
2. Able to enter the study within 72 hours of admission 
 
Exclusion criteria: 
1. Age <18 years 
2. Pregnancy (based on history as β-hCG will not be routinely performed) 
3. Inability to give informed consent 
4. Moribund or not for active treatment 
5. Critical illness requiring high dependency or intensive care 
6. Prior or new diagnosis of diabetes mellitus (Type 1/Type 2) at/during admission 
7. Patients on a Dextrose infusion 
	  
	  
2.1.5	  Subject	  Recruitment	  Process*	  	  
Eligible patients were informed that a research project was underway and they were offered 
the opportunity to participate. If they expressed interest, they were provided with an overview 
of the project, including its objectives, nature, burdens and risks. It was emphasised that 
participation was entirely voluntary.   
If they remained keen to proceed, they were provided with a copy of the participant 
information leaflet, which was also explained to them. Time was provided to consider the 
contents of the leaflet and ask as many questions as necessary.  If patients remained positive 
about participation, and no exclusion criteria were identified, informed consent was sought. 
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The participant leaflet was reviewed by ‘Drive’ a local (diabetes) patient involvement group. 
A number of changes were made to the leaflet based on their suggestions. 
* -Parts of this section reproduced with kind permission of Metformin in COPD study team (see section 2.2) 
	  
	  
2.1.6	  Informed	  Consent*	  	  
Informed consent was obtained by the Investigator who received training in Good Clinical 
Practice (GCP) and was familiar with the study protocol.  The Investigator explained that 
there was no obligation to enter the study and withdrawal was possible at any time without 
having to give a reason. A copy of the signed Informed Consent was given to the participant 
and a second copy placed in the clinical notes. The original was securely stored at the study 
site.  
	  
2.1.7	  Screening	  assessments*	  	  
A more detailed assessment of eligibility for inclusion was obtained by reviewing the clinical 
history and examination, obtained as part of routine care. Any components required to 
determine eligibility but not contained in the clinical notes were obtained directly from the 
patient during the screening assessment. 
	  
2.1.8	  Study	  Group	  Formation	  
Following successful screening and recruitment, standard peripheral venipuncture was used 
to obtain a random plasma glucose (RPG) sample. Participants were placed into study group 
1 or 2 based on their random plasma glucose (RPG) value.  Participants diagnosed with DM 
during this process (group 4) were excluded from the study and clinical follow-up plans were 
made (Figure	  7). 
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2.1.9	  Study	  Measures	  
	  
Group	  1:	  Baseline	  visit	  
Identified through: 
• 1st random plasma glucose (RPG) reading 7.1-11.0mmol/L  
• 1st RPG ≥11.1 mmol/L, no symptoms of diabetes, and repeat RPG <11.1 mmol/L.  
A baseline assessment was completed for participants during their admission. All relevant 
study information was handwritten into a case report form (CRF) and then scanned directly 
into IBM SPSS Statistics (versions 21 and 22) using the	  TELEform© program (version 8.2, 
see section 2.1.16). Table	   3 contains the study measures collected during the baseline 
assessment. The rationale for these measures is discussed in section 3.1.1. Where possible, 
information was collected with minimum disruption to the participant. In some occasions, 
more than one visit was required.	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Figure	  7:	  Schematic	  of	  Study	  Group	  Formation,	  prospective	  study	  
*Symptomatic	  refers	  to	  classic	  symptoms	  of	  DM	  such	  as	  polyuria,	  polydipsia	  and	  weight	  loss	  
	  
	  
	  
	  
With	  patient's	  permission,	  refer	  to	  GP	  
for	  further	  investigation	  and	  
management.	  Inform	  clinical	  care	  team 
EXCLUDE	  FROM	  STUDY:	  
GROUP	  4	  
ENTER	  STUDY:	  GROUP	  1 ENTER	  STUDY:	  GROUP	  2 
New	  DM Stress	  Hyperglycaemia 
Repeat	  RPG	   
RPG	  ≥11.0mmol/L 
RPG	  ≥11.1	  mmol/L RPG	  7.1-­‐11.0	  mmol/L RPG	  	  ≤	  	  7.0mmol/L 
Random	  Plasma	  Glucose	  (RPG)	  
Measured	  <72hrs	  of	  hospitalisation	  in	  
patients	  without	  a	  prior diagnosis of DM	   
RPG	  <	  11.0	  mmol/L 
‘Normal’	  Glucose	  Tolerance	   
Symptomatic* 	  	  Not	  Symptomatic 
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Demographics Date of birth, gender, ethnicity 
 
Admission Details Primary/secondary/other diagnosis, illness severity 
(CEWS), presenting RPG* (time of sample and duration 
since last meal), baseline visit date 
Associated Conditions Family history, drug history, steroid treatment, history of 
HTN* & NASH*  
 
Anthropometrics Height, weight, BMI*, BP*, neck and waist circumference, 
BIVA* 
 
Clinical Score Epworth score, Depression score 
 
Blood tests Fasting glucose & insulin, (HOMA-2*), HbA1c*, urea, 
Cr*, eGFR*, lactate, morning cortisol, CRP*, troponin I, 
BNP*, blood ketones, copeptin, pro-ADM* 
Short-Term Outcomes LOS*, metabolic abnormalities (including T2DM risk) 
 
Table	  3:	  Study	  information	  collected	  in	  Case	  Report	  Form	  (CRF)	  during	  baseline	  assessment	  for	  group	  1	  participants.	  
*See	  Abbreviation	  Section.	  Measures	  in	  italics	  relate	  to	  primary	  study	  hypotheses.	  
	  
A letter was sent to the participant and the GP following baseline visit 1 if any abnormal 
results were identified (see section 3.10.2). 
	  
Group	  1:Visit	  1	  
All group 1 participants were invited to a follow up visit (visit 1) at 30 days post-discharge. 
Following discharge, participants were contacted by telephone to check if they were still 
happy and well enough to attend. If so, a date was booked in for visit 1. The hospital 
electronic patient data and management system (Last Word Client version 4.1, IDX system©) 
was checked before contacting participants to ensure that only living participants were 
contacted. 
Participants who agreed to attend visit 1 were reminded that they would be having an OGTT 
and what this involved, including 12 hours of preparatory fasting. Participants were advised 
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to take their normal medication with water and contact the investigator on the 24 hour study 
phone should they have any questions or concerns. 
On arrival, participants were met at the entrance to the phlebotomy department and 
introduced to the phlebotomist who was expecting them. Following the ingestion of a 75g 
glucose solution for the OGTT, and acquisition of selected blood samples using a standard 
peripheral venepuncture technique, the participant was taken to a dedicated study area nearby 
and the remaining study measures were checked/requested (Table	  4).  
Anthropometrics  Height, weight, BMI*, waist and neck circumference, 
BP*, BIVA* 
 
Clinical Score Epworth score 
 
Blood tests OGTT* -0hr plasma glucose, 2hr glucose, fasting insulin, 
HOMA2*, HbA1c*, 9am cortisol, CRP*, BNP*, Troponin 
I, proADM*, copeptin 
 
Outcome Diagnosis of Diabetes, IGR* 
Table	  4:	  Study	  information	  collected	  in	  Case	  Report	  Form	  (CRF)	  during	  visit	  1	  for	  group	  1	  participants.	  *See	  abbreviation	  
section.	  
	  
During this period, the participant was asked to keep as still as possible to avoid any 
interference with the OGTT. They were then provided with reading material, a glass of water 
and asked to rest until it was time to return to phlebotomy for the final OGTT glucose test. 
The waiting time was generally about 30 minutes. 
After 2 hours, the participant was accompanied back to the phlebotomy department and 
placed in contact with the same phlebotomist they had seen 2 hours previously. Whilst they 
were having their final blood test taken (OGTT, 2 hour glucose), the investigator purchased a 
hot drink and some lunch for them to end their fast. Finally, they were thanked for their kind 
participation and a letter was sent to both the patient and their GP with the results of visit 1.  
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Group	  2:	  Baseline	  visit	  	  
Identified through: 
• Random glucose <7.0mmol/L 
All the same study measures were collected for group 2 as group 1 participants. Notably, no 
visit 1 was requested for this group. Figure	  8 summarises the study processes for group 1 and 
2 participants. 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  8:	  Schematic	  of	  Prospective	  Study	  Design	  
Group	  1	  
Stress	  Hyperglycaemia	  	  
	  
Group	  2	  
Normal	  Glucose	  Tolerance	  
	  
BASELINE	  VISIT:	  
Demographics,	  Admission	  details,	  Severity/Risk	  Factors	  for	  DM,	  Anthropometrics,	  Clinical	  Score,	  	  
Blood	  Tests,	  Outcome	  
Participants	  invited	  to	  wear	  
a	  CGM	  to	  assess	  GV	  
Participants	  invited	  to	  wear	  a	  
CGM	  to	  assess	  GV	  
END	  OF	  STUDY	  FOR	  GROUP	  2	  
VISIT	  1	  (30	  DAYS)	  
Anthropometrics	  
Clinical	  Score	  
Blood	  Tests	  
Outcomes	  
END	  OF	  STUDY	  FOR	  
GROUP	  1	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CGM	  patients	  
All participants were invited to wear a Medtronic iPro2TM Continuous Glucose Monitor 
(CGM) during the study to assess Glycaemic Variability (a novel measure of interest, see 
section 1.5 and also section 4.1.1). Those who expressed an interest, were provided with 
written information (included in the participant leaflet) and given time to consider the 
potential disadvantages and risks, notably a small amount of discomfort on sensor insertion 
and a very low risk of infection/inflammation related to the adhesive used to hold the sensor 
in place.  
For participants happy to proceed, the CGM sensor was inserted using a sensor insertion 
device. An abdominal insertion site, at least 1 inch away from the umbilicus was selected. 
Following insertion, the introducing needle was disposed of in a sharps container and a 
transparent dressing was applied to the CGM sensor. After a period of 15 minutes, the CGM 
monitor was attached to the sensor and appropriate placement (flashing of ipro2 green light) 
was confirmed. An aseptic technique was used throughout. The staff nurse caring for the 
participant and the participant were given advice on its basic management and provided with 
the investigator’s 24hr study phone number for any queries or concerns. 
Participants were asked to wear the CGM for a minimum of 24 hours and a maximum of 6 
days if possible. They were also provided with the iPro2TM ‘Patient Instruction’ leaflet. 
Whilst they wore the monitor, the following occurred: 
• Participants were asked to keep a food diary outlining daily meals and snacks 
• Capillary blood glucose (CBG)/BM was measured 4 times a day by the investigator or 
staff nurse for calibration purposes 
	  	  	  	  	  	  	  62	  
	  
• The CGM insertion site was inspected regularly by the investigator for any signs of 
inflammation 
• Blood samples were taken for 25-OH Vitamin D and C-peptide 
A removal date/time for the CGM was proposed based on the participant’s experience with 
the monitor and anticipated discharge date. CGM removal was completed using an aseptic 
technique and a transparent dressing was applied. The whole process was documented in the 
clinical notes along with the investigator’s phone number. The participant and staff nurse 
were advised to contact the investigator if there were any concerns with the CGM site. 
The CGM was taken back to the clinical study area and sterilised according to manufacturer’s 
guidelines. It was then taken to the study office and connected to the study computer. Sensor 
glucose values were uploaded into the CareLink ipro2TM programme and subsequently 
downloaded into Microsoft excel.  The standard deviation around the mean SG value was 
used to express glycaemic variability (Kohnert, Lutz, & Salzsieder, 2010). All data were 
anonymised. Finally, the CGM was attached to the iPro2TM dock to be fully charged. 
The initial plan was to recruit 35 patients to wear a continuous glucose monitor (CGM) 
during admission. Once again, the practical aspects of conducting this within the AAU setting 
made it clear that this would not be possible. A total of 12 participants were recruited. The 
challenges encountered during recruitment are discussed in more detail in section 2.1.20 and 
6.12.2. 
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2.1.10	  Newly	  Diagnosed	  Diabetes	  Mellitus:	  Group	  4	  
Identified through: 
• One random venous plasma glucose ≥11.1 and symptoms of DM including polyuria, 
polydipsia, unexplained weight loss 
• Two random glucose levels ≥11.1 in the absence of any symptoms suggestive of DM 
These patients were excluded from the study. With their permission, a letter was sent to their 
GP advising further investigation and management. The clinical team caring for the patient 
were also informed of the abnormal findings and advised to monitor CBG during admission. 
A number of other metabolic abnormalities were noted during the course of the study, 
including IGT, IFG and ‘High Risk for Diabetes’. Their diagnostic criteria are described in 
section 3.10.2. Of note, some participants fulfilled (single) biochemical criteria for diabetes 
but, for a number of reasons, it was not possible to assess for symptoms of diabetes/request a 
second test. For the purposes of the study they were described as having ‘biochemical 
features of diabetes’ and their GPs were advised to repeat a RPG/FPG and assess for 
symptoms following discharge to formally diagnose DM (Table	  28). 
	  
2.1.11	  Laboratory	  Procedures	  	  
All blood samples were taken using standard peripheral venipuncture technique. 
Venipuncture was coordinated with the clinical team wherever possible to avoid multiple 
procedures on one patient. All blood samples were handled according to standard hospital 
procedure. Of note, fasting insulin sample were placed on ice immediately after venipuncture 
and transported directly to the pathology laboratory by the investigator. A few blood samples 
required special procedures and handling: 
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BNP and Troponin I  
Following specialist training, participant samples (taken in EDTA tubes) were processed in 
the clinical study area on a near-patient (Biosite Triage®) meter. The sample was inverted 7 
times to enable mixing and then aspirated into a 250µl transfer pipette. The pipette was filled 
completely and slowly squeezed to dispense the participant’s blood onto a test strip. The strip 
was then slotted inside the Biosite Triage® meter and a result for BNP and Troponin I was 
available in 15 minutes. The test strip was then disposed of appropriately. 
 
The meter required a daily Quality Control (QC) procedure (using a QC device) as well as 
calibration with external control solutions for each new test cartridge lot. A log of these 
procedures and results was kept within a folder on the study site. 
	  
ProADM	  and	  Copeptin	  	  
A minor/non-substantial amendment was requested for external processing of these samples, 
as facilities for analysis were not available within the hospital.  This amendment was 
approved by the NRES on the 24th July 2012. The blood samples were prepared for external 
processing in the following manner:	  
 
• Samples collected in 2 EDTA tubes  
• Centrifuged within allied laboratory at 3000 rpm for 10 minutes to separate serum.  
• Serum pipetted into cryotubes and stored in -20°C freezer within another allied 
laboratory. Cryotubes labelled with participant initials, study number, date of sample 
collection and study name.  
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• Frozen cryotube samples packaged in dry ice and sent by special courier (along with a 
material transfer agreement and signature of hospital Caldicott guardian) to Thermo 
Fisher Scientific laboratory in Hennigsdorf, Germany for analysis.  
 
Samples were analysed using B.R.A.H.M.STM	   KRYPTOR	   automated	   immunofluorescent	  assays. Four Samples for 2 participants (participants 057 and 065 at baseline and visit 1) 
were processed at the University of Oxford, using the same techniques and assays. No patient 
identifiable data were sent and all samples were destroyed in Germany and Oxford after 
analysis. 
	  
 
HOMA2 
 
Several methods have been developed to assess insulin resistance. The Homeostasis Model 
Assessment for Insulin Resistance (HOMA-IR) was used in this study, as it is a simple and 
inexpensive method, frequently utilised in clinical trials.  HOMA2 is an updated version of 
the HOMA-IR model and considers variations in hepatic and peripheral glucose resistance, 
increases in the insulin secretion curve for plasma glucose concentrations above 10 mmol/L 
and the contribution of circulating proinsulin in its calculation (Levy, Matthews, & Hermans, 
1998; T. Wallace, Levy, & Matthews, 2004).  
In this study, a validated computer programme (HOMA2 calculator: 
http://www.dtu.ox.ac.uk/homacalculator/index.php, released by the Oxford Centre for 
Diabetes, Endocrinology and Metabolism)	  was used to calculate HOMA2-IR, %B and %S 
values from measured variables (fasting insulin and glucose).  It is worth noting that HOMA-
IR measures correspond well, but are not necessarily equivalent to, non-steady state estimates 
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of insulin sensitivity derived from models such as the hyperglycaemic clamp (see link 
above).  
	  
Blood Ketones 
Blood ketones were predominantly checked as a study safety measure (see section 6.10.7). A 
lancing device was used to obtain a CBG sample from the participant’s fingertip.  The sample 
was applied to a (Abbott) blood β-ketone test strip that had been inserted into an (Optium 
Xceed) blood ketone meter. A beeper and status bar on the meter indicated when ketone 
testing had begun. The test strip was left undisturbed until a blood ketone value was 
displayed on the meter screen, typically within minutes.  The lancet was then disposed of 
appropriately. An aseptic technique was used throughout. The blood ketone meter was 
calibrated by using a calibrator test strip. This was performed when the meter was used for 
the first time and each time a new lot of β-ketone test strips were opened.  
	  
2.1.12	  Non-­‐Laboratory	  Study	  Procedures	  
With the participant’s permission, the clinical notes and hospital Lastword database were 
searched to obtain as much study information as possible. The participants were directly 
questioned for any information not recorded in these locations. 
 
Clinical questionnaires (Epworth and Hospital Anxiety and Depression HAD), measurement 
of height, weight, BP, waist and neck circumference were undertaken according to standard 
methods based on published recommendations and local guidelines (Ben-Noun, Sohar, & 
Laor, 2001; Johns, 1991; WHO, 2008; Zigmond & Snaith, 1983).  
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A relatively novel measure (see section 1.5 and 3.1.1) – BIVA (Bioelectrical Impedance 
Vector Analysis) -was used to describe hydration and nutrition status in participants. The 
BIVA scores were obtained by attaching 2 disposable, adhesive electrodes or ‘BIVAtrodes’ 
to the participant’s upper and lower limb. Specifically, the apex of one electrode was attached 
to a line bisecting the ulnar head on the upper limb, whilst the second electrode was attached 
to the medial malleolus on the lower limb. The participant was asked to remain in a still, 
supine position if possible. The BIVAtrodes were then connected to the BIVA machine using 
‘patient cables’ and the machine was switched on.  
 
Before taking the reading, the individual’s study ID, height and gender were entered into the 
machine. Following this, the participant was pre-warned that they might feel a small ‘tingle’ 
and an AC microcurrent (typically 50 KHz ±1%) was introduced through the BIVAtrodes. 
Impedance to the current, measured as Resistance (R) and Reactance (Xc) values were 
divided by the participant’s height (h) and resultant ‘R/h’ ‘Xc/h’ values were plotted on a 
BiaVector® plot, displayed on the BIVA screen to provide a nutrition and hydration status 
for each participant. The ellipses shown on the plot (Figure	  9) represent 50%, 75% and 95% 
confidence intervals derived from the ‘R/h’ and ‘Xc/h’ data of, ‘18 000 healthy male and 
female volunteers of various body shapes, gender and heights.’  (Copyright EFG Diagnostics, 
version 2.02, March 2012) 
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Figure	  9:	  Anonymised	  BiaVector	  ®	  plot	  for	  prospective	  study	  participant	  as	  displayed	  on	  the	  BIVA	  screen	  (taken	  by	  
investigator). 
 
Participants’ illness severity was assessed through the Chelsea Early Warning Score 
(CEWS), a physiological scoring system analogous to the NHS Early Warning Score in 
widespread use (NEWS). Scores were obtained directly from the participants’ nursing notes 
and recorded in the CRF. Components of the CEWS score included: temperature, heart rate, 
blood pressure, respiratory rate, oxygen saturation, conscious level and urine output (Austen 
et al., 2012). 
 
2.1.13 Definition of end of trial* 
This trial concluded when the last participant attended their follow-up appointment and 
reasonable steps had been taken to contact all participants due a follow-up visit. 
 
2.1.14 Subject withdrawal procedure* 
Participants were withdrawn from the study if they were unable or unwilling to continue the 
study and/or follow-up arrangements. Where possible, consent was sought to analyse the data 
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and samples already collected although participants were not asked to attend for follow-up.  
Attempts were then made to enrol a replacement subject. 
 
2.1.15 Confidentiality* 
All data were handled in accordance with the Data Protection Act 1998. The Case Report 
Forms (CRFs) did not bear the subject’s name or other personal identifiable data. The 
subject’s initials, date of birth and study identification number were used for identification. 
All data pertaining to identifiable persons were regarded as confidential.  
 
2.1.16 Data Collection Tool 
Case report forms (CRFs) were designed by the investigator and produced on the Cardiff 
TELEform© Design program (version 8.2) with the assistance of Mrs Sylvia Chalkley, 
research coordinator. It was the responsibility of the investigator to ensure the accuracy of all 
data entered in the CRFs. The delegation log identified all those personnel with 
responsibilities for data collection and handling.  
 
2.1.17 Data handling and analysis*  
All CRFs and person-identifiable study data were kept in a locked room within a keypad-
accessed area of the study site, protected by 24-hour on-site security personnel, fire detection 
and alarm system.   
 
Data were transferred to IBM SPSS Statistics (versions 21 and 22) by scanning of the CRFs 
using the TELEform© Scan and Verify programs (version 8.2). The resulting SPSS database 
was scrutinised to identify missing and spurious data. Such data were corrected with 
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reference to the Case Report Forms. Some data were also transferred from SPSS to Microsoft 
Excel (2010) for further analysis.   
 
Electronic data were kept in encrypted databases, on a restricted access area of the study site 
computer network. This was backed up locally on a daily basis, and monthly backups were 
held securely in an offsite location. No patient identifiable data were stored on laptop 
computers, portable storage devices, or sent by electronic mail. The computer network was 
protected by an intrusion detection system. Data held within SPSS were anonymised, 
compressed and password-protected. 
 
2.1.18 Archiving arrangements* 
The trial documents (including case report forms and consent forms) will be kept for a 
minimum of five years. They will be stored in locked offices at the study site or in an 
archiving site as recommended and/or approved by the local Research and Development 
(R&D) office. The trial database will be kept electronically on the Imperial College computer 
network at the Chelsea and Westminster site, for a minimum of five years. 
 
2.1.19 Statistical input in trial design 
The trial design and statistical analysis plan have been constructed with input from Dr Tom 
Woodcock, principal information analyst/programme lead for NIHR CLAHRC North West 
London and Mrs Sylvia Chalkley, research coordinator. 
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2.1.20 Feasibility Study 
A feasibility study was undertaken before the commencement of the prospective 
observational study.  During this period, an exploratory hypothesis (related to glycaemic 
variability and insulin resistance) was examined. It soon became apparent that a formal 
power calculation would not be possible for this hypothesis due to a lack of published studies 
relating to the selected measures in people with SH. As an alternative, some exploratory 
calculations using linear regression (Dupont & Plummer, 1998) were performed using 
information on the selected measures in people with diabetes. This suggested that an optimal 
number of participants for recruitment would be n=125 with n=35 wearing a CGM.  
 
It was initially thought that this would be feasible: local informatics revealed that a total of 
5877 patients (>18 years) were admitted to Chelsea and Westminster Hospital between April 
2010 and March 2011. In addition, a previous local study identified 245 patients with SH in a 
6 month period (defined as RPG>7.8mmol/L). Upon commencing a practical trial of 
recruitment, however, it became apparent that a sole investigator would not be able to recruit 
to these numbers in the busy AAU environment. In particular, assessment of GV required 
consenting participants to wear a CGM for at least 24 hours – a challenge given the rapid 
patient turnover observed.  Therefore, the exploratory hypothesis was deemed unfeasible.  
 
Following further consideration, discussion and review of the literature, the five central 
hypotheses (originally considered as research questions) described in section 1.5 were 
selected for study. The experiences of the feasibility study informed the final prospective 
study –measures chosen for study were deemed to make a significant contribution to the field 
whilst also being feasible for collection by one investigator in the challenging environment 
and timeframe.  Once again, there was insufficient published evidence to enable a formal 
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power calculation. A pragmatic approach was hence taken: attempts were made to recruit as 
many participants as reasonably possible within the available timeframe (whilst operating 
safely within GCP and ethical frameworks). It was also considered that given the absence of 
related literature, any number of participants would inform future power calculations and 
make an unique contribution to the field of stress hyperglycaemia. 
 
2.1.21	  Statistical	  Analysis 
Descriptive statistics (including correlations), inferential statistics (one-way Analysis of 
Variance post-hoc tests and independent samples/paired samples t-tests) were all performed 
using the SPSS database.  Glycaemic Variability (GV) was represented as a Standard 
Deviation (see sections 4.3.9 and 5.7) and was also calculated using SPSS. Assumptions for 
all tests were carefully checked before their application (Altman, Gore, Gardner, & Pocock, 
1983; Bland, 1987). Additionally, an online tool, the GUARD Type 2 Diabetes Risk 
Calculator (http://www.cphs.mvm.ed.ac.uk/diabetes-risk/), was used to predict an 
individual’s 3-year risk of developing Type 2 Diabetes (McAllister et al., 2014). This tool 
was validated in a country with a relatively small non-white population, similar to the 
prospective study population (Figure	  13). 
 
 
*2.2 Methodology for the ‘Stress Hyperglycaemia in COPD’ (Metformin) Study 
Data for this study were obtained from the adopted, multicentre study: ‘A randomised, 
double-blind, placebo-controlled trial of metformin in chronic obstructive pulmonary disease 
(COPD) exacerbations: a pilot study’ (Metformin in COPD, EudraCT number 2010-020818-
28). In total, 9 UK study sites were involved in recruitment. Co-investigator, Dr Anjali 
Balasanthiran and local collaborators collected data at the Chelsea and Westminster study 
site. Relevant sections of the study protocol* (version 4.0, 29th June 2012) have been 
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reproduced with the kind permission of Dr Andrew Hitchings, Co-Investigator at St 
George’s, University of London (study sponsor).  
Full details of this study including study governance and pharmacovigilance are contained 
within the metformin in COPD study protocol. Certain broad sections (e.g.: informed 
consent, confidentiality) are applicable to both the metformin in COPD and the prospective 
study. These sections have been included within the prospective study methodology and 
marked with  ‘* ‘ to indicate that they apply to both studies (and are reproduced with kind 
permission of the metformin in COPD team). Results from this study are reported in chapter 
5. 
	  
2.2.1	  Overall	  trial	  design	  and	  objectives	  
This was a randomised, double-blind, parallel-group, placebo-controlled trial. An overview 
of the study is provided in Figure	  10. A double-blinded design was adopted to provide the 
best possible evidence for the efficacy of metformin in this context by minimising the risk of 
bias. Blinding was implemented by means of visually identical active and placebo treatments. 
The primary study objective was to determine whether, ‘in patients hospitalised for COPD 
exacerbations and receiving conventional treatment, the addition of metformin, as compared 
with placebo, ameliorates hyperglycaemia’. The objectives of the secondary analysis differ 
and focus on examining the following in the recruited COPD population: 
i) Prevalence of stress hyperglycaemia  
ii) Characteristics of people with SH  
iii) Glucose patterns and glycaemic variability (GV)  
iv) The effect of metformin on GV 
v) Diabetes risk  
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2.2.2	  Study	  population	  
Based on existing literature and primary study objectives, the sample size was set at 69 
patients, randomised to metformin or placebo in a 2:1 ratio. The patients were drawn from the 
population of patients admitted to the study sites with an exacerbation of COPD, and who 
were able to enter the study within 48 hours of admission. Data for 52 patients were available 
for the secondary analysis. 
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2.2.3	  Schematic	  of	  trial	  design	  
	  
 
Figure	  10:	  Schematic	  of	  metformin	  in	  COPD	  trial	  design	  (including	  up	  to	  28-­‐35	  day	  follow-­‐up).	  Image	  reproduced,	  with	  
permission,	  from	  original	  study	  protocol 
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2.2.4 Subject	  recruitment	  process	  
Process as per section 2.1.5 (Prospective study) although there was no involvement of ‘Drive’ 
patient involvement group in this study 
 
2.2.5	  Randomisation	  procedure	  
Patients were allocated in a 2:1 ratio to metformin or placebo in blocks of six. Randomisation 
was performed by the IMP manufacturer, in accordance with the method agreed by the study 
team. The randomisation list was produced electronically by the drug manufacturer (Bilcare 
[GCS] Europe Ltd). Following allocation to a study treatment, patients were given a trial 
participant card, which contained the study title, IMP details, patient trial number and contact 
details for advice and emergency unblinding. 
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2.2.6	  Summary	  flow	  chart	  of	  study	  assessments	  
	  
Table	  5:	  Summary	  flow	  chart	  of	  study	  assessments	  for	  metformin	  in	  COPD	  study.	  Image	  reproduced,	  with	  permission,	  
from	  original	  study	  protocol 
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2.2.7	  Practical	  Procedures	  and	  Study	  Assessments	  
All blood samples were taken using standard peripheral venepuncture technique. 
Measurement of height, weight, and waist circumference were undertaken according to 
published guidelines (University of Leicester, 2008). The COPD Assessment Test (CAT), 
Exacerbations of Chronic Pulmonary Disease Tool (EXACT), and Malnutrition Universal 
Screening Tool (MUST) were administered in accordance with their user instructions. 
Spirometric measurements were performed in accordance with published guidelines (BTS, 
2005).    Blood glucose measurements were taken using a CE-marked device licensed for this 
purpose. A summary flow chart of study assessments is presented in Table	  5. 
 
2.2.8	  Subject	  withdrawal	  procedure	  
Process as per section 2.1.14 (Prospective study) with the exception that patients withdrawn 
from the metformin study were invited to attend study follow-up to establish health status and 
occurrence of any further COPD exacerbations 
 
2.2.9	  Data	  handling	  and	  analysis	  
Similar to section 2.1.21 except that data were transferred to an electronic database in the 
Excel software programme by double entry (rather than transferred to SPSS using 
theTELEform© program). 
The prospective study definition of SH was used in this study (see section 1.5). As per 
section 2.1.21, descriptive statistics (including correlations), inferential statistics (one-way 
Analysis of Variance post-hoc tests and independent samples t-tests) were all performed 
using the SPSS database. Again, the GUARD risk calculator was used to calculate an 
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individual’s 3-year risk for T2DM (McAllister et al., 2014). Additional analyses performed 
for this study include:  
• Mann-Whitney U non-parametric test –performed due to data distribution, section 5.7 
• Glycaemic Variability, (again expressed as a SD and calculated using SPSS), was 
compared between all study groups (section 5.7) by calculating the GV for each 
individual participant and obtaining a mean GV value for each study group 
(prospective study groups 1 and 2 and metformin study groups A and B). The mean 
values were then compared using one-way ANOVA  
As before, assumptions for all statistical tests were carefully checked before their application 
(Altman et al., 1983; Bland, 1987). 
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Chapter	  3:	  Prospective	  Study	  Results,	  Part	  1	  
	  
3.1 Introduction 
3.1.1	  Study	  Measures	  
As described in section 1.5, the main research objective relates to the metabolic profile of 
people with stress hyperglycaemia and differences between individuals with and without the 
condition. These results are presented in section 3.3.  A number of variables, linked to the 
development of DM were examined in the metabolic profile including: BMI (Looker, 
Knowler, & Hanson, 2001), waist circumference (Diabetes Prevention Program Research 
Group, 2006), blood pressure (Conen, Ridker, Mora, Buring, & Glynn, 2007), Epworth score 
for OSA (Idris et al., 2009) and copeptin (Enhörning et al., 2010).  
In addition to the hypotheses-related data, a few further measures, related to the metabolic 
profile, were also included to provide a fuller picture. Participants were asked about their 
family history of diabetes as well as past medical history of hypertension (HTN) and Non-
alcoholic steatohepatitis (NASH). The IDF definition of metabolic syndrome (Alberti, 
Zimmet, & Shaw, 2006) was also considered (section 3.3) but could not be formally 
diagnosed on a single study assessment.  
 
As well as the metabolic profile, a number of additional measures are described in people 
with SH (see section 2.1.9). Comparisons are made between people with and without the 
condition. Such detailed profiling of people with SH is novel work. The following sections 
describe the rationale for the selection of these measures and how they may, with further 
work, address the broader questions (3 and 5) described in section 1.4. 
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Demographics and Primary Diagnosis of People with SH (section 3.2):  
Although a number of different diagnostic populations with SH have been described, there is 
little work describing all-comers in an acute care setting (Umpierrez et al., 2002). Building a 
fuller profile of people with the condition could support the practising clinician in identifying 
at-risk individuals (perhaps demonstrating conditions particularly associated with SH) as well  
as focusing management. 
 
Glucose Values in People with SH (section 3.4) 
There is currently no biochemical definition of SH but notably, modest levels of 
hyperglycaemia have been associated with harm in several common conditions (>7.0mmol/L 
in respiratory disease (Baker et al., 2006) and >6.1 mmol/L in AHF (Sud et al., 2015). A local 
study identified 245 patients with a RPG>7.8mmol/L in a 6 month period. Otherwise, there is 
a scarcity of data examining SH glucose values in the acute care setting and, in particular, 
fasting glucose values have not been examined in this context. This information would be of 
interest when considering management options. 
 
Steroids in people with SH (section 3.5) 
Glucocorticoids are frequently prescribed in the acute care setting, particular for patients with 
acute exacerbations of COPD (Lindenauer et al., 2010). Resultant glucocorticoid-induced 
hyperglycemia (GIH) is common (Katsnelson et al., 2013), and considered by many to fall 
under the umbrella of SH. The odds ratio for new-onset diabetes mellitus in patients treated 
with glucocorticoids ranges from approximately 1.5 to 2.5 (Perez et al., 2014) with steroid 
dose and duration strong predictors of diabetes induction (Clore & Thurby-Hay, 2009).  A 
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comparison was made between the steroid-treated proportions of participants with and 
without SH and metabolic abnormalities (section 3.10.2). 
 
Nutrition and Hydration Status in people with SH (section 3.6) 
BIVA has been used to predict outcomes (Peacock, 2010) as well as to assess nutritional and 
hydration status in a variety of situations (Tuy & Peacock, 2011; Valle et al., 2011; Walter-
Kroker, Kroker, Mattiucci-Guehlke, & Glaab, 2011). Methodology for measurement and 
analysis is described in section 2.1.12. Within the context of this study, it is anticipated that 
the measurement will add an extra dimension to the metabolic profile of patients with stress 
hyperglycaemia. 
 
Anxiety & Depression in people with SH (section 3.7)	  
Depression is a common, under-diagnosed condition which has also been proposed as a risk 
factor for the development of T2DM (M. M. Williams, Clouse, & Lustman, 2006). Possible 
aetiological mechanisms include activation of the immune system and HPA axis, leading to 
increased insulin resistance. To provide a different perspective on ‘stress’ and further flesh 
out the profile of the individual with SH, the HAD questionnaire was used to determine 
anxiety and depression scores in people with and without stress hyperglycaemia. 
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Stress Profile in people with SH (section 3.8) 
Whilst the pathogenesis of SH has been reasonably well elucidated, (section 1.2) there is little 
work investigating the contribution of (scored) illness severity to the development of SH in 
the acute setting. This addition could enhance real-world risk stratification and management.  
 
Biomarkers in people with SH (section 3.9) 
The association between SH and poor outcomes is well established (Chapter 1).  One 
particular outcome of interest is the development of a metabolic abnormality (see section 
3.10.2). Various biomarkers have been shown to have prognostic utility in a number of 
common conditions (John et al., 2010; Maisel et al., 2011; Martins, Rodrigues, Miranda, & 
Nunes, 2009) and, in particular, several have been associated with glucose intolerance in SH 
(Carmen Wong et al., 2010). Despite this interesting work, there is a scarcity of similar 
research and it is not clear what, if any, popular biomarkers may add to the prognostic utility 
of glucose.  
To start, biomarker values in participants with and without SH were investigated. Values at 
baseline and follow-up were also scrutinised in group 1 participants. Biomarkers selected for 
study are presented in results section 3.9 and discussed in more detail in discussion section 
6.10. 
 
Short-term outcomes in people with SH (section 3.10): 
The question, ‘do people with Stress Hyperglycaemia actually have underlying glucose 
intolerance, unmasked during acute illness, rather than a genuinely transient disorder?’ was 
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considered. Metabolic abnormalities were screened for and recorded (see section 3.10.2). 
Given the relatively short duration of study follow-up, a risk calculator was utilised to 
estimate an individual’s 3-year risk of developing Type 2 Diabetes (see section 2.1.21). 
Additionally, as hyperglycaemia has been suggested as a risk factor for prolonged length of 
stay, (Takada et al., 2012) these results are presented in section 3.10.1. Further information 
on LOS in people with SH could enhance triage and decision-making. 
	  
3.1.2	  Recruitment	  Statistics	  
Participants were suitable for inclusion if there were >18 years of age, admitted to the Acute 
Assessment Unit (AAU) at Chelsea and Westminster hospital and able to enter the study 
within 72 hours of admission. Full inclusion/exclusion criteria are described within the 
methods chapter (section 2.1.4) 
 
A total of 196 patients (16%) were formally screened and found to be eligible for inclusion. 
Type 1 or 2 Diabetes Mellitus was the most frequently encountered exclusion criterion. Of 
those eligible (n=196), the investigator was able to approach n=93 to discuss participation in 
the study - a total of 64 patients agreed to participate whilst 29 declined (Figure 11)  
 
Of those recruited within the available time-frame, 21 were allocated to group 1 (Stress 
Hyperglycaemia) and 41 to group 2 (‘normal’ glucose tolerance). Two patients who were 
recruited to the study were subsequently withdrawn –one with DM and another on request 
(see section 3.10.2).  Recruitment took place between 11/7/2012 and 16/05/2013. 
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3.2 Demographics and Primary Diagnosis 
The mean age for all participants was 68 years. Using an independent samples t-test (Table	  8), 
no statistically significant difference was found between the age distribution (Table	   7) of 
participants from group 1 and 2 at baseline. 
 
Descriptive Statistics Group 1 Group 2 
Mean Age in years (± SD) 67.6 (± 16.04) 67.5 (± 16.07) 
Minimum Age (yrs.) 27 22 
Maximum Age (yrs.) 91 89 
N 21 41 
Table	  7:	  Descriptive	  statistics	  of	  age	  for	  group	  1	  and	  2	  participants,	  prospective	  study	  
	  
	  
	  
Equal Variances Assumed t df Sig. (2-tailed) 
Yes 0.014 60 0.989 
No 0.014 40 0.989 
Table	  8:	  Independent	  samples	  t-­‐test	  of	  age,	  group	  1	  and	  2	  participants	  (prospective	  study) 
 
 
Figure	  12 displays skewing of the age distribution in all participants towards an older age.  
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Figure	  12:	  Age	  distribution	  and	  random	  plasma	  glucose	  levels	  by	  study	  group,	  prospective	  study	  
 
Sixty percent of all participants were men. Gender distribution was also similar in group 1 
and 2 participants. (Table	  9)	  
Descriptive Statistics Group 1 Group 2 
Gender, male/female (%) 14/7 (66.7/33.3) 23/18 (56.1/43.9) 
N 21 41 
Table	  9:  Gender	  distribution	  of	  participants	  recruited	  to	  group	  1	  and	  2,	  prospective	  study 
 
In keeping with the local AAU population (local informatics), the majority of participants in 
both study groups were of White British ethnicity (Table 10, Figure 13) 
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Figure	  13:	  Percentage	  distribution	  of	  ethnicity	  between	  participants	  of	  group	  1	  and	  2,	  prospective	  study	  
	  
Ethnicity Group 1 % (N) Group 2 % (N) 
White British (A) 71.4 (15) 68.3 (28) 
White Non-British (B/C) 9.5 (2) 19.5 (8) 
Asian/British Asian (H,J,K,L) 4.8 (1) 2.4 (1) 
Black/Black British (M,N,P) 4.8 (1) 2.4 (1) 
Mixed/Other (D,E,F,G,R, S) 9.5 (2) 7.3 (3) 
Total 100 (21) 100 (41) 
Table	  10:	  Distribution	  of	  ethnicity	  between	  participants	  of	  group	  1	  and	  2,	  prospective	  study	  
(%	  and	  frequencies)	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41 different primary diagnoses (ICD codes) were recorded across 62 patients. Figure	  14 and 
Table	   11 display these diagnoses within broad categories for participants from both study 
groups (for a full breakdown of all ICD-10 diagnoses, see Appendix 1). Respiratory disease 
was the primary diagnosis for the majority of participants from group 1 and 2. 
 
	  
Figure	  14:	  Percentage	  distribution	  of	  primary	  diagnoses	  categories,	  group	  1	  and	  2	  participants	  (prospective	  study)	  
	  
Primary Diagnosis Number of Participants  
 
Group 1/2 Participants 
Respiratory Disease 28 6/22 
Falls/Syncope 8 3/5 
Cardiovascular Disease 6 4/2 
Metabolic/Haematological 2 1/1 
Skin/Rheum Disease 11 3/8 
GI and Renal 5 3/2 
Pain 1 0/1 
Unclear 1 1/0 
Table	  11:	  Frequency	  distribution	  of	  primary	  diagnoses	  categories,	  group	  1	  and	  2	  participants	  (prospective	  study)	  
	  	  	  	  	  	  	  90	  
	  
 
3.3 Metabolic profiling 
Participants from group 1 and 2 had similar (mean) values for BMI (hypothesis 1), waist 
circumference (hypothesis 2), weight, blood pressure (hypothesis 3), Epworth score 
(hypothesis 4) and neck circumference. (Table	  12).  Of note, a similar proportion of group 1 
and 2 participants were treated with anti-hypertensives (38% and 39& respectively). An 
Independent samples t-test revealed no statistically significant differences in the mean or 
variance of these variables between group 1 and 2 participants (Table	  13). 
 Group 1 Group 2 
BMI (kg/m2)* 
Mean (± SD) 25.7 (± 4.77) 26.7 (±5.78) 
Min/Max 17.6/33.9 16.6/43.4 
N 20 39 
 
Waist circumference (cm)* 
Mean (± SD) 101.4 (±10.54) 101.6 (±16.27) 
Min/Max  84.0/124.0 77.0/157.0 
N 19 36 
 
Weight (kg) 
Mean  (±SD) 73.3 (±16.44) 74.9 (±22.74) 
Min/Max  47.7/112.5 42.0/160.0 
N 20 40 
 
SBP (mmHg)* 
Mean (±SD) 125 (±14.49) 133 (±19.28) 
Min/Max  105/154 101/173 
N 20 41 
 
DBP (mmHg)* 
Mean (±SD) 72 (±7.70) 75 (±11.17) 
Min/Max  56/85 54/97 
N 20 41 
 
Epworth Score* 
Mean (±SD) 5.5 (±5.02) 4.7 (±3.43) 
Min/Max  0/19 0/11 
N 21 41 
 
Neck Circumference (cm) 
Mean (±SD) 39.9 (±5.74) 39.1 (±5.46) 
Min/Max  29.0/53.0 28.0/51.0 
N 19 38 
Table	  12:	  Descriptive	  statistics	  of	  Body	  Mass	  Index,	  weight,	  systolic	  blood	  pressure,	  diastolic	  blood	  pressure,	  waist	  
circumference,	  neck	  circumference	  and	  Epworth	  score	  for	  group	  1	  and	  2	  participants	  (prospective	  study)	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                           Equal Variances Assumed 
Levene's Test for Equality 
of Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
BMI Yes 0.672 0.416 -0.665 57 0.509 
No   -0.707 45.457 0.483 
Waist 
circumference 
Yes 1.737 0.193 -0.056 53 0.956 
No   -0.064 50.586 0.949 
Neck 
circumference 
Yes 0.099 0.755 0.499 55 0.619 
No   0.491 34.506 0.627 
Weight 
 
Yes 1.763 0.189 -0.277 58 0.783 
No   -0.308 50.317 0.760 
SBP Yes 3.590 .063 -1.668 59 0.101 
No   -1.839 48.714 0.072 
DBP Yes 4.512 0.038 -.976 59 0.333 
No   -1.106 52.016 0.274 
Epworth Score Yes 1.390 0.243 0.711 60 0.480 
No   0.631 29.868 0.533 
Table	  13:	  Independent	  samples	  t-­‐test	  of	  selected	  metabolic	  variables,	  group	  1	  and	  2	  participants	  (prospective	  study)	  
	  
Table 14 describes copeptin values for group 1 and participants (hypothesis 5). An 
independent samples t-test did not reveal a statistically significant difference in the mean 
value between group 1 and 2 participants (Table	   15). However, a highly statistically 
significant difference was found in the variance of copeptin between group 1 and 2 (Table	  15, 
Figure	  15). 
 Study Group N Mean SD Min Max 
Copeptin (pmol/L) 
1 20 8.88 6.49 2.3 24.5 
2 34 15.19 18.13 1.6 86.1 
Table 14: Descriptive statistics of copeptin values for group 1 and 2 participants, prospective study 
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Table	  15:	  Independent samples t-test for copeptin, group 1 and 2 participants (prospective study) * statistically 
significant p<0.05, ** statistically highly significant p<0.01 
 
	  
 
 
 
 
Levene's Test for Equality of 
Variances t-test for Equality of Means 
Equal 
variances 
Assumed F Sig. t df 
Sig. (2-
tailed) 
Copeptin (pmol/L) Yes 7.435 0.009** -1.497 52 0.140 
No   -1.840 45.216 0.072 
Figure	  15:	  Copeptin	  values	  in	  n=54	  group	  1	  and	  2	  participants,	  prospective	  study 
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As described in section 3.1.1, a number of further questions were asked of participants to 
complete their metabolic profile: 
• Do you have a family history of diabetes? 
• Do you have a Past Medical History (PMH) of hypertension? 
• Do you have a PMH of  Non-alcoholic Steatohepatitis (NASH)? 
Only 1 participant from group 2 reported a history of NASH. Responses to the questions on 
diabetes and hypertension are displayed in Figure	  16 and Figure	  17 respectively. 
 
	  
Figure	  16:	  Percentage	  of	  participants	  with	  a	  family	  history	  of	  diabetes	  mellitus	  in	  group	  1	  and	  2,	  prospective	  study	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Figure	  17:	  Percentage	  of	  participants	  reporting	  a	  past	  medical	  history	  of	  hypertension	  in	  group	  1	  and	  2,	  	  
prospective	  study	  
 
Considering the IDF definition of metabolic syndrome (see section 3.1.1), four participants 
from group 1 (27% of n=15) and 10 participants from group 2 (34% of n=29) loosely met the 
diagnostic criteria at baseline visit. Notably, this is only a estimate given lack of follow-up 
data in all participants (to assess persistence of hypertension) and lipid values. In addition, it 
is important to note that, although a higher proportion of participants in group 1 self-reported 
a history of hypertension, similar proportions of participants from groups 1 and 2 were 
actually prescribed anti-hypertensives (38% and 39% respectively).   
	  
3.4 Glucose values  
The mean (baseline) plasma glucose for all prospective study participants was 6.7mmol/L. 
Recruited participants were placed into group 1 if their initial random plasma glucose (RPG)  
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was 7.1-11.0 mmol/L. The prevalence of SH was 34% in the prospective study population (as 
recruited within the available time-frame). 
 
As described in section 2.1.10, participants with a RPG ≥11.1 were screened for diabetes and 
excluded as appropriate. Table	   16 contains descriptive statistics for RPG whilst Figure	   18 
displays 95% confidence intervals and demonstrates clear separation between the 2 study 
groups as per study group definition (see section 2.1.8).  
 
RPG Descriptors Group 1 Group 2 
N 21 41 
Mean random plasma glucose in mmol/L (±SD) 8.4 (±1.02) 5.8 (±0.80) 
Min/Max random plasma glucose in mmol/L 7.2/10.7 3.6/7.0 
Table	  16:	  Random	  plasma	  glucose	  levels	  (mean/SD/min/max)	  in	  group	  1	  and	  2	  participants,	  prospective	  study	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Figure	  18:	  Random plasma glucose values in group 1 and 2 prospective study participants (n=62) 
 
One-way Analysis of Variance (one-way ANOVA) post-hoc tests were performed to 
investigate any differences in mean RPG value between diagnostic categories for participants 
in groups 1 and 2.  Categories ‘metabolic/haematological’, ‘unclear’ and ‘pain’ (with the 
lowest frequencies) were removed to allow the analysis to proceed.  
Tukey-HSD testing showed that within study group 2, the only statistically significant 
differences in mean RPG values were for participants with renal and cardiovascular disease. 
Of this small number of participants (n=4), mean RPG were found to be significantly lower 
(p<0.05) than for those group 2 participants with diagnoses of falls/syncope, respiratory and 
skin/rheum disease. There were no significant differences in mean RPG values between 
participants in different diagnostic categories within study group 1. (Table	  17). 
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Random plasma glucose (mmol/L) 
 
Groups/Primary Diagnosis N 
Subset for alpha = 0.05 
1 2 3 
Student-Newman-Keulsa,b G2/GI/Renal 2 5.200   
G2/Cardiovascular 2 5.550   
G2/Falls/Syncope 5 5.700   
G2/Respiratory Disease 22 5.745   
G2/Skin/Rheum 8 5.938   
G1/Skin/Rheum 3  7.800  
G1/GI/Renal 3  8.200  
G1/Cardiovascular 4  8.300  
G1/Falls/Syncope 4  8.450  
G1/Respiratory Disease 7  8.600  
Sig.  0.812 0.763  
Tukey HSDa,b G2/GI/Renal 2 5.200   
G2/Cardiovascular 2 5.550   
G2/Falls/Syncope 5 5.700 5.700  
G2/Respiratory Disease 22 5.745 5.745  
G2/Skin/Rheum 8 5.938 5.938  
G1/Skin/Rheum 3  7.800 7.800 
G1/GI/Renal 3   8.200 
G1/Cardiovascular 4   8.300 
G1/Falls/Syncope 4   8.450 
G1/Respiratory Disease 7   8.600 
Sig.c.  0.984 0.085 0.972 
Means for groups in homogeneous subsets are displayed. (a) Uses Harmonic Mean Sample Size = 3.731. (b) The group 
sizes are unequal . The harmonic mean of the group sizes is used. Type I error levels are not guaranteed. (c) This p value 
refers to all variables within the same column, demonstrating no difference between the values in the homogenous subset.   
Table	  17:	  One-­‐way	  Analysis	  of	  Variance	  (one-­‐way	  ANOVA)	  post-­‐hoc	  tests	  to	  examine	  differences	  in	  mean	  Random	  
Plasma	  Glucose	  (RPG)	  values	  between	  diagnostic	  categories	  for	  group	  1	  and	  2	  participants.	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Figure	  19	  and	  Table	  18	  display the FPG, taken the morning after study entry, for participants in 
study group 1 and 2.  
 
	  
Figure	  19:	  Fasting	  plasma	  glucose	  values	  in	  group	  1	  and	  2	  prospective	  study	  participants	  (n=46)	  
	  
	  
FPG Descriptors Group 1 Group 2 
N 16 30 
Mean fasting plasma glucose (mmol/L) ±SD 5.4(±0.87) 5.5 (±0.78) 
Min/Max fasting plasma glucose (mmol/L) 4.3/8.0 4.0/7.9 
Table	  18:	  	  Descriptive	  statistics	  of	  Fasting	  Plasma	  Glucose	  (FPG)	  values	  for	  group	  1	  and	  2	  participants	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  Figure	  20 displays FPG and RPG on one figure for comparison: 
 
 
 
	  	  	  	  	  	  	  	  	  	  Figure	  20:	  Random	  and	  fasting	  plasma	  glucose	  levels	  in	  group	  1	  and	  2	  prospective	  study	  participants	  
	  	  	  	  	  	  	  100	  
	  
 
One-way Analysis of Variance (one-way ANOVA) post-hoc tests were performed to 
investigate any differences in the mean RPG and FPG values of participants in 
groups 1 and 2 (Table 19). As expected, mean RPG was significantly higher for 
participants in study group 1 compared to other glucose groups (p <0.05). Mean FPG 
from both groups and RPG in group 2 were placed in the same homogenous subset 
and were not statistically different.	  
	  
Table	  19	  One-­‐way	  ANOVA	  post-­‐hoc	  tests	  to	  examine	  differences	  in	  FPG	  and	  RPG	  values	  of	  group	  1	  and	  2	  prospective	  
study	  participants 
	  
 
3.5 Steroid Prescriptions 
48% of participants in group 1 (n=10) and 45% of participants in group 2 (n=18) were steroid 
treated at the time of study entry  (Figure	  21). The most frequent steroid prescribed in both 
Plasma Glucose (mmol/L) 
 
Study Group/Sample Type N 
Subset for alpha = 0.05 
1 2 
Student-Newman-Keulsa,b Group 1/ Fasting Glucose 16 5.444  
Group 2/ Fasting Glucose 31 5.561  
Group 2/ Random Glucose 41 5.771  
Group 1/ Random Glucose 21  8.410 
Sig.  0.449 1.000 
Tukey HSDa,b Group 1/ Fasting Glucose 16 5.444  
Group 2/ Fasting Glucose 31 5.561  
Group 2/ Random Glucose 41 5.771  
Group 1/ Random Glucose 21  8.410 
Sig.  0.621 1.000 
Means for groups in homogeneous subsets are displayed.   (a) Uses Harmonic Mean Sample Size = 
23.986 (b)  The group sizes are unequal. The harmonic mean of the group sizes is used. Type I error 
levels are not guaranteed.  
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study groups was oral prednisolone at a dose of 30mg (12% of all prednisolone prescriptions 
in group 1 and 9.5% of all prednisolone prescriptions in group 2). 
 
 
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  21:	  Steroid-­‐treated	  participants	  in	  group	  1	  and	  2,	  prospective	  study	  (n=62)	  
 
	  
3.6 Nutrition and Hydration Status 
An independent samples t-test did not reveal any statistically significant differences in the 
mean or variance of BIVA scores between group 1 and 2 participants (see methods section 
2.1.12) Table	   20 summarises the BIVA-derived hydration and body-type values for all 
participants. 
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Study	  Group	   Hydration	  (Mean	  Value)	   Nutrition	  (Body	  Type)	  
1 Mean value for this group was 77% 
defined as ‘mildly wet’  
Obese 31% (n=5) 
Cachectic 25% (n=4) 
Muscular 25% (n=4) 
Lean 19% (n=3) 
16 total 
2 Mean value for this group was 73% 
defined as ‘normal hydration’  
Cachectic 61% (n=11) 
Obese 28% (n=5) 
Muscular 11% (n=2) 
Lean 0% 
18 total 
	  	  	  	  	  	  	  	  Table	  20:	  Mean	  BIVA-­‐derived	  hydration	  scores	  for	  group	  1	  and	  2	  participants	  as	  well	  as	  proportions	  of	  group	  1	  and	  2	  
participants	  with	  obese,	  cachectic,	  muscular	  and	  lean	  body	  types,	  prospective	  study	  (baseline	  visit)	  
	  
 
 
3.7 Hospital Anxiety and Depression (HAD)  
An independent samples t-test did not reveal any significant differences between the mean 
depression and anxiety scores (Table	  21) of participants from group 1 and 2.  All mean values 
were within the normal range (0-7). 
 
                      Study Group N Mean Std. Deviation Min/Max 
Depression score 1 19 3.84 3.89 0/16 
2 41 2.88 2.40 0/9 
Anxiety score 1 19 5.05 3.47 0/12 
2 41 4.34 3.62 0/16 
Table	  21:	  	  Descriptive	  statistics	  of	  Hospital	  Anxiety	  and	  Depression	  (HAD)	  scores	  for	  group	  1	  and	  2	  participants,	  
prospective	  study	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                Equal Variances Assumed 
Levene's Test for Equality of 
Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) 
Depression 
score 
             Yes 2.736 0.104 1.180 58 0.243 
             No   0.996 24.6 0.329 
Anxiety 
score 
            Yes 0.175 0.678 0.716 58 0.477 
             No   0.728 36.6 0.471 
 
Table	  22:	  Independent	  sample	  t-­‐test	  of	  HAD	  scores,	  group	  1	  and	  2	  participants	  (prospective	  study)	  *	  statistically	  
significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	  
 
 
3.8 Stress profiling 
Descriptive statistics for participant CEWS scores at the time of study entry are contained in 
Table	  23. The scoring system is described in more detail in section 2.1.12 and is scored out of 
21. The CEWS score was ‘0’ in all but 3 group 1 participants who had a score of ‘1’. A 
greater number of group 2 participants had a CEWS score of >0 (n=8). Independent sample t-
testing did not demonstrate a statistically significant difference between the CEWS score for 
participants from group 1 and 2.  
 
                                            Study Group N Mean Std. Deviation Min/Max 
CEWS Score 1 21 0.14 0.36 0/1 
2 41 0.27 0.63 0/3 
Table	  23:	  Descriptive	  statistics	  of	  CEWS	  scores	  for	  group	  1	  and	  2	  participants,	  prospective	  study,	  n=62	  
 
 
3.9 Biomarkers  
Table	  24 summarises the biomarker values of group 1 and 2 participants taken at the baseline 
visit (with reference ranges where appropriate).  Cortisol samples were taken between 07:30 
and 09:00 on the morning after study entry. The mean cortisol value for all participants was 
406nmol/L. 
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 Study Group N Mean SD Min Max 
HbA1c  
(20-42 mmol/mol) 
1 20 39.75 4.63 33 52 
2 33 39.67 3.92 32 51 
eGFR  
(>59 ml/min/m2) 
1 21 78.38 17.05 39.0 91.0 
2 40 78.70 18.87 17.0 91.0 
Lactate  
(0.6-2.5 mmol/L) 
1 20 1.51 0.85 0.57 3.47 
2 37 1.25 0.63 0.56 3.34 
Cortisol  
(160-550 nmol/L) 
1 15 326.93 179.84 <20 569.0 
2 30 432.23 301.14 <20 1650.0 
hsCRP  
(0.0-5.0mg/L) 
1 21 72.21 71.96 0.5 224.4 
2 41 75.53 96.73 0.3 339.9 
Troponin 1  
(<0.05 ng/mL) 
1 19 0.18 0.73 <0.05 3.18 
2 34 0.005 0.03 <0.05 0.17 
BNP  
(0.0-100 pg/mL) 
1 19 149.37 198.69 <0.5 784.0 
2 35 114.38 166.15 <0.5 774.0 
Ketones 
(<0.6 mmol/L) 
1 19 0.05 0.06 0.0 0.2 
2 39 0.47 1.16 0.0 5.1 
Pro-ADM  
(nmol/L) 
1 20 1.00 0.48 0.41 2.00 
2 34 1.07 0.63 0.23 2.97 
25-OH-Vitamin D 
(70-150 nmol/L) 
1 5 23.38 8.91 9.9 33.7 
2 8 52.84 33.45 13.8 118.7 
Table	  24:	  Descriptive	  statistics	  of	  biomarker	  values	  for	  group	  1	  and	  2	  participants,	  prospective	  study	  with	  local	  
biomarker	  reference	  ranges.	  Cortisol	  reference	  range	  applies	  to	  samples	  take	  at	  approximately	  9am.	  
 
	  	  
An independent samples t-test (Table	  25) demonstrated a statistically significant difference (p 
<0.05) between mean blood ketone (Figure	  22) and 25-OH-Vitamin D (Figure	  23) values of 
group 1 and 2 participants.	  A statistically significant difference was also found in the variance 
between group 1 and 2 for blood ketones. 
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Table	  25:	  Independent	  samples	  t-­‐test	  for	  biomarkers,	  group	  1	  and	  2	  participants	  (prospective	  study)	  *	  statistically	  
significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	  
 
 
 
 
Levene's Test for Equality of 
Variances t-test for Equality of Means 
Equal 
variances 
Assumed F Sig. t df 
Sig. (2-
tailed) 
HbA1c 
(mmol/mol) 
Yes 0.697 0.408 0.070 51 0.944 
No   0.067 35.128 0.947 
eGFR 
(ml/min/m2) 
Yes 0.001 0.972 -0.065 59 0.949 
No   -0.067 44.533 0.947 
Lactate  
(mmol/L) 
Yes 2.426 0.125 1.283 55 0.205 
No   1.172 30.415 0.250 
Cortisol  
(nmol/L) 
Yes 0.353 0.556 -1.244 43 0.220 
No   -1.463 41.446 0.151 
hsCRP  
(mg/L) 
Yes 1.581 0.214 -0.139 60 0.890 
No   -0.152 51.916 0.879 
BNP  
(pg/mL) 
Yes 0.251 0.619 0.690 52 0.494 
No   0.654 31.830 0.518 
Ketones  
(mmol/L) 
Yes 6.324 0.015*  -1.562 56 0.124 
No   -2.243 38.429 0.031* 
Pro-ADM 
(nmol/L) 
Yes 0.054 0.816 -0.424 52 0.673 
No   -0.455 48.371 0.651 
25-OH-Vitamin 
D (nmol/L) 
Yes 4.181 0.066 -1.899 11 0.084 
No   -2.361 8.487 0.044* 
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Figure	  22:	  Blood ketone values (log scale) in group 1 and 2 participants, prospective study (n=58) 
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Figure	  23:	  25-­‐OH	  Vitamin	  D	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study	  (n=13) 
 
	  
No differences were found between mean HbA1c (Figure	  24) or cortisol values (Figure	  25) for 
group 1 and 2 participants. All participants apart from n=3 had a troponin I value of <0.05 
ng/mL.	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Figure	  24:	  HbA1c	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study	  (n=53) 
	  
	  
	  
Figure	  25:	  Cortisol	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study	  (n=45) 
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Table	  26 describes significant and highly significant biomarker correlations noted in all 
participants (groups 1 and 2 combined).  
 
 
Variable 1 
 
 
Variable 2 
 
 
Pearson Correlation 
 
 
Sig.(2-tailed) 
 
 
N 
Fasting insulin 
(mIUL) 
Copeptin (pmol/L) 0.376* 
 
0.012 
 
44 
hsCRP (mg/L) 
 
0.321* 0.031 45 
Pro-ADM (nmol/L) Copeptin (pmol/L) 
 
0.749** 
 
0.000 54 
Table	  26:	  Notable	  statistically	  significant	  Pearson	  correlations	  between	  biomarkers	  -­‐	  all	  prospective	  study	  participants	  	  
(groups	  1	  and	  2	  combined)*	  statistically	  significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	  
	  
 
3.10 Short-Term Outcomes  
As described in section 2.1.9, a number of short-term outcomes were studied. They include: 
• Length of stay 
• Metabolic outcomes: new diagnoses of Impaired Glucose Regulation (IGR) and 
Diabetes Mellitus (DM) 
• A selection of variables for consenting group 1 participants at dedicated follow-up  
A description of these outcomes and relevant analyses are described in section 3.10.1 to 
3.10.3. 
	  
3.10.1	  Length	  of	  Stay	  
The mean Length of Stay (LOS) for all participants was 4.5 days (n=58, SD ±4.94, min/max 
1/32 days). Table	  27 contains descriptive data on LOS for each study group. An independent 
samples t-test did not show a statistically significant difference in length of stay between 
group 1 and 2 participants. 
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Variable  Study Group N Mean  Std. Deviation Min/Max 
LOS (days) 
 
1 20 6.3 7.07 1/32 
2 38 3.6 3.06 1/18 
Table	  27:	  Descriptive	  statistics	  of	  Length	  of	  Stay	  for	  group	  1	  and	  2	  participants,	  prospective	  study 
 
LOS was positively correlated with variable ‘copeptin’ in group 1 but not group 2 
participants (Pearson correlation 0.472, p<0.05).   
 
3.10.2	  Metabolic	  Outcomes	  
	  
Newly	  Diagnosed	  Diabetes	  Mellitus	  
As described in section 3.1.2, one participant was withdrawn from the study during the 
screening process. The reason for withdrawal was a new diagnosis of T2DM (RPG of 
11.2mmol/L, HbA1c 51mmol/mol and symptoms of DM). Procedures outlined in section 
2.1.10 were followed. 
 
Metabolic Abnormalities: Introduction 
The term ‘metabolic abnormalities’ is used by the investigator to describe a number of related 
disorders. Table	   28 summarises the diagnostic criteria for these disorders, the majority of 
which did not necessitate participant withdrawal. Disorders ‘IFG’, ‘IGT’ and ‘high risk for 
diabetes’ may also be summarised as ‘Impaired Glucose Regulation’ or IGR (see section 6.3). 
During the course of the study it became apparent that, due to the study design, rapid patient 
turnover in the recruitment setting and the timing of pathology results, a new category would 
have to be added to  ‘metabolic abnormalities’. This category was entitled ‘biochemical 
features of DM’ by the investigator and is used to describe participants in whom 1 
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biochemical value met the diagnostic criteria for DM but, for a number of reasons, it was not 
possible to assess for symptoms of DM/request a second test and formally diagnose DM. As 
per participants diagnosed with DM, a letter was sent to their GPs advising further follow-up 
(section 2.1.10). 
 
Metabolic Abnormality Diagnostic Criteria 
Diabetes Mellitus (DM) Diabetes symptoms plus: 
 
• RPG ≥ 11.1 mmol/l or FPG ≥ 7.0 mmol/l  
• or 2hr plasma glucose concentration ≥ 11.1 mmol/l 
after 75g oral glucose load 
 
In the absence of symptoms, at least one additional glucose test 
result on another day, with a value in the diabetic range, is 
required for diagnosis. (WHO/IDF, 2006), (Diabetes UK) 
 
Biochemical features of DM (BFD) Single biochemical value fulfilling the diagnostic criteria for 
DM but, due to study design/recruitment setting, a formal 
diagnosis of DM not made (defined by the study team) 
  
Impaired Fasting Glucose (IFG) Fasting Plasma Glucose (FPG) between 6.1-6.9mmol/L 
(WHO/IDF, 2006) 
Impaired Glucose Tolerance (IGT) FPG <7.0mmol/L and 2hr venous plasma glucose (after 
ingestion of 75g oral glucose load) 7.8-11.1mmol/L (NICE 
2012, WHO/IDF, 2006)  
High Risk for Diabetes (HRD) HbA1c 42-47 mmol/mol (NICE 2012) 
Impaired Glucose Regulation (IGR) Term encompassing IFG, IGT and HRD (NICE 2012) 
Table	  28:	  Diagnostic	  criteria	  for	  metabolic	  abnormalities	  detected	  in	  the	  prospective	  and	  metformin	  studies.	  
 
Impaired Glucose Tolerance (IGT) 
Considering the definitions in Table	  28, one participant was diagnosed with IGT during study 
follow-up (Table	  29): 
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Variable Value 
 
Patient ID & Study Group 
 
011, Group 1 
Admission RPG (mmol/L) 8.9 
Admission FPG (mmol/L) 4.9 
OGTT Glucose 0/2hr (mmol/L) 5.4/10.0 
Admission HbA1c (mmol/mol) 39 
HOMA2 IR 1.0 
Table	  29:	  Random	  plasma	  glucose,	  fasting	  plasma	  glucose,	  OGTT,	  HbA1c	  and	  HOMA2	  values	  for	  participant	  011	  
diagnosed	  with	  IGT	  during	  prospective	  study	  follow-­‐up	  
 
Impaired Fasting Glycaemia (IFG) 
Eight patients were diagnosed with Impaired Fasting Glycaemia (IFG) during the course of 
the study. Notable variables are described in Table	  30. 
Variable Value 
Study Group distribution (group 1/2) 2/6 
Mean Admission RPG (mmol/L) 7.1 
Min/Max RPG (mmol/L) 6.1/6.7 
Mean Diagnostic FPG (mmol/L) 6.3 
Mean Admission HbA1c (mmol/mol) 39 
Min/Max HbA1c (mmol/mol) 33/45 
Mean HOMA2 IR (n=7) 2.8 
Min/Max HOMA2 IR 0.7/6.8 
Table	  30:	   Study	  group,	  random	  and	  fasting	  plasma	  glucose,	  HbA1c,	  HOMA2-­‐IR	  (mean/min/max)	  values	  for	  n=8	  
prospective	  study	  participants	  diagnosed	  with	  Impaired	  Fasting	  Glycaemia	  (IFG)	  
 
OGTT results were only available for 1 participant with IFG (0hr: 6.1 mmol/L, 2hr: 
6.2mmol/L) as some participants with IFG were from group 2 (no study follow-up/OGTT) 
and 1 participant from group 1 declined follow-up. GPs were advised that all participants 
diagnosed with IFG using FPG should have an OGTT to determine glucose tolerance status 
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(WHO/IDF, 2006). Three participants with IFG (054,056 and 059) consented to wear a 
CGMS -their detailed profiles are illustrated in section 4.3. 
 
High risk for Diabetes Mellitus 
The mean HbA1c for all participants was 40mmol/mol. Twelve participants were highlighted 
as ‘high risk for DM’ (Table	  28). Notable variables are summarised in Table	  31. 
Variable Value 
Study Group distribution (group 1/2) 6/6 
Mean Admission RPG (mmol/L) 7.0 
Min/Max RPG (mmol/L) 
 
4.6/10.7 
Mean Admission FPG (mmol/L) 5.5 (n=9) 
Min/Max FPG (mmol/L) 
 
4.9/6.0 
Mean Admission HbA1c (mmol/mol) 43 
Min/Max HbA1c (mmol/mol) 
 
42/45 
Mean HOMA2-IR 1.0 (n=8) 
Min/Max HOMA2-IR 0.5/1.5 
Table	  31:	  Study	  group,	  random	  and	  fasting	  plasma	  glucose,	  HbA1c,	  HOMA2IR	  (mean/min/max)	  values	  for	  12	  prospective	  
study	  participants	  considered	  to	  be	  at	  high	  risk	  for	  Diabetes	  Mellitus	  based	  on	  HbA1c	  values 
 
OGTT results were available for 3 participants highlighted as ‘high risk for DM’. Mean 
glucose values for these patients were: 
• 0hr: 4.9 mmol/L 
• 2hr: 4.7 mmol/L 
Two participants at high risk for diabetes (057 and 063) consented to wear a CGMS. These 
detailed profiles are illustrated in section 4.3. 
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Biochemical Features of DM 
Four participants displayed ‘biochemical features of DM’ (Table	  28). The characteristics of 
these participants are outlined in tables 32-35 with the variable suggestive of DM highlighted 
in bold font. Of note, participant 041 had pre-existing IGT. Participant 023 was defined as 
having ‘biochemical features of DM’ due to a HbA1c value of 51 mmol/mol which although 
meets the diagnostic criteria for DM (WHO, 2011), should not, according to UK guidance, be 
used solely for the diagnosis of DM in the acute setting (see section 6.4).  
 
In addition, one participant (061) displayed SG readings of >20mmol/L on CGM (see section 
4.3.2). This participant’s biochemical characteristics are summarised in table 57 but are not 
further included within this section. Procedures for participants with ‘newly diagnosed 
diabetes mellitus’ were followed (see section 2.1.10).   
 
Variable Value 
Study Group 1 
Age (years) 53 
Gender Female 
Ethnicity Black 
Weight (kg) 74.1 
BMI (kg/m2) 28.9 
Waist circumference (cm) 102 
Neck circumference (cm) 35.5 
Epworth score 1 
Admission RPG (mmol/L) 8.1 
Admission FPG (mmol/L) 5.9 
OGTT 0/2hr glucose (mmol/L) 10.2/6.7 
Admission HbA1c (mmol/mol) 44 
Admission HOMA2-IR 1.3 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  32:	  Demographic,	  clinical	  and	  biochemical	  features	  of	  participant	  002R	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Variable Value 
Study Group 2 
Age (years) 46 
Gender Male 
Ethnicity White British 
Weight (kg) 90.0 
BMI (kg/m2) 29.7 
Waist circumference (cm) 99 
Neck circumference (cm) 39 
Epworth score 4 
Admission RPG (mmol/L) 4.6 
Admission FPG (mmol/L) 7.9 
OGTT 0/2hr glucose (mmol/L) N/a 
Admission HbA1c (mmol/mol) 42 
Admission HOMA2-IR 1.2 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  33:	  Demographic,	  clinical	  and	  biochemical	  features	  of	  participant	  007	  	  
 
 
Variable Value 
Study Group 2 
Age (years) 58 
Gender Female 
Ethnicity Black/Black British 
Weight (kg) 84.6 
BMI (kg/m2) 33.0 
Waist circumference (cm) Not taken 
Neck circumference (cm) Not taken 
Epworth score 10 
Admission RPG (mmol/L) 4.9 
Admission FPG (mmol/L) 4.5 
OGTT 0/2hr glucose (mmol/L) N/a 
Admission HbA1c (mmol/mol) 51 
Admission HOMA2-IR 0.9 
                        Table	  34:	  Demographic,	  clinical	  and	  biochemical	  features	  of	  participant	  023	  
 
Variable Value 
Study Group 1 
Age (years) 81 
Gender Male 
Ethnicity White British 
Weight (kg) 74.3 
BMI (kg/m2) 30.9 
Waist circumference (cm) 104 
Neck circumference (cm) 45 
Epworth score 5 
Admission RPG (mmol/L) 7.9 
Admission FPG (mmol/L) 8.0 
OGTT 0/2hr glucose (mmol/L) 6.1/11 
Admission HbA1c (mmol/mol) 52 
Admission HOMA2-IR 1.0 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  35:	  	  Demographic,	  clinical	  and	  biochemical	  features	  of	  participant	  041	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Metabolic Abnormalities: Summary 
A total n=11 participants from group 1 and n=14 participants from group 2 were diagnosed 
with metabolic abnormalities giving a prevalence of 40% for all recruited prospective study 
participants. (Table	  36). IGR (encompassing IFG, IGT, HRD) was diagnosed in 34% (n=21) 
of all participants. Individuals 024 and 042 had an HbA1c value which fell in the ‘high risk 
for DM’ category but, as they were formally diagnosed with IFG, they were only included in 
the latter category.  
Fifty two percent of participants with metabolic abnormalities were steroid-treated 
(oral/topical/inhaled) at the time of study entry. Table	  37 displays the metabolic profile and 
other selected variables in participants with and without MA. It should be noted that 
metabolic outcomes in group 1 and 2 are not directly comparable as only group 1 had a study 
follow-up phase. 
 
Diagnosis Group 1 (n=21) Group 2 (n=41) 
IGT 1 0 
IFG 2 6 
High risk for DM 6 6 
Biochemical Features of DM 2 2 
TOTAL (% of study group) 11 (52%) 14 (34%) 
Table	  36:	  Numbers	  and	  proportions	  of	  participants	  diagnosed	  with	  IGT,	  IFG,	  ‘high	  risk	  for	  DM’	  and	  with	  ‘biochemical	  
features	  of	  DM’	  from	  study	  group	  1	  and	  2	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Table	  37:	  Mean	  values	  for	  metabolic	  profile	  measures	  (in	  bold)	  and	  selected	  variables	  in	  participants	  with	  and	  without	  
Metabolic	  Abnormalities	  (MA),	  prospective	  study	  
 
An independent samples t-test demonstrated statistically significant differences between BMI 
(p<0.05) and waist circumference (p<0.01) in participants with and without metabolic 
abnormalities.	  There were no statistical differences between the groups with regards copeptin, 
BP, Epworth score and CRP. Due to data distribution, BNP and lactate values were assessed 
using the nonparametric Mann-Whitney test. Again there was no statistically significant 
 Group ‘MA’ (n=25) Group  ‘no MA’ (n=37) 
Age (mean, years) 68 68 
Gender (% male) 64% 57% 
BMI (mean, kg/m2) 28.6 (n=24) 24.8 (n=35) 
Waist circumference (mean, cm) 106.9 (n=22) 97.9 (n=33) 
SBP (mean, mmHg) 131 (n=24) 129 
DBP (mean, mmHg) 74 (n=24) 73 
Epworth score (mean) 4 5 
Copeptin (mean,) 16.9 (n=18) 11.8 (n=28) 
HbA1c (mean, mmol/mol) 42 (n=23) 38 (n=30) 
Morning Cortisol (mean, nmol/L) 415 (n=19) 399 (n=25) 
HOMA2-IR (mean) 1.7 (n=19) 1.1 (n=18) 
LOS (mean, days) 4 (n=24) 5 (n=34) 
BNP (pg/mL) 176 (n=21) 97.7 (n=34) 
CRP (mg/L) 63 (n=25) 82 (n=37) 
Lactate (mmol/L) 1.25 (n=23) 1.42 (n=35) 
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difference between the groups for these 2 variables. Variables ‘HbA1c’, ‘cortisol’, ‘HOMA2-
IR’ and ‘LOS’ were not tested. 
Finally, half of the participants who wore a CGM (n=6) were diagnosed with a metabolic 
abnormality during the course of the study. No statistically significant differences were found 
in glycaemic variability between the groups with and without metabolic abnormalities (total 
n=12, Appendix 5).	  
 
Type 2 Diabetes Risk 
Using the GUARD Type 2 Diabetes Risk Calculator, the 3 year risk of developing Type 2 
Diabetes was calculated at a mean score of 5.4% for group 1 participants (n=19) and 1.7% for 
group 2 participants (n=31). Not all participants were included in this calculation as a number 
(n=12) had an age/admission glucose that fell outside of the calculator range. A GUARD 
score of 5% and over broadly corresponds to a ‘high risk’ category as described by NICE. 
Table	  38 summarises the metabolic profile of participants with a GUARD score < and ≥ 5% 
as well as neck circumference, fasting insulin and HbA1c values. All Participants with a 
GUARD score ≥5% were from group 1. 
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Variable 
 
GUARD <5% 
 
GUARD ≥5% 
Mean BMI (kg/m2) 26.4 25.8 
Mean SBP (mmHg) 131 124 
Mean DBP (mmHg) 74 74 
Mean Waist circumference (cm) 100.9 104.9 
Mean Neck circumference (cm) 39.1 41.1 
Mean Epworth Score 5 7 
Mean HbA1c (mmol/mol) 40 40 
Mean Fasting Insulin (mIU/L) 12.8 7.1 
Table	  38:	  ‘Metabolic	  profile’,	  neck	  circumference,	  HbA1c	  and	  fasting	  insulin	  of	  participants	  with	  a	  GUARD	  score	  	  
<	  and	  ≥	  5%,	  prospective	  study	  
 
	  
3.10.3	  Group	  1	  Study	  Follow-­‐up	  	  
As described in section 3.1.2, n=10 participants from group 1 attended visit 1, whilst n=11 
were lost to follow-up. The mean duration from discharge to visit 1 was 115 days (min 94, 
max 190 days).  
Tables in Appendix 4 display selected baseline and follow-up study variables for participants 
with a full data set. ‘Baseline’ refers to variables measured during hospital admission and 
‘f/up’ refers to variables measured at visit 1.	  	  
Table	  39	  summarises all ‘paired’ variables with values available at baseline and visit 1. A 
paired samples t-test did not demonstrate a statistically significant difference between 
baseline and visit 1 variables (Table	  40). 
Notably, given that an OGTT was performed at visit 1, a RPG could not be checked at this 
visit and is only available for the baseline visit. 
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Table	  39:	  Baseline	  and	  visit	  1	  variables	  for	  group	  1	  participants	  attending	  follow-­‐up,	  prospective	  study	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
 
Variable Study Point N Mean SD 
Weight (kg) Baseline 
 
10 84.6 13.03 
Visit 1 
 
10 86.1 14.52 
FPG (mmol/L) Baseline 
 
8 5.7 0.99 
Visit 1 
 
8 5.9 1.86 
Fasting Insulin (mIU/L) 
 
Baseline 
 
8 6.9 1.88 
Visit 1 
 
8 11.0 10.12 
HbA1c (mmol/mol) 
 
 
Baseline 
 
10 41 4.85 
Visit 1 
 
10 38 3.35 
HOMA2-IR 
 
Baseline 
 
7 0.9 0.28 
Visit 1 7 1.4 1.37 
 
Copeptin (pmol/L) Baseline 10 9.28 6.87 
 
Visit 1 
 
10 7.56 4.78 
ProADM (nmol/L) Baseline 
 
10 1.05 0.47 
Visit 1 
 
10 0.79 0.32 
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Paired Differences 
t df 
Sig. (2-
tailed) Mean 
Std. 
Deviation 
 Weight (kg)                
 -1.56000 7.50840 -0.657 9 0.528 
 Fasting plasma glucose 
(mmol/L)                                                     
 
-.17500 1.87293 -0.264 7 0.799 
 Fasting insulin (mIU/L)                                                                      
 
 
-4.06250 9.57168 -1.200 7 0.269 
 HbA1c (mmol/mol)  
 3.10000 4.70106 2.085 9 0.067 
 HOMA2-IR 
 -0.48571 1.31584 -0.977 6 0.366 
 Copeptin (pmol/L)  
 1.72100 4.72306 1.152 9 0.279 
 Pro-ADM                                                              0.26100 .38757 2.130 9 0.062 
Table	  40:	  Paired	  samples	  t-­‐test	  for	  paired	  baseline	  and	  visit	  1	  variables,	  group	  1	  participants	  
	  *	  statistically	  significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	  
	  
	  
	  
3.11 Summary of Chapter 3 
	  
• The prevalence of SH was 34% in the recruited prospective study population. 
• Participants from study group 1 and 2 were similar in terms of age, gender, and 
ethnicity.  
• The most frequently occurring primary diagnosis within both study groups was 
‘respiratory disease’ 
• Mean values of the metabolic profile (including BMI, waist circumference, BP 
and Epworth score, copeptin variables) were not statistically significantly 
different between group 1 and 2 participants (hypotheses 1-5). Proportions of 
participants treated with anti-hypertensives were similar in group 1 and 2 
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• Despite this, group 1 did have a lower variance in copeptin compared to group 2 
participants (p≤0.01)   
• Group 1 and 2 contained similar proportions of participants with a positive family 
history of DM. There appeared to be a higher proportion of people with a PMH of 
hypertension in group 1 compared to group 2 
• Although only a estimate, similar proportions of participants from group 1 and 2 met 
the IDF diagnostic criteria for metabolic syndrome 
• The mean baseline RPG was 6.7mmol/L for all prospective study participants: 
8.4mmol/L in group 1 and 5.8mmol/L in group 2 participants 
• Mean RPG values were not statistically significantly different across different 
diagnostic categories of group 1 participants  
• The mean FPG values for group 1 and 2 participants were 5.4 and 5.5 mmol/L 
respectively. One-way ANOVA testing did not demonstrate a statistically significant 
difference in the FPG of participants from group 1 and 2 or the FPG and RPG of 
participants from group 2. RPG was (statistically significantly) higher than FPG in 
group 1 participants 
• Similar proportions of participants from group 1 and 2 were steroid treated at the time 
of study entry (48% and 45% respectively). Fifty two percent of participants 
diagnosed with metabolic abnormalities during the study were steroid-treated at the 
time of study entry. 
• There were no statistically significant differences in the BIVA-related hydration and 
nutrition scores between participants in group 1 and 2 
• There were no statistically significant differences in the HAD scores between 
participants in group 1 and 2 
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• CEWS score was low (0) in most participants. Participants from group 1 did not have 
significantly higher CEWS scores compared to participants in group 2. 
• Group 1 participants had lower mean ketone values (p ≤0.05) as well as lower 
variance in ketone values (p≤0.01) compared to group 2 participants. A greater 
proportion of group 2 participants also had a ‘cachectic’ body type (61% compared to 
25% in group 1). 
• Group 1 participants had lower mean 25-OH-Vitamin D values compared to group 2. 
Of note, numbers analysed were small (whole group n=13) 
• No statistically significant differences were found between mean HbA1c or cortisol 
values for group 1 and 2 participants. 
• A number of correlations were observed between biomarkers and other variables. Of 
note, in all participants (group 1 and 2 combined), a statistically significant positive 
correlation was noted between fasting insulin and copeptin (p<0.05) 
• A highly significant positive correlation was noted between proADM and Copeptin 
for all participants (p<0.000) 
• Copeptin was noted to be positively correlated with length of stay for group 1 but not 
group 2 participants 
• An independent samples t-test did not show a statistically significant difference in 
length of stay between group 1 and 2 participants 
• Although not strictly comparable, it is of interest to note that 52% of group 1 
participants and 34% of group 2 participants (40% of all recruited participants) were 
diagnosed with metabolic abnormalities (including IGT, IFG, high risk for DM and 
biochemical features of DM) during the course of the study 
• The 3-year risk of developing T2DM was calculated (using the GUARD calculator) at 
5.4% for group 1 participants (n=19) and 1.7% for group 2 participants (n=31). 
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• There was no statistically significant difference in GV between participants who wore 
a CGM and were diagnosed with MA (n=6) compared to participants who wore a 
CGM and were not diagnosed with MA (n=6) 
• There was no statistically significant difference between a number of variables, 
including copeptin, in participants with and without MA 
• A paired samples t-test did not demonstrate a statistically significant difference 
between baseline and visit 1 variables (including HbA1c and HOMA2-IR) for group 1 
participants attending study follow-up 
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Chapter	  4:	  Prospective	  Study	  Results,	  Part	  2	  
	  
4.1 Introduction 
4.1.1	  Study	  Measures	  
As described in section 2.1.20, an exploratory hypothesis relating to associations between 
glycaemic variability and insulin resistance was initially considered. Despite the challenges 
encountered and subsequent shift in focus, it was decided that the emerging data would make 
a substantial contribution to the field of study and thereby justified ongoing recruitment. The 
following sections provide a brief introduction into insulin resistance and glycaemic 
variability in SH. Methodology is described in sections 2.1.9 and 2.1.11 and further 
discussion is continued in sections 6.6 and 6.8.	  	  
	  
Insulin levels (and resistance) in people with SH (section 4.2):  
The central role of IR in SH is introduced in section 1.2.  To our knowledge, however, this is 
the first study to compare IR in SH with that of a ‘normoglycaemic’, non-critically unwell 
population. The comparison is useful as any differences could predict future glucose 
intolerance (question 3, section 1.4); adverse outcomes (Das et al., 2009) and guide therapy 
(question 5, section 1.4). Insulin resistance in SH is discussed in more detail in section 6.8. 
 
Glycaemic variability in people with SH (section 4.3):  
Glycaemic variability, which may be defined as ‘excursions of blood glucose around the 
mean’ (Archer, Misra, Simmgen, Jones, & Baker, 2011), is estimated by computing 
characteristic indices from glucose profiles (Louis Monnier, Colette, & Owens, 2008) and is 
an emerging research interest. It has been identified as an independent predictor of mortality 
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in critically ill patients, (M Egi, Bellomo, Stachowski, French, & Hart, 2006; Krinsley, 2008) 
as well as those with heart failure (Dungan, Braithwaite, & Preiser, 2009) and sepsis (Ali et 
al., 2008) and has therefore been proposed as a confounder, correlating with both glucose 
levels and mortality. Such a confounder may explain the trial result variability described in 
section 1.1.4 and 1.1.5.  
In vitro, increased GV has been linked to an increased production of reactive oxygen species 
and a detrimental effect on endothelial function (Kilpatrick, Rigby, & Atkin, 2010). This has 
led some investigators to examine GV in the context of micro-vascular complications (Bragd 
et al., 2008; Nalysnyk, Hernandez-Medina, & Krishnarajah, 2010) (DM) and endothelial 
dysfunction (metabolic syndrome) (Buscemi et al., 2009). These associations, although 
demonstrated in some studies, remain controversial.   
GV has not been examined in all-comers in the acute care setting and could, in this context, 
advance understanding of the differences between people with and without SH as well as 
guide treatment. GV was examined in a small number of participants who consented to wear 
a CGM (see section 2.1.9). Associations with outcomes (LOS), metabolic abnormalities and 
any differences between participants in group 1 and 2 were noted. GV was also compared 
between this group and a separate, metformin-treated population (see section 5.7). 
The CGM provided a unique opportunity to appreciate detailed fluctuations in blood glucose 
levels. The iPro2 model provided a maximum of 288 plasma glucose values in 24 hours, 
allowing the construction of detailed sensor glucose profiles for individual participants 
(section 4.3.2 and 4.3.2).  
As both glycaemic variability and insulin resistance have been associated with adverse 
outcomes, it is worth considering whether IR is independently associated with GV – a 
scientifically plausible explanation. Only a small number of participants had data available 
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4.2 Insulin and HOMA2 Values  
	  
4.2.1	  Fasting	  Insulin	  
	  
Fasting insulin levels were checked on the morning after study entry (Table	  41,	  Figure	  27). An 
independent samples t-test demonstrated a highly statistically significant difference in 
variance and a statistically significant difference in mean fasting insulin values between 
participants in group 1 and 2 (Table	  42). 
	  
 
	  
Figure	  27:	  Fasting	  insulin	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study	  (n=45)	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                                          Study Group N Mean Std. Deviation Min/Max 
Fasting insulin (mIU/L) 1 16 5.76 2.32 1.1/9.3 
2 29 15.33 20.15 1.3/82.0 
Table	  41:	  Descriptive	  statistics	  of	  fasting	  insulin	  values	  for	  group	  1	  and	  2	  participants,	  prospective	  study	  
	  
	  
 
                    Equal Variances Assumed 
Levene's Test for Equality of 
Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) 
Fasting insulin 
(mIU/L) 
 
Yes        11.862 0.001** -1.884 43 0.066 
No   -2.528 29.331   0.017* 
Table	  42:	  Independent	  samples	  t-­‐test	  of	  fasting	  insulin	  values,	  group	  1	  and	  2	  participants	  (prospective	  study)	  	  
*	  Statistically	  significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	  
 
Figure	  28 and Figure	  29 display fasting insulin against RPG and FPG values in study group 1 
and 2. They demonstrate lower fasting insulin values in study group 1 participants and clear 
separation between FPG and RPG values in study group 1 as described in section 3.4. 
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Figure	  28:	  Study	  Group	  1	  –	  Random	  and	  Fasting	  Plasma	  Glucose	  compared	  to	  fasting	  insulin,	  prospective	  study	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Figure	  29:	  Study	  Group	  2	  –	  Random	  and	  Fasting	  Plasma	  Glucose	  compared	  to	  fasting	  insulin	  
	  
	  
4.2.2	  C-­‐Peptide	  
Local permissions were granted to measure (fasting) C-peptide values in all participants who 
wore a CGMS (see section 2.1.9).  Results were available for 11 out of 12 participants. Table	  
43 describes the values obtained and Figure	  30 displays them. 
                              Study Group N Mean SD Min/Max 
C-peptide (pmol/L) 1 5 752.60 246.66 394/986 
2 6 1070.8 368.36 457/1513 
Table	  43:	  Descriptive	  statistics	  of	  C-­‐peptide	  values	  for	  group	  1	  and	  2	  participants,	  prospective	  study	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Figure	  30:	  C-­‐Peptide	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study,	  n=11 
	  
	  
4.2.3	  HOMA2	  
As described in more detail within section 2.1.11, HOMA2 values (%B, %S and IR) were 
calculated electronically by using fasting insulin and glucose samples obtained from 
participants on the morning after study entry. These values are displayed in Table	  44. Figures 
displayed demonstrate a clear difference in HOMA2-IR (Figure	  31), %B (Figure	  32) and %S 
(Figure	  33) values between group 1 and 2 participants. HOMA 2 could not be calculated in 6 
participants whose fasting insulin levels which were out of range of the calculator (2.9-57.6 
µU/ml). 
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Study Group N Min Max Mean SD 
1 HOMA2-IR 13 0.5 1.3 0.854 0.24 
%B  13 36.0 101.7 70.631 19.35 
%S  13 79.7 212.1 127.800 39.10 
      
2 HOMA2-IR 24 0.5 6.8 1.650 1.70 
%B  24 40.5 228.5 96.417 43.13 
%S  24 14.8 194.3 97.267 48.34 
      
 
Table	  44:	  Descriptive	  statistics	  of	  HOMA2,	  %B	  and	  %S	  for	  group	  1	  and	  2	  participants,	  prospective	  study	  
	  
	  
Figure	  31:	  HOMA2-­‐IR	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study	  (n=37) 
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Figure	  32:	  HOMA2	  %B	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study	  (n=37) 
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Figure	  33:	  HOMA	  2	  	  %S	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study	  (n=37) 
 
An independent samples t-test demonstrated a statistically significant difference between the 
mean and variance of HOMA2-IR values of group 1 and 2 participants. A difference was also 
found between the mean %B value for group 1 and 2 participants. No statistically significant 
differences were found between the mean %S values (Table	  45). 
 
                           Equal Variances Assumed 
Levene's Test for 
Equality of Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) 
HOMA 
2-IR 
              Yes 6.976 0.012* -1.667 35 0.105 
               No   -2.250 24.658 0.034* 
%B                Yes 1.313 0.260 -2.037 35 0.049 
               No   -2.501 34.215 0.017* 
%S                Yes 0.256 0.616 1.954 35 0.059 
               No   2.082 29.532 0.046 
Table	  45:	  Independent	  samples	  t-­‐test	  of	  HOMA2,	  %B	  and	  %S,	  group	  1	  and	  2	  participants	  (prospective	  study)	  
*	  statistically	  significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	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HOMA2 values were correlated with various variables as displayed in Table	  46. 
Variable 1 
  
Variable 2 Pearson Correlation Sig. (2-tailed) N 
HOMA2 %B Waist circumference (cm) 
 
0.534** 0.001 35 
ProADM (nmol/L) 
 
-0.335* 
 
0.045 36 
HOMA2 %S BNP (pg/mL) 
 
0.361* 0.033 35 
Table	  46:	  Pearson	  correlations	  between	  HOMA2	  values	  and	  other	  variables	  for	  all	  prospective	  study	  participants	  (groups	  
1	  and	  2	  combined)	  *	  statistically	  significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	  
	  
Figure	  34 demonstrates that there is no clear association between HOMA2 and RPG in either 
study group. HOMA2 was also not significantly correlated with LOS. 
 
 
Figure	  34:	  HOMA2	  and	  random	  plasma	  glucose	  values	  in	  group	  1	  and	  2	  participants,	  prospective	  study 
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4.3 Glycaemic Variability 
 
4.3.1	  CGMS	  Introduction	  
 
A total of n=2396 SG values were recorded across all 12 participants: 1051 in group 1 and 
1345 in group 2 participants. Table	   47 contains a summary of valid and missing sensor 
readings for all participants in groups 1 and 2 based on the duration of time the CGMS was 
worn. ‘Missing’ values refer to time slots recorded on the CGMS without a corresponding SG 
level. Sensor Glucose (SG) values of participants are profiled in more detail in sections 4.3.2 
and 4.3.3.  
 
 
 
                                           Study Group 
SG Values 
Valid Missing Total 
N % N % N % 
Sensor Glucose (mmol/L) Group 1 1051 56% 811 44% 1862 100% 
Group 2 1345 44% 1691 56% 3036 100% 
Table	  47:	  Summary	  of	  valid	  and	  missing	  sensor	  readings,	  group	  1	  and	  2	  participants,	  prospective	  study 
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4.3.2	  CGMS	  Profiles	  for	  Group	  1	  	  
Participant 40 
	  
Figure	  35:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  40	  
CGMS readings  Participant Features 
 
N valid 275 Participant ID 40 
N missing 181 Study Group 1 
CGMS mean 7.7 RPG (mmol/L) 7.6 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 33 
Median 7.4 HOMA2-IR 0.8 
Std. Deviation 1.7 LOS (days) 15 
Minimum 5.4 
Maximum 12.8 
% ≥7.1mmol/L* 63.2 
%  ≥11.1mmol/L** 3.6 
 
Table	  48:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  40	  	  	  
* % of valid readings ≥ 7.1mmol/L (7.1-max inclusive) ** % of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 41 
 
 
	  
Figure	  36:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  41 
CGMS readings  Participant Features 
 
N valid 150 Participant ID 41 
N missing 87 Study Group 1 
CGMS mean 7.0 RPG (mmol/L) 7.9 
Std. Error of Mean 0.2 HbA1c (mmol/mol) 52 
Median 7.1 HOMA2-IR 1.0 
Std. Deviation 2.1 LOS (days) 3 
Minimum 4.3 
Maximum 11.8 
% ≥7.1mmol/L* 50.7 
%  ≥11.1mmol/L** 4.0 
	  
Table	  49:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  41  
*% of valid readings ≥7.1mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 55 
 
 
	  
Figure	  37:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  55 
CGMS readings  Participant Features 
 
N valid 212 Participant ID 55 
N missing 288 Study Group 1 
CGMS mean 6.0 RPG (mmol/L) 7.6 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 36 
Median 5.8 HOMA2-IR 0.5 
Std. Deviation 1.0 LOS (days) 6 
Minimum 4.3 
Maximum 8.1 
% ≥7.1mmol/L* 18.9 
%  ≥11.1mmol/L** 0 
 
Table	  50:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  55.	    
*% of valid readings ≥7.1mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
 
 
 
	  	  	  	  	  	  	  141	  
	  
Participant 57 
 
 
	  
Figure	  38:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  57 
CGMS readings  Participant Features 
 
N valid 137 Participant ID 57 
N missing 192 Study Group 1 
CGMS mean 5.3 RPG (mmol/L) 9.5 
Std. Error of Mean 0.0 HbA1c (mmol/mol) 42 
Median 5.2 HOMA2-IR Not available 
Std. Deviation 0.3 LOS (days) 1 
Minimum 4.7 
Maximum 6.2 
% ≥7.1 mmol/L* 0 
%  ≥11.1mmol/L** 0 
	  
Table	  51:	  	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  57 
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 60 
 
 
	  
Figure	  39:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  60 
CGMS readings  Participant Features 
 
N valid 277 Participant ID 60 
N missing 63 Study Group 1 
CGMS mean 6.5 RPG (mmol/L) 9.5 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 36 
Median 6.6 HOMA2-IR Not available 
Std. Deviation 1.9 LOS (days) 12 
Minimum 3.9 
Maximum 11.0 
% ≥7.1mmol/L* 37.9 
%  ≥11.1mmol/L** 0 
	  
Table	  52:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  60 
*% of valid readings ≥7.1mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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4.3.3	  CGMS	  Profiles	  for	  Group	  2	  
Participant 54 
 
 
	  
Figure	  40:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  54 
CGMS readings  Participant Features 
 
N valid 255 Participant ID 54 
N missing 81 Study Group 2 
CGMS mean 5.4 RPG (mmol/L) 6.0 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 38 
Median 4.9 HOMA2-IR 0.5 
Std. Deviation 1.9 LOS (days) 18 
Minimum 2.7 
Maximum 9.1 
% ≥7.1 mmol/L* 26.3 
%  ≥11.1mmol/L** 0 
	  
Table	  53:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  54 
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 56 
 
 
Figure	  41:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  56 
 
CGMS readings  Participant Features 
 
N valid 132 Participant ID 56 
N missing 278 Study Group 2 
CGMS mean 5.3 RPG (mmol/L) 6.1 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 33 
Median 4.6 HOMA2-IR 2.8 
Std. Deviation 1.5 LOS (days) 2 
Minimum 3.4 
Maximum 8.1 
% ≥7.1 mmol/L* 14.4 
%  ≥11.1mmol/L** 0 
	  
Table	  54:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  56 
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 58 
 
 
 
Figure	  42:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  58 
 
CGMS readings  Participant Features 
 
N valid 47 Participant ID 58 
N missing 861 Study Group 2 
CGMS mean 11.0 RPG (mmol/L) 5.6 
Std. Error of Mean 0.3 HbA1c (mmol/mol) 41 
Median 11.3 HOMA2 0.9 
Std. Deviation 2.4 LOS (days) 3 
Minimum 6.1 
Maximum 15.7 
% ≥7.1 mmol/L* 95.8 
%  ≥11.1mmol/L** 51.1 
	  
Table	  55:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  58  
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 59 
 
 
 
Figure	  43:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  59 
CGMS readings  Participant Features 
 
N valid 220 Participant ID 59 
N missing 187 Study Group 2 
CGMS mean 7.2 RPG (mmol/L) 6.5 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 41 
Median 6.7 HOMA2-IR Not available 
Std. Deviation 1.8 LOS (days) 1 
Minimum 4.4 
Maximum 11.2 
% ≥7.1 mmol/L* 43.6 
%  ≥11.1mmol/L** 0.9 
	  
Table	  56:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  59  
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
 
 
 
 
	  	  	  	  	  	  	  147	  
	  
Participant 61 
 
 
 
 
Figure	  44:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  61 
CGMS readings  Participant Features 
 
N valid 245 Participant ID 61 
N missing 80 Study Group 2 
CGMS mean 10.7 RPG (mmol/L) 6.3 
Std. Error of Mean 0.3 HbA1c (mmol/mol) 40 
Median 10.3 HOMA2-IR 1.1 
Std. Deviation 4.2 LOS (days) 3 
Minimum 5.4 
Maximum 22.2 
% ≥7.1 mmol/L* 74.7 
%  ≥11.1mmol/L** 45.3 
 
Table	  57:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  61 
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 63 
 
 
Figure	  45:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  63 
CGMS readings  Participant Features 
 
N valid 237 Participant ID 63 
N missing 81 Study Group 2 
CGMS mean 6.8 RPG (mmol/L) 4.6 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 44 
Median 6.7 HOMA2-IR 1.5 
Std. Deviation 2.1 LOS (days) 4 
Minimum 3.3 
Maximum 12.6 
% ≥7.1 mmol/L* 38.8 
%  ≥11.1 mmol/L** 5.9 
	  
Table	  58:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  63 
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
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Participant 64 
 
 
Figure	  46:	  Frequency	  of	  each	  recorded	  sensor	  glucose	  value,	  participant	  64 
CGMS readings  Participant Features 
 
N valid 209 Participant ID 64 
N missing 123 Study Group 2 
CGMS mean 5.9 RPG (mmol/L) 6.8 
Std. Error of Mean 0.1 HbA1c (mmol/mol) 41 
Median 6.0 HOMA2-IR 0.9 
Std. Deviation 1.4 LOS (days) 5 
Minimum 2.2 
Maximum 8.9 
% ≥7.1mmol/L* 17.2 
%  ≥11.1mmol/L** 0 
 
Table	  59:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  and	  selected	  associated	  features	  for	  participant	  64 
*% of valid readings ≥7.1 mmol/L (7.1-max inclusive) ** %  of valid readings ≥11.1mmol/L (11.1-max inclusive) 
 
	  
	  
	  	  	  	  	  	  	  150	  
	  
	  
4.3.4	  Sensor	  Glucose	  Values	  ≥ 7.1	  mmol/L	  in	  Group	  1	  	  
 
Figures 47-50 illustrate the proportion of SG values ≥ 7.1mmol/L for each group 1 
participant. Participant 57 recorded 100% of values <7.1mmol/L and is not included in this 
section. 
 
 
    
Figure	  47:	  %	  of	  SG	  values	  ≥	  and	  <7.1mmol/L,	  participant	  40	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  48:	  %	  of	  SG	  values	  ≥	  and	  <	  7.1mmol/L,	  participant	  41 
 
   
Figure	  49:	  %	  of	  SG	  values	  ≥	  and	  <	  7.1mmol/L,	  participant	  55	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  50:	  %	  of	  SG	  values	  ≥	  and	  <	  7.1mmol/L,	  participant	  60	  	  	  	  	  	  
 
  	  
 
	   	  	  	   
 
 
%	  <7.1	  
%	  ≥	  7.1	  
	  	  	  ParZcipant	  40,	  Group	  1	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  41,	  Group	  1	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  55,	  Group	  1	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  60,	  Group	  1	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4.3.5	  Sensor	  Glucose	  Values	  ≥ 7.1	  mmol/L	  in	  Group	  2	   
Figures 51-57 illustrate the proportion of SG values ≥ 7.1 mmol/L for each group 2 
participant.  
 
    
Figure	  51:	  %	  of	  SG	  values	  ≥	  and	  <	  7.1mmol/L	  ,	  participant	  54               Figure	  52:	  %	  of	  SG	  values	  ≥	  and	  <	  7.1mmol/L,	  participant	  56       
 
	  	  	  	  	   	  
Figure	  53:	  %	  of	  SG	  values	  ≥	  and	  <7.1mmol/L,	  participant	  58	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Figure	  54:	  %	  of	  SG	  values	  ≥	  and	  <7.1mmol/L,	  participant	  59 
  	    
	  	  	  Figure	  55:	  %	  of	  SG	  values	  ≥	  and	  <7.1mmol/L,	  participant	  61              Figure	  56:	  %	  of	  SG	  values	  ≥	  and	  <7.1mmol/L,	  participant	  63       
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  54,	  Group	  2	   ParZcipant	  56,	  Group	  2	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  58,	  Group	  2	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  59,	  Group	  2	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  61,	  Group	  2	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  63,	  Group	  2	  
%	  <7.1	  
%	  ≥	  7.1	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Figure	  57:	  %	  of	  SG	  values	  ≥	  and	  <7.1mmol/L,	  participant	  64 
 
4.3.6	  Sensor	  Glucose	  Values	  ≥ 11.1	  mmol/L	  	  in	  Group	  1	  	  
Figures 58 and 59 illustrate the proportion of SG values ≥ 11.1mmol/L for each group 1 
participant. Participants 55, 57, and 60 recorded 0% of values ≥ 11.1mmol/L and are not 
included in this section. 
 
   
	  	  	  	  	  	  Figure	  58:	  %	  of	  SG	  values	  ≥	  and	  <	  11.1mmol/L,	  participant	  40          Figure	  59:	  %	  of	  SG	  values	  ≥	  and	  <11.1mmol/L,	  participant	  41       
	  
	  
4.3.7	  Sensor	  Glucose	  Values	  ≥ 11.1	  mmol/L	  	  in	  Group	  2	  
Figures 60-62 illustrate the proportion of SG values ≥ 11.1 mmol/L for each group 2 
participant.	  Participants 54, 56, 64 recorded 0% of values ≥ 11.1 mmol/L whilst participant 
59 recorded 0.9% of values ≥ 11.1 mmol/L. These participants are not included in this 
section.	  
ParZcipant	  64,	  Group	  2	  
%	  <7.1	  
%	  ≥	  7.1	  
ParZcipant	  40,	  Group	  1	  
%	  <11.1	  
%	  ≥	  11.1	  
ParZcipant	  41,	  Group	  1	  
%	  <11.1	  
%	  ≥	  11.1	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  Figure	  60:	  %	  of	  SG	  values	  ≥ and <	  11.1	  mmol/L,	  participant	  58	  	  	  	  	  	  	  	  	  	  	  	  Figure	  61:	  %	  of	  SG	  values	  ≥ and <11.1	  mmol/L,	  participant	  61           
 
 
Figure	  62:	  %	  of	  SG	  values	  ≥ and <	  11.1	  mmol/L,	  participant	  63                
 
 
	  
4.3.8	  Summary	  of	  CGMS	  Sensor	  Glucose	  (SG)	  Values	  	  
Appendix 2 contains descriptive statistics of SG values for each individual CGM participant. 
Of note, 5 participants (study numbers 054, 056, 060, 063, 064) recorded SG values of 
<4.0mmol/L. Table	  60 describes the SG values within selected ranges (study definition of SH, 
see section 2.1.8 and WHO biochemical definition of DM using RPG) for all CGMS 
participants.  Table	  61 displays this information by study group. 
 
 
ParZcipant	  58,	  Group	  2	  
%	  <11.1	  
%	  ≥	  11.1	  
ParZcipant	  61,	  Group	  2	  
%	  <11.1	  
%	  ≥	  11.1	  
ParZcipant	  63,	  Group	  2	  
%	  <11.1	  
%	  ≥	  11.1	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SG Range (mmol/L) 
 
 
 
    Number of SG values within range 
 
 
% of SG values within range 
 
< 7.1 
 
1463 61 
7.1-11.0 
 
766 32 
≥ 11.1 
 
167 7 
Table	  60:	  Frequency	  and	  Percentage	  of	  Sensor	  Glucose	  (SG)	  values	  within	  selected	  ranges,	  all	  CGMS	  participants,	  
prospective	  study	  
	  
	  
	  
SG	  Range	  
(mmol/L)	  
	  
Study	  Group	  
	  
Number	  of	  SG	  values	  within	  range	  
	  
%	  SG	  values	  within	  range	  
	  
	  
<	  7.1	  
	  
	  
	  
1	  
	  
656	  
	  
62	  
	  
2	  
	  
807	  
	  
60	  
	  
7.1-­‐	  11.0	  
	  
	  
	  
1	  
	  
379	  
	  
36	  
	  
2	  
	  
387	  
	  
29	  
	  
≥	  11.1	  
	  
	  
	  
1	  
	  
16	  
	  
2	  
	  
2	  
	  
151	  
	  
11	  
Table	  61:	  Frequency	  and	  percentage	  of	  Sensor	  Glucose	  (SG)	  values	  within	  selected	  ranges	  for	  group	  1	  and	  2	  CGMS	  
participants,	  prospective	  study	  
	  
Figure	  63 and Figure	  64 illustrate the frequency of SG readings at each SG value for each 
group 1 and 2 participant. Horizontal lines represent SG values of 7.1mmol/L (SH study 
definition 7.1-11.0mmol/L) and 11.1 mmol/L (WHO/IDF, 2006). Figure	  65 plots all group 1 
and 2 SG readings together. 
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Figure	  63:	  Frequency	  of	  SG	  readings	  at	  each	  SG	  value	  for	  all	  group	  1	  CGMS	  participants	  (n=5)	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Figure	  64:	  Frequency	  of	  SG	  readings	  at	  each	  SG	  value	  for	  all	  group	  2	  CGMS	  participants	  (n=7)	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Figure	  65:	  Sensor	  Glucose	  values	  for	  all	  group	  1	  and	  2	  CGMS	  participants,	  prospective	  study	  
 
Table	  62 summarises the mean, min/max and standard deviation of SG values for all CGM 
participants. As suggested in figures 63-65, an independent samples t test confirmed a highly 
statistically significant difference in the variance and mean of SG values between group 1 
and 2 participants  (Table	  63). 
 
                                                   Study Group N Mean Std. Deviation Min/Max 
Sensor Glucose (mmol/L) Group 1 1051 6.6 1.80 3.9/12.8 
Group 2 1345 7.2 3.14 2.2/22.2 
 
Table	  62:	  Descriptive	  statistics	  of	  sensor	  glucose	  values	  for	  group	  1	  and	  2	  CGMS	  participants 
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                           Equal variances assumed 
Levene's Test for 
Equality of Variances t-test 
F Sig. t df 
Sig. (2-
tailed) 
SG (mmol/L)             Yes 120.170 0.000** -4.942 2394 0.000** 
   
              No 
   
-5.258 
 
2211.142 
 
0.000** 
 
Table	  63:	  Independent	  samples	  t-­‐test	  for	  sensor	  glucose	  (SG)	  values,	  group	  1	  and	  2	  participants.	  	  
*	  statistically	  significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	  
 
 
One-way Analysis of Variance (one-way ANOVA) post-hoc tests were then performed to  
investigate SG differences between individual participants (from both study groups). 
Homogenous subsets contained a mix of group 1 and 2 participants. The participants with the 
highest mean SG values were from group 2 (Appendix 3).  
 
4.3.9	  Glycaemic	  Variability	  and	  Associations	  
As described in section 2.1.21, the Standard Deviation of SG values (SDSG) was used to 
describe Glycaemic Variability (GV) for each CGMS participant. The SDSG ranged from 
0.32 to 4.17 mmol/L for all CGM participants (n=12). Table	  64 contains this information by 
study group.  
Group Min/Max SDSG (mmol/L) N 
 
1 
   
  0.32/2.14 5 
 
2 
   
 1.36/4.17 7 
Table	  64:	  Descriptive	  statistics	  of	  the	  SDSG	  measure	  for	  Glycaemic	  Variability,	  group	  1	  and	  2	  CGMS	  participants 
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Using one-way ANOVA (see section 5.7), no statistically significant differences were found 
between the variances or means of SDSG between group 1 and 2, indicating no difference in 
glycaemic variability between the study groups.	  
The SDSG value was then examined in association with other variables. Of note, no 
correlation was found between SDSG and Length of Stay (Figure	  66) or SDSG and HbA1c 
(Figure	  67). SDSG is referred to as ‘Std Deviation of CGMS Data’ in figures 66 and 67. 
	  
	  
	  
Figure	  66:	  Comparison	  of	  Length	  Stay	  (days)	  against	  Standard	  Deviation	  of	  Sensor	  Glucose	  values	  (SDSG,	  mmol/L)	  in	  
n=12	  group	  1	  and	  2	  CGMS	  participants	  	  
	  
	  	  	  	  	  	  	  160	  
	  
	  
Figure	  67:	  Comparison	  of	  HbA1c	  (mmol/mol)	  against	  Std	  Deviation	  of	  Sensor	  Glucose	  values	  (SDSG,	  mmol/L)	  in	  n=12	  
group	  1	  and	  2	  CGMS	  participants	  
	  
	  
In group 1, a trend was apparent between SDSG and HOMA2-IR. A ‘perfect correlation’ was 
found between these variables in the 3 participants for whom HOMA2 values were available 
(Figure	  68).  
	  	  
	  
	  
	  
	  
	  
	  
	  
	  	  	  	  	  	  	  161	  
	  
	  
Figure	  68:	  Comparison	  of	  HOMA2-­‐IR	  against	  Std	  Deviation	  of	  CGMS	  Data	  (SDSG,	  mmol/L)	  in	  groups	  1	  and	  2	  
	  
	  
 
Table	  65:	  Correlation	  of	  SDSG	  with	  HOMA2-­‐IR	  for	  group	  1	  and	  2	  CGMS	  participants 
 
Std Deviation of Sensor Glucose values (SDSG) HOMA2-IR 
 Group 1 Pearson Correlation 1.000 
Sig. (2-tailed) 0.002** 
N 3 
Group 2 Pearson Correlation -0.237 
Sig. (2-tailed) 0.650 
N 6 
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4.4 Summary of Chapter 4 
	  
• Group 1 participants had lower (mean, fasting) insulin values (p<0.05) as well as  
lower variances  (p<0.01) compared to group 2 participants.  
• Group 1 participants were found to have a lower HOMA2 model-derived estimate of 
steady state B-cell function (%B) compared to group 2 (p<0.05). No significant 
differences were found in mean %S values.  
• A statistically significant difference was also found between the mean and variance of 
HOMA2-IR values of group 1 and 2 participants (p<0.05). Despite this, HOMA2-IR 
was not found to be significantly correlated with RPG or length of stay for all 
participants 
• HOMA2 %B was significantly correlated with waist circumference and proADM 
whilst HOMA2 %S was significantly correlated with BNP (all participants) 
• HOMA2-IR appeared to be higher in participants diagnosed with a MA compared to 
those who were not although values were not available for all participants and 
inferential statistics were not performed 
• A small number of participants (n=5 from group 1 and n=7 from group 2) consented 
to wear a CGMS to measure (frequent) interstitial glucose readings. There were a 
substantial proportion of ‘missing values’ 
• Uniquely, CGMS profiles were obtained for 3 participants diagnosed with IFG and 2 
participants at ‘high risk of DM’ 
• CGMS profiles often demonstrated a discrepancy between RPG and SG values, 
notably marked episodes of hyperglycaemia (participant 061) and hypoglycaemia 
(participants 054, 063, 064) 
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• 11% of SG values from group 2 participants were ≥ 11.1 mmol/L compared to 2% 
from group 1 
• 62% of group 1 SG values were  <7.1mmol/L 
• Group 1 participants had significantly lower mean SG values and lower SG variance 
compared to group 2 participants. (p<0.01). Despite this, no statistically significant 
differences were found in the Glycaemic Variability of group 1 and 2 participants 
• Glycaemic variability was not correlated with LOS or HbA1c (all participants) 
• In group 1, a trend towards a correlation between HOMA2 and SDSG was observed 
although only 3 participants were studied. 
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Chapter	  5:	  Stress	  Hyperglycaemia	  in	  COPD	  (Metformin)	  Study	  Results	  
 
5.1 Introduction  
Respiratory disease was the primary diagnoses for the majority of participants from both 
group 1 and 2 in the prospective study (section 3.2) and COPD accounted for 31% of all 
these respiratory cases. (Appendix1). This work looks more closely at the prevalence of stress 
hyperglycaemia as well as glycaemic variability (GV) and diabetes risk in people with 
COPD.  The effect of metformin on GV was also noted. Full study objectives are listed in 
section 2.2.1. 
As described in section 2.2, this study is a secondary analysis of a multi-centre study entitled, 
‘A Randomised, Double-Blind, Placebo-Controlled Trial of Metformin in Chronic 
Obstructive Pulmonary Disease (COPD) Exacerbations: A Pilot Study’. In summary, a total 
of 52 patients were recruited over 9 sites between 2011 and 2014. Group A were actively 
treated with metformin and group B were treated with placebo. Primary study methodology 
and investigator’s contributions are described in more detail in section 2.2. 
 
5.2 Metformin Study Participants  
 
Table	  66 and Figure	  69  display the gender distribution for all metformin study participants.  
    
 Frequency Percentage 
 Female 20 38.5 
Male 32 61.5 
Total 52 100.0 
	  	  	  	  	  	  	  	  	  
Table	  66:	  Gender	  distribution	  (percentage	  and	  frequency)	  for	  all	  metformin	  study	  participants	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Figure	  69:	  Percentage distribution of gender for all metformin study participants	  
 
In terms of ethnicity, 1 participant was Mauritian whilst the remaining participants were of 
white ethnicity.  Table	   67 contains descriptive data for age, weight, systolic and diastolic 
blood pressure for all participants. 
 
 N Mean Min Max Std. Deviation 
Age (years) 52 67.4 43 89 9.35 
Weight at baseline (kg) 52 72.2 44.5 140.3 19.64 
SBP (mmHg) 52 134 85 215 21.36 
DBP (mmHg) 52 77 56 104 10.89 
      
Table	  67:	  Descriptive	  statistics	  for	  age,	  weight,	  SBP	  and	  DBP	  at	  baseline	  visit	  for	  all	  metformin	  study	  participants	  
 
 
5.3 Baseline Biochemical Values 
	  
Table	  68 contains the descriptive statistics for (baseline) plasma glucose, HbA1c and lactate 
values of all metformin study participants. In comparison, the mean (baseline) plasma 
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glucose and HbA1c for all prospective study participants was 6.7mmol/L and 40mmol/mol 
respectively (see sections 3.4 and 3.10.2). 
 
 N Min Max Mean Std. Deviation 
Glucose (mmol/L) 41 4.4 29.5 8.0 4.24 
HbA1c (mmol/mol) 32 33 72 43 8.12 
 Lactate (mmol/L) 42 0.86 3.90 2.0 0.74 
      
Table	  68:	  Descriptive	  statistics	  for	  plasma	  glucose,	  HbA1c	  and	  lactate	  at	  baseline	  visit	  for	  all	  metformin	  study	  
participants 
	  
Plasma glucose samples were taken at the time of recruitment and values are therefore 
referred to as ‘random’ rather than ‘fasting’ plasma glucose. Figure	  70 displays the frequency 
of (baseline) plasma glucose readings at each glucose value.  
	  
Figure	  70:	  Histogram	  displaying	  frequency	  of	  glucose	  values	  at	  each	  2mmol/L	  glucose	  range	  for	  all	  metformin	  study	  
participants	  (n=41)	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Sixteen participants had a baseline Random Plasma Glucose (RPG) value between 7.1 and 
11.0 mmol/L making the prevalence of SH in the recruited COPD study group 39% (using 
the prospective study definition). Table	  69 displays the percentage and frequency of glucose 
values at ranges <7.1, 7.1-11.1 and ≥ 11.1 mmol/L. Figure	  71 illustrates the percentage of 
values at each of these ranges. 
RPG Range Frequency in range Percentage in range 
 
< 7.1mmol/L 
 
20 48.8 
7.1-11.0 mmol/L 
 
16 39.0 
≥ 11.1 mmol/L 
 
5 12.2 
Table	  69:	  	  Baseline	  random	  plasma	  glucose	  values	  within	  selected	  ranges	  (n	  and	  %)	  for	  n=41	  metformin	  study	  
participants 
 
	  
Figure	  71:	  Percentage	  of	  metformin	  study	  participants	  with	  random	  plasma	  glucose	  values	  less	  than	  (LT)	  7.1,	  7.1	  to	  less	  
than	  (LT)	  11.1	  and	  greater	  or	  equal	  to	  (GE)	  11.1	  mmol/L	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5.4 Stress Hyperglycaemia and Baseline Variables  
Various baseline variables including age, weight, biomarkers and COPD assessment test 
(CAT) score were examined in relation to the baseline glucose range. Table	   70 contains 
descriptive statistics for these variables at each glucose range described in Table	   69. 
Participants with stress hyperglycaemia (using definition in section 2.1.8) are highlighted in 
italics in each category.  
 
Baseline Variable N Mean SD Min Max 
Age (years) Glucose LT 7.1 20 65.6 10.59 43 81 
Glucose 7.1 - LT 11.1 16 68.6 9.07 58 89 
Glucose GE 11.1 5 73.8 5.22 66 78 
      
Weight (kg) Glucose LT 7.1 20 67.8 18.92 50.3 133.6 
Glucose 7.1 - LT 11.1 16 70.3 11.60 44.5 87.0 
Glucose GE 11.1 5 78.3 15.95 64.7 101.0 
      
Lactate  
(mmol/L) 
Glucose LT 7.1 19 1.8 0.513 0.86 2.8 
Glucose 7.1 - LT 11.1 16 2.1 0.80 1.00 3.9 
Glucose GE 11.1 5 2.4 1.18 1.00 3.8 
      
eGFR  
(mL/min) 
Glucose LT 7.1 17 73.1 14.70 45 90 
Glucose 7.1 - LT 11.1 13 78.1 13.44 60 90 
Glucose GE 11.1 4 62.3 23.89 32 90 
      
 HbA1c 
(mmol/mol) 
Glucose LT 7.1 15 40.2 4.60 33 51 
Glucose 7.1 - LT 11.1 12 42.2 2.89 39 49 
Glucose GE 11.1 4 60.0 10.95 48 72 
      
CAT Glucose LT 7.1 20 28.0 7.03 8 37 
Glucose 7.1 - LT 11.1 16 27.9 7.19 13 37 
Glucose GE 11.1 5 22.4 6.80 14 31 
      
Table	  70:	  Descriptive	  statistics	  for	  baseline	  variables	  within	  selected	  random	  plasma	  glucose	  ranges,	  all	  metformin	  study	  
participants	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One-way Analysis of Variance (one-way ANOVA) showed a statistically highly significant 
difference in variance between the RPG groups for HbA1c only (p<0.01). Post-hoc tests 
demonstrated no statistically significant difference between most baseline variables across 
differing glucose ranges.  (LT 7.1, 7.1-11.1 and GE 11.1) The exception being baseline 
HbA1c which was found to be significantly different (p<0.05) in the glucose GE 11.1 
participants (Table	  71). 
 
 
                                                      Glucose Levels N 
Subset for alpha = 0.05 
1 2 
Student-Newman-Keulsa,b Glucose LT 7.1 15 40.20  
Glucose 7.1 - LT 11.1 12 42.17  
Glucose GE 11.1 4  60.00 
Sig.c  0.467 1.000 
Tukey HSDa,b Glucose LT 7.1 15 40.20  
Glucose 7.1 - LT 11.1 12 42.17  
Glucose GE 11.1 4  60.00 
Sig.c  0.744 1.000 
Means for groups in homogeneous subsets are displayed. (a) Uses Harmonic Mean Sample Size = 7.500. (b)The group 
sizes are unequal. The harmonic mean of the group sizes is used. Type I error levels are not guaranteed. (c)This p 
value refers to all variables within the same column, demonstrating no difference between the values in the 
homogenous subset 
 
Table	  71:	  Analysis	  of	  Variance	  (one-­‐way	  ANOVA)	  with	  Student-­‐Newman-­‐Keuls	  (SNK)	  and	  Tukey	  tests	  demonstrating	  
homogenous	  subsets	  for	  HbA1c	  values	  within	  random	  plasma	  glucose	  ranges,	  all	  metformin	  study	  participants 
 
5.5 Metabolic Abnormalities & Type 2 Diabetes Risk 
As discussed in section 3.10.2, HbA1c values between 42-47mmol/mol are defined as ‘high 
risk for diabetes’(D.M. Nathan et al., 2009; NICE 2012). A total of n=18 (35%) metformin 
study participants fell within this definition and the mean HbA1c for all participants was also 
in this high risk range (43mmol/mol).  
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Additionally, in terms of Type 2 Diabetes (T2DM) risk, the GUARD risk calculator 
(McAllister et al., 2014) predicted a 4.9% 3 year risk of developing T2DM in the metformin 
group overall and a 6.8% risk in the metformin SH group (participants with a RPG 7.1-
11.0mmol/L). Although a formal diagnosis was not made in the acute setting, 15% of 
participants were also found to have biochemical features of Diabetes Mellitus (BFD) during 
the course of the study (Table	  28).  
 
5.6 Capillary Glucose Values: All Study Participants 
A total of 1250 Capillary Blood Glucose (CBG) values were recorded across all participants -
a mean of 24 (min n=3, max n=72) for each participant (n=52) during the in-patient phase of 
the study. Table	  72 displays these values within CBG ranges: ‘Less than’ (LT) 7.1; 7.1 to LT 
11.1 and ‘Greater than or equal to’ (GE) 11.1 mmol/L.  
 
Capillary Blood Glucose Category 
Capillary Blood Glucose Values (mmol/L) 
N Min Max Mean SD 
LT 7.1  721 2.2 7.0 5.50 0.91 
      
7.1-LT 11.1  460 7.1 11.0 8.49 1.09 
      
GE 11.1  69 11.1 27.2 15.21 4.57 
      
Table	  72:	  Descriptive	  statistics	  for	  capillary	  blood	  values	  within	  ranges	  ‘Less	  than	  (LT)	  7.1’,	  7.1	  to	  Less	  Than	  (LT)	  11.1‘	  and	  
‘Greater	  than	  or	  equal	  to	  (GE)	  11.1mmol/L’,	  all	  metformin	  study	  participants	  
	  
The CBG values were then examined in relation to baseline RPG categories. CBG values 
reached a maximum of 23.2mmol/L within the lowest RPG category (RPG LE 7.0).Table	  73 
 
 
	  	  	  	  	  	  	  171	  
	  
 
 
RPG Category (mmol/L) N Min Max Mean SD 
LT 7.1  383 3.7 23.2 7.059 2.34 
      
7.1 – LT 11.1  519 2.2 16.3 6.775 2.03 
      
GE 11.1  90 4.1 27.2 10.128 6.15 
      
Table	  73:	  Descriptive	  statistics	  for	  capillary	  blood	  glucose	  values	  in	  relation	  to	  baseline	  Random	  Plasma	  Glucose	  (RPG)	  
categories,	  all	  metformin	  study	  participants 
	  
As with the prospective observational study, the standard deviation was used to express 
glycaemic variability. Figure	   72 plots SD of CBG for all participants within the RPG 
categories described in Table	  69. 
	  
	  
Figure	  72:	  Standard	  deviation	  of	  CBG	  values	  for	  RPG	  ranges	  LT	  7.1,	  7.1-­‐11.1	  and	  GE	  11.1,	  all	  metformin	  study	  participants 
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5.7 Capillary Glucose Values: Group A and B Participants 
 
12 participants had recorded episodes of hypoglycaemia (defined as CBG<4.0mmol/L, NHS 
Diabetes, 2010) during the in-patient phase of the study. Six participants were from the 
metformin group (group A) and 6 from the placebo-treated group (group B). In total, there 
were 33 individual episodes of hypoglycaemia: n=25 were recorded in group A participants; 
and n=8 in group B participants. 
Figure	  73 illustrates the mean CBG by study day for group A and B participants during the in-
patient phase of the study. 
	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  73:	  Mean	  capillary	  blood	  glucose	  by	  study	  day	  for	  group	  A	  and	  B	  metformin	  study	  participants	  
 
Figure	  74 illustrates the overall CBG values for group A (metformin) and group B (placebo) 
participants. Descriptive statistics are contained within Table	  74. 
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Figure	  74:	  Capillary	  Blood	  Glucose	  values	  for	  group	  A	  and	  B	  metformin	  study	  participants	  
	  
 
Study Group 
Capillary Blood Glucose  (mmol/L) 
N Mean  SD 
 A 829 6.971 2.32 
B 421 7.456 3.56 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  74:	  Descriptive	  statistics	  for	  capillary	  blood	  glucose	  values,	  group	  A	  and	  B	  metformin	  participants 
 
 
An independent samples t-test demonstrated a highly statistically significant difference 
between the CBG variances (p<0.01). Therefore the Mann-Whitney U non-parametric test 
was performed to check whether the distribution of glucose was the same across group A and 
B (rather than comparison of means using an independent samples t-test). The asymptotic 
significance (equivalent to significance in parametric statistical tests) was >0.05 (0.43) 
confirming that there was no statistically significant difference in the distribution of glucose 
across group A and B (Figure	  75).  
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Figure	  75:	  Mann-­‐Whitney	  U	  test	  to	  test	  null	  hypothesis,	  ‘there	  is	  no	  difference	  between	  groups	  A	  and	  B	  with	  regard	  
capillary	  glucose	  values’	  (metformin	  study	  participants) 
 
 
Glycaemic variability was then examined in group A and B participants. Firstly, using the 
independent samples t-test, equal variances not assumed, the mean capillary glucose SDs for 
Groups A and B were compared.  There was no statistically significant difference between 
the means for the two groups, significance levels > 0.05 (Table	  75). 
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Table	  75:	  Independent	  samples	  t-­‐test	  of	  mean	  capillary	  blood	  glucose	  standard	  deviation	  (measure	  of	  glycaemic	  
variability),	  group	  A	  and	  B	  metformin	  study	  participants.	  *p<0.05	  –statistically	  significant,	  **p<0.01	  statistically	  highly	  
significant 
 
Secondly, the distribution of the capillary glucose SD was compared for Groups A and B 
using the Mann-Whitney U Test; there was no statistically significant difference between the 
distributions of the data for the two groups (asymptotic significance 0.45).  
Finally, the mean GV (CBG SD) of 4 study groups: metformin study groups A and B 
(n=1250 glucose values) and mean GV (SG SD) of prospective study group 1 and 2 (n=2396 
glucose values) were compared using the One-Way Analysis of Variance (One-Way 
ANOVA) with the Student-Newman-Keuls Test (SNK Test) and the Tukey’s Honestly 
Significant Difference Test (Tukey’s HSD) for homogeneity of subsets. No statistically 
significant differences were found between the variances or means of the four groups 
indicating no difference in glycaemic variability between the 4 groups. As the distribution 
was slightly different from a normal curve, the nonparametric Kruskal-Wallis test was run for 
extra reassurance. This agreed with the ANOVA. 
	  
5.8 Follow-up Variables 
As described in methodology section 2.2.3, a follow-up visit was organised at days 28-35 
where possible. Table	  76 contains descriptive statistics of baseline and follow-up glucose and 
HbA1c for all participants (where available). 
 
Equal variances assumed 
Levene's Test for 
Equality of Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
 Yes 2.033 0.160 -0.289 50 0.774 
No   -0.246 23.043 0.808 
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 N Min Max Mean SD  
Baseline glucose (mmol/L) 41 4.4 29.5 8.1 4.24 
Follow-up glucose (mmol/L) 33 2.8 17.4 6.6 3.16 
Baseline HbA1c (mmol/mol) 32 33 72 43.4 8.12 
Follow-up HbA1c (mmol/mol) 33 32.0 78.0 41.7 8.35 
      
Table	  76:	  Descriptive	  statistics	  of	  baseline	  and	  follow-­‐up	  glucose	  (mmol/L)	  and	  HbA1c	  (mmol/mol)	  for	  all	  metformin	  
study	  participants 
 
A paired samples t-test demonstrated a statistically significant difference between baseline 
and follow-up glucose (follow-up glucose lower than baseline) but no statistically significant 
difference between baseline and follow-up HbA1c for all participants.Table	  77 
 
 
Paired Differences 
t df 
Sig.  
(2-tailed) Mean Std. Deviation 
Pair 1 Baseline glucose  
Follow Up glucose 1.63 3.43 2.472 26 0.020* 
Pair 2 Baseline HbA1c 
Follow Up HbA1c -0.33 3.43 -0.446 20     0.660 
Table	  77:	  Paired	  samples	  t-­‐test	  for	  baseline	  and	  follow-­‐up	  glucose	  and	  baseline	  and	  follow-­‐up	  HbA1c,	  all	  metformin	  
study	  participants.  * Statistically significant p<0.05, ** statistically highly significant p<0.01 
 
Table	   78 contains descriptive statistics of baseline and follow-up glucose and HbA1c for 
group A (metformin) and B (placebo) participants separately. 
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                                Group N Mean SD 
Baseline glucose 
 
A 28 7.3 2.54 
B 13 9.6 6.45 
Baseline HbA1c A 19 42.2 5.36 
B 13 45.1 11.03 
 Follow Up glucose A 21 5.8 2.05 
B 12 7.8 4.32 
Follow Up HbA1c A 22 40.7 5.62 
B 11 43.7 12.26 
Table	  78:	  Descriptive	  statistics	  of	  baseline	  and	  follow-­‐up	  glucose	  (mmol/L)	  and	  HbA1c	  (mmol/mol)	  for	  groups	  A	  and	  B	  
metformin	  study	  participants	  
 
An independent samples t-test did not show a statistically significant difference between the 
mean values for baseline glucose, follow-up glucose, baseline HbA1c and follow-up HbA1c 
between group A and B participants (Table	  79). 
 
                                  Equal variances Assumed 
Levene's Test for 
Equality of 
Variances t-test for Equality of Means 
F Sig. t df 
Sig. (2-
tailed) 
Baseline glucose Yes 3.302 0.077 -1.643 39 0.108 
No   -1.237 13.762 0.237 
Baseline HbA1c Yes 2.883 0.100 -0.981 30 0.335 
No   -0.869 15.912 0.398 
Glucose Follow Up Yes 7.181 0.012 -1.790 31 0.083 
No   -1.493 13.876 0.158 
HbA1c Follow Up Yes 2.145 0.153 -0.972 31 0.339 
No   -0.772 12.153 0.455 
Table	  79:	  Independent	  samples	  t-­‐test	  of	  baseline	  and	  follow-­‐up	  glucose	  and	  HbA1c	  between	  group	  A	  and	  B	  metformin	  
study	  participants 
 
Length of stay for all participants is presented in Table	  80 and for group A and B participants 
separated in Table	   81. An independent samples t-test did not demonstrate a statistically 
significant difference for length of stay between group A and B participants. 
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 N Min Max Mean SD 
Length of Stay (Days) 50 3 50 10.52 8.63 
      
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  80:	  Descriptive	  statistics	  for	  length	  of	  stay,	  all	  metformin	  study	  participants 
 
 
 
Group N Min Max Mean SD 
A Length of Stay (Days) 32 3 50 11.00 9.847 
      
B Length of Stay (Days) 18 5 27 9.67 6.068 
      
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Table	  81:	  Descriptive	  statistics	  for	  length	  of	  stay,	  group	  A	  and	  B	  metformin	  study	  participants 
	  
	  
5.9 Correlations 
Table	  82	  describes significant and highly significant correlations noted in all metformin study 
participants (group A and B combined). Notably, SD of CBG was not correlated with length 
of stay (all participants and group A and B separated.) 
Variable 1 
 
Variable 2 Pearson 
Correlation 
Sig. (2-tailed) N 
Baseline HbA1c 
(mmol/mol) 
Age (years) 0.393* 0.026 32 
Discharge CAT score -0.631** 
 
0.000 28 
SD of CBG (GV) 0.691** 0.000 32 
Discharge CAT score Baseline glucose (mmol/L) 
 
-0.469** 0.006 33 
SD of CBG (GV) Baseline glucose (mmol/L) 
 
0.578** 0.000 41 
Discharge CAT score 
 
-0.575** 0.000 40 
Table	  82:	  Pearson	  correlations	  between	  variables	  for	  all	  metformin	  study	  participants	  (groups	  A	  and	  B	  combined)	  *	  
statistically	  significant	  p<0.05,	  **	  statistically	  highly	  significant	  p<0.01	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5.10 Summary of Chapter 5  
NB: Group A –metformin treated, Group B- placebo treated 
• The prevalence of SH was 39% in the recruited COPD population 
• The majority (61.5%) of participants were men. All apart from n=1 were of white 
ethnicity. The mean age was 67.4 years. There were some similarities with the 
prospective study population where the mean age was 68yrs and 60% of participants 
were men.  
• At baseline, mean RPG was 8.0mmol/L, mean HbA1c was 43 mmol/mol (classified 
as ‘high risk for DM’). In comparison, mean RPG and HbA1c for prospective study 
participants was 6.7mmol/L and 40mmol/mol respectively. 
• 15% of participants met the biochemical criteria for a diagnosis of T2DM  
• There were no statistically significant differences in age, weight, lactate, eGFR, and 
CAT values between participants with and without stress hyperglycaemia. However, 
baseline HbA1c was found to be significantly higher in participants with a baseline 
RPG ≥ 11.1mmol/L (n=4) compared to those with lower baseline RPG values (n=27).  
• Mean CBG was highest in GE11.1 RPG group but CBG values reached a maximum 
of 23.2mmol/L within the lowest RPG category (glucose LE 7.0). 
• Equal numbers of participants from group A and group B had episodes of 
hypoglycaemia during the in-patient phase of the study but total number of episodes 
were greater in group A  
• Glycaemic variability (SD of CBG) appeared to be highest in participants with a RPG 
≥ 11.1mmol/L   
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• The distribution of CBG values and glycaemic variability (expressed as SD) were not 
different between group A and B participants. There were also no statistically 
significant differences in GV between metformin and prospective study groups 
• There were also no differences between group A and B participants with regards: 
baseline RPG, follow-up RPG, baseline HbA1c, follow-up HbA1c and length of stay  
• Follow-up glucose was significantly lower than baseline glucose for all participants 
• Glycaemic Variability (SD of CBG) was not correlated with length of stay (all 
participants and group A and B separated.) A positive correlation was found between 
Glycaemic Variability and baseline RPG (p<0.01) for all participants 
• Overall (for all participants) follow-up glucose was significantly lower than baseline 
glucose (p<0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	  	  	  	  	  	  	  181	  
	  
Chapter	  6:	  Discussion	  
	  
6.1 Summary of Study Hypotheses and Research Objectives  
	  
To recap, the main research objective, addressed through a prospective observational study 
(see section 1.5), investigated the metabolic profile of people with and without Stress 
Hyperglycaemia through five separate null hypotheses: 
NULL HYPOTHESIS 1: There is no statistically significant difference between the mean 
Body Mass Index (BMI) values of people with and without stress hyperglycaemia 
NULL HYPOTHESIS 2: There is no statistically significant difference between the mean 
waist circumference values of people with and without stress hyperglycaemia 
NULL HYPOTHESIS 3: There is no statistically significant difference between the mean 
(systolic and diastolic) blood pressure values of people with and without stress 
hyperglycaemia 
NULL HYPOTHESIS 4: There is no statistically significant difference between the mean 
Epworth score of people with and without stress hyperglycaemia 
NULL HYPOTHESIS 5: There is no statistically significant difference between the mean 
Copeptin values of people with and without stress hyperglycaemia 
 
Independent samples t-tests displayed in table 12 did not reveal statistically significant 
differences in the mean (or variance) of hypothesis 1-4 variables between group 1 and 2 
participants (Table	   13). There was also no statistically significant difference in the mean 
copeptin values between group 1 and 2 participants (Table	   15). Therefore, there was 
insufficient evidence to reject any of the null hypotheses. 
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In addition to the central hypotheses, several research questions were also considered 
throughout this work: 
• Question 3: Do people with Stress Hyperglycaemia actually have underlying glucose 
intolerance, unmasked during acute illness, rather than a genuinely transient 
disorder? 
• Question 5: What is the best management for stress hyperglycaemia in the acute care 
setting? 
Study results as well as implications of findings will be discussed in the forthcoming 
sections. Results pertaining to hypotheses 1-4 are discussed in section 6.2, hypothesis 5 is 
discussed in more detail in section 6.10.10. 
 
6.2 Metabolic Profiling 
The heterogeneous mix of patients with SH in the AMU setting has not been well described. 
Previous studies have examined intensive care settings, (G van den Berghe et al., 2001) 
isolated diagnoses associated with SH (Lepper et al., 2012; Malmberg et al., 2005) or large 
population outcomes using registries and retrospective methodology. (McAllister et al., 2014)  
To our knowledge, this is the first prospective study to offer a detailed profile of a broad 
group of patients admitted to the acute care setting with SH. The overarching aim of this 
work is to improve understanding of the condition, potentially supporting clinical decision 
making. 
A number of studies have reported that people with SH may be at a greater risk of Diabetes 
Mellitus. (Carmen Wong et al., 2010; Gornik, Vujaklija, Lukić, Madžarac, & Gašparović, 
2010; Greci et al., 2003; Sewdarsen et al., 1987; Wahid et al., 2002) In a recent, large (n= 86 
634 patients) Scottish study, a ‘national database of hospital admissions was linked with a 
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national register of diabetes to describe the association between admission glucose and the 
risk of subsequently developing type 2 diabetes’ (McAllister et al., 2014). Plasma glucose 
levels measured during an emergency hospital admission were found to predict subsequent 
risk of developing type 2 diabetes. The 3 year risk of DM was <1% for a RPG of ≤5mmol/L 
and increased to 15% at 15 mmol/L. Unfortunately, the study could not confirm whether 
these were fasting or random plasma glucose levels.  Of interest, 90% of those with 
admission glucose of 11.1mmol/L were not diagnosed with diabetes within 3 years of 
discharge from hospital.  An earlier study also demonstrated that the level of RPG did not 
predict the future development of DM (Wahid et al., 2002). The nature and frequency of 
patient follow-up should be considered in interpreting this information. 
Aside from glucose levels, a number of other factors including BMI (Looker et al., 2001), 
waist circumference (Diabetes Prevention Program Research Group, 2006), blood pressure 
(Conen et al., 2007), OSA (Idris et al., 2009) and ethnicity (Shai et al., 2006) have been 
linked to the development of Type 2 diabetes. Given the retrospective nature of the Scottish 
study, the full phenotype of people with SH who developed DM was not available or 
therefore incorporated within the derived predictive model.  
Treatment of diabetes is guided by phenotype and NICE recommends that individualised 
goals are set for management (NICE, 2009).  If treatment is to be considered for SH in the 
acute setting, a similar approach should be adopted. Blanket use of insulin for modest levels 
of hyperglycaemia seem likely to be harmful (Finfer et al., 2009) and also impractical. In this 
context, the metabolic profile of patients with SH is of interest, particularly given the 
association with DM. Previous studies on the treatment of SH, in condition specific contexts, 
have generally used insulin treatment (Finfer et al., 2009).  Metabolic profiling could guide 
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therapy towards alternative treatments such as metformin. The metabolic profile is also of 
interest as a potential tool for the prediction of metabolic abnormalities (section 3.10.2). 
The results of the prospective study showed no difference in the metabolic profile (as defined 
in section 1.5) of people with and without stress hyperglycaemia (tables 12-14). Similar 
(estimated) proportions of participants from group 1 and 2 also met the IDF diagnostic 
criteria for metabolic syndrome.  
As described above, links between the metabolic profile and T2DM have been well 
established, with measures such as BMI, waist circumference and BP frequently incorporated 
into risk assessment tools for primary care (L. J. Gray et al., 2010; Griffin, Little, Hales, 
Kinmonth, & Wareham, 2000; Lindström & Tuomilehto, 2003). Studies have also shown 
associations between copeptin and DM (Enhörning et al., 2010).  
People with SH are thought to be at greater risk of T2DM as well as abnormal glucose 
tolerance with figures ranging from 16% (Gornik et al., 2010) to  75% (Sewdarsen et al., 
1987). These data are consistent with those studies in suggesting a higher 3-year risk for 
T2DM (section 3.10.2), as well as a possible higher proportion of metabolic abnormalities 
(Table	  36) in participants with SH.  It is therefore a surprise that the metabolic profile of 
people with SH did not significantly differ from that of people without SH. 
Additionally, the metabolic profile of participants with a GUARD score < and ≥ 5% (Table	  
38) appeared to be largely similar. BMI and waist circumference, however, was significantly 
different in those who did and didn’t develop MA (section 3.10.2). 
Although numbers involved in these calculations were relatively small, they imply that 
metabolic profiling has limited utility in risk prediction of MA in the acute setting (Table	  28). 
Therefore, it is possible that the metabolic profile of people with SH does not differ from that 
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of people without the condition whilst they still remain a group at high-risk of DM. Other 
explanations for these findings include: 
• The metabolic profile is a useful predictive tool but SH is mostly a ‘transient 
hyperglycaemia’ (Dungan et al., 2009) and only a small percentage are actually at risk 
of DM. This is not, however, consistent with existing literature (see chapter 1) 
• Aspects of the metabolic profile, whilst helpful in primary care, are not appropriate 
for risk prediction in the acute care setting 
• The GUARD tool and MA proportions (no inferential statistics performed) are  
insufficient to classify people with SH as having a higher DM risk compared to 
people without the condition. The GUARD tool in particular, whilst developed for 
unselected admissions, only required information on  ‘age’, ‘sex’ and ‘admission 
glucose’ in order to produce a score. Notably, fasting insulin and systolic BP values 
appeared lower in the higher risk GUARD group (table 38). 
In conclusion, people with SH do not appear to have a distinct metabolic profile as defined by 
this study. Perhaps these findings, along with the practical challenges of metabolic profiling 
in a fast-moving in-patient population with other care priorities suggest that this approach 
may be unproductive.  
  
6.3 The Diagnosis of Impaired Glucose Regulation (IGR) in the Acute Care Setting 
An unexpectedly high prevalence of Metabolic Abnormalities (MA), were seen in both the 
prospective and metformin studies (see sections 3.10.2 and 5.5). Whilst MA is used as a 
summary term for the purposes of this study, it is also important to consider the conventional 
definitions. 
Both IFG and IGT are known to be risk factors for future diabetes (David M Nathan et al., 
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2007) and are collectively termed ‘Impaired Glucose Regulation’ (IGR, see Table	   28).  
Patients with a HbA1c of 42-47mmol/mol have also been proposed as a high risk group, 
equivalent to IGR by an International Expert Committee (D.M. Nathan et al., 2009). The 
committee comments that ‘risk for diabetes based on levels of glycemia is a continuum; 
therefore, there is no lower glycemic threshold at which risk clearly begins.’ There is no 
consensus on this issue -the ADA recommends a lower HbA1c of 39-46mmol/mol as a cut-
off for IGR whilst the WHO does not recommend the use of HbA1c to diagnose IGR at all. 
(WHO, 2011) For this study, UK NICE guidance (HbA1c 42-47mmol/mol) has been used to 
define ‘high risk for DM’/IGR (NICE 2012). 
 
Given the biochemical definitions (requiring fasting plasma glucose and an OGTT), IGR is 
not routinely diagnosed in the acute setting and is also under-diagnosed in primary care 
(Gillett et al., 2012).  The prospective study noted a diagnosis of IGR in 34% of all 
participants (section 3.10.2) and uniquely, obtained CGM profiles on n=5 (participants 054, 
056, 057, 059 and 063, see sections 4.3.2 and 4.3.3).  
 
The figures of 34% is higher than previous national estimates for IGR (Gillett et al., 2012) 
although a similarly high/or higher prevalence has been reported in research studies 
describing patients with ACS (Attia, Ragy, Enany, & Elgamal, 2013; Bartnik et al., 2004; 
Norhammar et al., 2002; Okosieme et al., 2008; Ambady Ramachandran et al., 2005) and 
stroke. (Fonville, den Hertog, Zandbergen, Koudstaal, & Lingsma, 2014; C. S. Gray et al., 
2004; Jia et al., 2012). This figure could also be an underestimation as FPG is not as sensitive 
as OGTT in the diagnosis of IGR (Mostafa et al., 2010). The latter was only performed in a 
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handful of group 1 participants who attended follow-up (n=10, 16% of overall prospective 
population).  
IGR is of interest in this context as it is an analogous condition to SH: 
• Both IGR and SH are linked to T2DM. (David M Nathan et al., 2007; Sewdarsen et 
al., 1987) 
• Both IGR and SH may revert to normal glucose tolerance (Dungan et al., 2009; Lu et 
al., 2008)  
• Both IGR and SH may be under-recognised in the acute care setting.  
• Evidence exists linking IGR and SH to poor outcomes from associated, underlying 
conditions (Baker et al., 2006; Meier et al., 2002) 
• As with SH, the metabolic profile is not always striking. A national study of 9096 
people with IGT/IFG observed 30% with a ‘healthy/low’ BMI of <25 kg/m2. (Gillett 
et al., 2012) In the prospective study, a similar pattern was observed with 31% of 
participants in group 1 and 41% in group 2 found to have a BMI <25 kg/m2  
Given the similarities noted above, it is of interest to examine the standard approach to IGR. 
Studies have shown that preventative measures may prevent progression of IGT to frank DM 
(Knowler et al., 2002; Tuomilehto et al., 2001). Implementation of these evidence-based 
interventions does not, however, always occur (Karve & Hayward, 2010).  
UK guidelines (NICE 2012) recommend intensive lifestyle programmes and annual 
monitoring for people considered to be at high risk for DM (Figure	   76). Despite the 
similarities between IGR and SH, and the fact that SH could also be considered a high-risk 
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group for future DM, there are currently no UK guidelines on follow-on care or monitoring. 
Further work in this direction would benefit patients and clinicians. 
 
Figure	  76:	  Identifying	  and	  Managing	  Risk	  of	  Type	  2	  Diabetes.	  National	  Institute	  for	  Health	  and	  Clinical	  Excellence	  (2012)	  
PH	  38	  Preventing	  type	  2	  diabetes:	  risk	  identification	  and	  interventions	  for	  individuals	  at	  high	  risk.	  Manchester:	  NICE.	  
Available	  from	  www.nice.org.uk/PH38	  	  	  Reproduced	  with	  permission.	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6.4 The Diagnosis of Diabetes in the Acute Care Setting 
There are currently 3.2 million people with DM in the UK and it is estimated that a further 
850 000 people with Type 2 DM remain undiagnosed (Diabetes UK).  People with 
undiagnosed T2DM are often asymptomatic. Studies have demonstrated the presence of 
microvascular complications at the point of diagnosis, suggesting a lag of between 4-7 years 
between onset of the condition and a formal diagnosis of T2DM (M. I. Harris, Klein, 
Welborn, & Knuiman, 1992). Clearly there is a significant benefit in early diagnosis. 
An acute presentation may generate an opportunistic diagnosis of DM in people for whom 
diagnostic criteria are clearly met. A high index of suspicion may prompt a RPG check 
although, anecdotally, this practice often varies between clinicians. In 2012 the Endocrine 
society (USA) published guidelines recommending that ‘all patients, independent of a prior 
diagnosis of diabetes, have laboratory blood glucose testing on admission’ (Umpierrez et al., 
2012). There are currently no equivalent UK guidelines and although in some UK hospitals, 
mechanisms exist to ensure that a CBG must be entered into a discharge summary in order 
for the discharge to proceed, it is unclear how widespread this practice is. Additionally, the 
yield of DM pick-up using this approach has not been well studied.  
With the advent of new WHO advice (WHO, 2011) recommending that a HbA1c ≥ 
48mmol/mol may be used for the diagnosis of diabetes, the diagnosis of DM becomes 
potentially easier in the acute care setting - HbA1c testing does not require the patient to be 
fasting and can be taken at any time of day.   
One study, preceding the WHO advice, used FPG and a 2hr OGTT to identify HbA1c cut-
offs appropriate for the acute setting. An HbA1c value of > 42mmol/mol (6.0% DCCT) was 
found to be 100% specific and 57% sensitive for the diagnosis of diabetes (Greci et al., 
2003). HbA1c may, however, be affected by a number of factors (Figure	  77) and an expert 
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group recommend that it is not used as a sole test to diagnose DM in this context, stating that, 
‘as HbA1c reflects glycaemia over the preceding 2-3 months, it may not be raised in patients 
at high risk of DM who are acutely ill’ (Expert Group, 2012). 
 
 
Figure	  77:	  Factors	  influencing	  HbA1c.	  Reprinted	  from	  the	  Journal	  of	  Diabetes,	  volume	  1,	  issue	  1,	  Gallagher	  EJ,	  Le	  Roith	  D,	  
Bloomgarden	  Z.	  ‘Review	  of	  Hemoglobin	  A1c	  In	  the	  Management	  of	  Diabetes’,	  Figure	  1,	  p10.	  Copyright	  ©	  1999-­‐2015	  John	  
Wiley	  &	  Sons,	  Inc.,	  reproduced	  with	  permission	  from	  Rightslink	  (Appendix	  7)	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For a number of people presenting in the acute care setting, there will be little ambiguity over 
the diagnosis. For example, the prospective study identified one patient (participant 006) with 
an HbA1c above the WHO diagnostic criteria for DM (51mmol/L). This individual was 
excluded from the study and diagnosed with DM based on a RPG of 11.2mmol/L and 
symptoms suggestive of DM (see section 3.6.2). In addition, 4 participants had ‘Biochemical 
Features of Diabetes’ (see Table	   28 for definition and tables 32-35 and section 4.3 for 
detailed/CGM profiling). 
Patients with newly diagnosed DM may present to the acute setting anywhere on a spectrum 
from asymptomatic to severe metabolic decompensation. Greater clinical awareness and a 
high index of suspicion would increase the pick-up of Type 2 DM in the acute care setting.  A 
public health conversation is required to assess the impact and sustainability of this approach. 
Further work into the extent to which SH is a risk factor for DM might facilitate more 
appropriate intervention/investigation. 
 
6.5 The Prevalence of Occult Hyperglycaemia in the Acute Care Setting 
CGMS were first approved by the US Food and Drug Administration (FDA) in 1999 (Tavris 
& Shoaibi, 2004) and discussed by NICE in 2004 (NICE, 2004). Traditionally, they have 
been used to provide insights in people with type 1 DM. (Hoeks, Greven, & de Valk, 2011; 
Maia & Araújo, 2007; Tavris & Shoaibi, 2004). Increasingly, researchers have employed the 
technology for a variety of uses including diagnosis of DM in high risk groups (A. Soliman, 
DeSanctis, Yassin, Elalaily, & Eldarsy, 2014), assessment of GV (Gohbara et al., 2015; Ma et 
al., 2011), detection of hyperglycaemia during pregnancy  (Bühling et al., 2004), and the 
optimisation of glycaemic control in the critical care setting (Brunner et al., 2011; Goldberg 
et al., 2004).  As described in section 2.1.9, the device has many advantages: frequency of 
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glucose readings (up to 288 values in 24 hours); only minimal patient training required and 
few attendant risks. 
One study, conducted in an Australian stroke unit, reported novel insights with the utilisation 
of CGM, demonstrating frequent episodes of hyperglycaemia in people without DM. In a 
cohort of n=59 patients with ischaemic stroke, 50% of people without DM and 100% of 
people with DM had a sensor glucose value ≥ 7.0 mmol/L (defined as ‘hyperglycaemia’) 8 
hours post-stroke. This was followed by decrease in glucose and a later hyperglycaemic 
phase 48-88 hours post-stroke. Overall, 34% of people without DM and 86% of people with 
DM were hyperglycaemic for at least 25% of the monitoring period. (Allport et al., 2006) 
In this work, continuous glucose monitoring (prospective study) and capillary blood glucose 
readings (metformin study) revealed multiple episodes of otherwise clinically occult 
hyperglycaemia and unpredictable glycaemic patterns. Notably: 
• CBG 23.2mmol/L in a COPD patient despite a RPG of <7.1mmol/L (Table	  73)   
• Marked episodes of (CGM recorded) hyperglycaemia (participant 061) and 
hypoglycaemia (participants 054, 063, 064) with values ranging from 2.2-21.8mmol/L 
(see section 6.9 for further discussion on in-patient hypoglycaemia) 
• 11% of Sensor Glucose (SG) values from group 2 participants ≥ 11.1 mmol/L 
compared to 2% from group 1 (prospective study, Table	  61).  
• Mean SG lower for group 1 compared to group 2 participants (p<0.01, section 4.3.8).  
Without the additional monitoring employed for research purposes, these readings would 
have been missed in a clinical setting. As observed in other studies (Xu et al., 2012; Yu et al., 
2004), it suggests even those with supposed ‘normoglycaemia’, have a marked glycaemic 
variability and episodes of otherwise clinically occult hyperglycaemia. This demonstrates the 
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limitations of a single RPG in the diagnosis of SH as is already recognised in the diagnosis of 
DM (see section 6.4).   
To our knowledge, CGM has only rarely been utilised for people without DM in the acute 
care setting (Burt, Roberts, Aguilar-Loza, Frith, & Stranks, 2011) and there are few studies 
examining the accuracy of the technique and optimal wearing time. A number of the 
prospective study in-patient readings were classified as ‘missing’ (Table	  47).  There were also 
a number of practical challenges to managing the technology in this setting as well a 
substantial expense over CBG monitoring. Therefore, whilst the technology provided some 
interesting findings, particularly the glycaemic excursions of supposed ‘normoglycaemic’ 
individuals, it is unlikely to be implemented in the AMU setting as part of standard care. 
 
6.6 Glycaemic Variability in Stress Hyperglycaemia 
As outlined in section 4.3.1 Glycaemic Variability (GV), defined as glucose fluctuations 
around the mean, was studied in a small number of participants who consented to wear a 
CGM (n=12 from prospective study) as well as participants with CBG readings in the 
metformin study (sections 5.6 and 5.7). The Standard Deviation of Sensor Glucose (SDSG) 
was used as a measure of GV (section 2.1.21).  
Although a previous study used CBG readings to calculate GV in COPD patients (Archer et 
al., 2011), to our knowledge, this is one of the first times continuous glucose monitoring has 
been used to examine glycaemic variability in an undifferentiated patient cohort with stress 
hyperglycaemia.  This was considered useful for a number of reasons (see also sections 1.4 
and 4.1.1): 
	  	  	  	  	  	  	  194	  
	  
• Studies have shown the importance of GV in predicting mortality/adverse outcomes 
in hospitalised patients (Ali et al., 2008; Dungan, Binkley, Nagaraja, Schuster, & 
Osei, 2011; M Egi et al., 2006) 
• Given the rapid onset and short-term nature of hyperglycaemia in some patients with 
SH (Dungan et al., 2009), glycaemic variability may be a more appropriate measure 
than HbA1c for predicting short-term outcomes and guiding treatment  
The results of this work did not show a statistically significant difference in GV between the 
4 study groups (prospective groups 1 and 2 and metformin groups A and B, see section 5.7). 
The groups were not, however, case matched and serial glucose assessment was with CBG in 
metformin study versus SBG in prospective study.  
Unfortunately, this is a consistent problem within this field of study as a variety of glucose 
measurements and GV indices have been used including standard deviation, glucose 
variability index and MAGE. This lack of uniformity has led to difficulties in drawing robust 
conclusions from existing studies (Eslami, Taherzadeh, Schultz, & Abu-Hanna, 2011).   
Although GV was not different across the 4 study groups, it is useful to compare our findings 
to existing literature. Interestingly, the lowest (mean) GV recorded in our study was in the SH 
group (1.42mmol/L). This is lower than the median value reported from n=4 ICU studies 
(Eslami, de Keizer, de Jonge, Schultz, & Abu-Hanna, 2008). The highest GV was in the 
metformin study, placebo group (2.23 mmol/L). In comparison, a study of insulin-treated 
COPD patients (Archer et al., 2011) reported a median GV (SD) of 2.9mmol/L using CBG 
monitoring. Metformin study participants with a higher RPG were also found to have a 
higher GV (Table	  73, Figure	  72). This is discussed in more detail in section 6.9.  
 
	  	  	  	  	  	  	  195	  
	  
Factors linked to increased GV include exogenous insulin treatment (Archer et al., 2011) as 
well as endogenous insulin reserve (Kohnert et al., 2010). GV was seen to increase with 
HOMA2-IR in group 1 participants only (Figure	   68). Although only small numbers were 
examined, (n=12), this is a novel finding meriting further work. As described in section 4.1.1, 
a body of literature links both glycaemic variability and insulin resistance to adverse 
outcomes. If a causative link is established, this could have implications for the treatment of 
SH. 
In terms of outcomes there was no (statistically significant) correlation between GV and 
length of stay in either the prospective (Figure	   66) or metformin studies (section 5.9). 
Additionally, GV was not significantly different between CGM participants with and without 
MA (Appendix 5). Further work to examine correlations between GVs and metabolic and 
longer-term outcomes would be of benefit and could guide management for patients with SH 
in the acute care setting.  
 
6.7 Fasting Insulin Values in Stress Hyperglycaemia 
Although C-peptide is generally preferred over fasting insulin for assessment of insulin 
secretion (A. G. Jones & Hattersley, 2013), insulin values may be used in the description of 
the metabolic syndrome  (Alberti et al., 2006) or, as in this case, to provide HOMA2 values.  
One of the striking results of the prospective study was a significantly lower mean fasting 
insulin value in group 1 compared with group 2 participants (p<0.05, section 4.2.1) as well as 
other populations (Table	  83).  
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Population 
 
 
 
Fasting Insulin  
(Original study units) 
 
 
Fasting Insulin 
(Prospective study units) 
Melanesian island of Kitava (Lindeberg, Eliasson, 
Lindahl, & Ahrén, 1999) 
(60-74 yr. old males and females) 
3.5 uIU/mL 3.5 mIU/L 
Prospective study, group 1 5.76 mIU/L 5.8 mIU/L 
Whitehall II study (Tabák et al., 2009) 
(baseline visit, group without DM) 
47 pmol/L 6.8 mIU/L 
Swedish population (Lindeberg et al., 1999) 
(60-74 years) 
7.3 uIU/ml 7.3 mIU/L 
NHANES III (Maureen I Harris et al., 2002) 
(US males) 
8.8 uIU/ml 8.8 mIU/L 
NHANES III (Maureen I Harris et al., 2002) 
(US females) 
8.4 uIU/ml 8.4 mIU/L 
Whitehall II study (Tabák et al., 2009) 
(baseline visit, group with DM) 
73 pmol/L 10.5 mIU/L 
Prospective study, group 2 15.33 mIU/L 15.33 mIU/L 
Table	  83:	  Mean	  fasting	  insulin	  levels	  in	  the	  prospective	  study	  compared	  to	  other	  populations	  (group	  1	  in	  grey).	  Unit	  
conversion	  performed	  using:	  http://www.endmemo.com/medical/unitconvert/Insulin.php	  
 
It is firstly worth considering the timing of the insulin sample. A rise in BG to >5mmol/L 
should lead to a release in insulin and c-peptide. Insulin is cleared in the liver and has a half-
life of approximately 5 minutes. Given that FPG for group 1 and 2 were similar the morning 
after recruitment (FPG 5.4 mmol/L group 1 and 5.5mmol/L group 2, section 3.4), and CGM 
demonstrated lower mean sensor glucose in group 1 compared to group 2 participants (6.6 
mmol/L v 7.2mmol/L respectively, Table	  62), it seems likely that SH was short-lived. In this 
context, it is possible that insulin levels peaked at the time of recruitment but fell the next 
morning when measured. Even considering this, and the pulsatile nature of insulin secretion, 
lower levels compared to group 2 suggests suppression of insulin.  
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This concept is supported by existing literature. It is well recognised that counter-regulatory 
hormones released during SH (glucagon, cortisol, epinephrine) oppose insulin activity 
(Halter, Beard, & Porte, 1984) and a number of studies have demonstrated that insulin levels 
are normal or reduced in this context (Clowes et al., 1978; Dahn et al., 1985; Marik & 
Raghavan, 2004; Mizock, 2001; Opie, 1971; Schalch, 1967). Other factors linked to a 
suppression in insulin release during stress hyperglycaemia include IL-1 and TNF-α (V. K. 
Mehta, Hao, Brooks-Worrell, & Palmer, 1994).  
Finally, as recognised in IGT (Kahn, 2003; David M Nathan et al., 2007), it is worth 
considering that low insulin levels may be linked to beta cell exhaustion (Cerf, 2013). The 
GUARD Type 2 Diabetes risk calculator predicted a 5.4% three year risk of developing Type 
2 Diabetes compared to 1.7% for participants without SH (section 3.10.2).  If this is accurate, 
then it is possible that reduced insulin secretory capacity is an indicator of incipient diabetes 
mellitus in certain participants with SH. This was predicted in the HOMA2 model (lower 
estimate of steady state B-cell function (%B) in group 1 compared to group 2 participants 
(p<0.01).  
 
6.8 Insulin Resistance in Stress Hyperglycaemia 
Although HOMA modelling has been reported in over 500 publications (T. Wallace et al., 
2004), this is the first study to use HOMA2 in a non-critically unwell population with SH.  It 
is an attractive method of IR assessment given its relative ease of use and low cost. 
The results of this study show significantly lower HOMA2-IR and %B  (beta cell function) 
values in group 1 compared to group 2 participants (p<0.05). Building on section 6.7, the 
HOMA2 model also suggests a higher insulin sensitivity in group 1 participants which, 
although not statistically significant, may justify the lower beta-cell function and insulin 
levels seen (T. Wallace et al., 2004). 
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Other studies using the HOMA2 model are presented in tables Table	   84 and Table	   85. 
HOMA2-IR (as well as %B) in the SH group appear to be the lowest across all the 
populations.  This is particularly interesting given that waist circumference, a good predictor 
of insulin resistance (Wahrenberg et al., 2005), was not statistically different between group 1 
and 2 participants (table 12). 
 
  
Population 
 
 
 
Fasting glucose 
(mmol/L) 
 
 
HOMA2  
(%B/%S) 
Prospective study, group 1 5.4 70.6 / 127.8 
Whitehall II cohort (Ikehara et al., 2015) 
(baseline visit, white participants without DM) 
5.2 80.2 / 113.2 
Prospective study, group 2 5.5 96.4 / 97.3 
Table	  84:	  Fasting	  glucose	  and	  HOMA2	  %B	  and	  %S	  values	  for	  all	  prospective	  study	  participants	  and	  (British	  White)	  
participants	  without	  Diabetes	  Mellitus	  in	  Whitehall	  II	  cohort.	  
	  
 
Population 
 
 
     HOMA2-IR 
Prospective study, group 1 0.85 (0.24) 
BRAMS population (Geloneze et al., 2009) 
(healthy group n=297) 
0.87 (0.66-1.30) 
**Tehran lipid and glucose study (Ghasemi et al., 2015) 
(optimal cut-off for T2DM prediction) 
1.41 
*BRAMS population (Geloneze et al., 2009) 
(whole group n=1203 aged 18-78 years 
1.5 (0.9-2.6) 
Prospective study, group 2 1.65 (1.70) 
**BRAMS population (Geloneze et al., 2009) 
(defined cut-off value for IR) 
>1.8 
GREAT2DO study cohort (Mavros et al., 2013) 
(resistance training group, baseline) 
2.73 (0.95) 
GREAT2DO study cohort (Mavros et al., 2013) 
(sham group, baseline) 
3.09 (1.26) 
Table	  85:	  HOMA2-­‐IR	  values	  from	  prospective	  study	  groups	  and	  other	  populations.	  All	  values	  are	  mean	  (±SD)	  except	  
*median	  (interquartile	  range)	  and	  **cut-­‐off	  values 
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Insulin resistance in SH has been described as having central and peripheral components. 
Centrally, an inability to suppress hepatic glucose production has been described (Dungan et 
al., 2009). Peripherally, a number of factors lead to reduced insulin-mediated glucose uptake 
(Fan, Li, Wojnar, & Lang, 1996; Lang et al., 1989). Whilst the updated HOMA2 model is 
said to take into account ‘variations in hepatic and peripheral glucose resistance’ (Levy et al., 
1998), it is ultimately estimating insulin sensitivity from plasma insulin and glucose 
concentrations and assumptions about normal homeostasis. In SH, where a multitude of 
factors including counter-regulatory hormones and excessive gluconeogenesis contribute to 
glucose metabolism and insulin levels, it may be that HOMA2 is not the best model to assess 
insulin resistance. Alternatively, it could be considered that the model incorporates these 
factors in its expression of insulin resistance. In this case, group 2 participants with higher 
HOMA-IR and %B values may, in fact, have trained beta cells from pre-existing insulin 
resistance which are therefore more capable of mounting an insulin response to the IR 
associated with acute illness and thereby protecting against SH.   
This finding requires further consideration and exploration. 
 
6.9 Metformin in Stress Hyperglycaemia 
Only a few studies have reported on hyperglycaemia in non-diabetic patients hospitalised 
with COPD. Although it should be noted that there is substantial heterogeneity in terms of 
population type studied and measurements of glycaemia obtained, a high prevalence of 
hyperglycaemia has been described (Table	  86). 
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Study Description of Hyperglycaemia 
(Islam, Limsuwat, 
Nantsupawat, 
Berdine, & Nugent, 
2015) 
 
 
‘The first database included 30 patients admitted to non-intensive care 
unit (ICU) hospital beds. Six of 20 non-diabetic patients had peak 
glucoses above 200 mg/dl.’ (>11.1mmol/L) 
 
(McAllister et al., 
2014) 
Retrospective study. Glucose available in n=3003 patients hospitalised 
with COPD: glucose 7.0-11.0mmol/L in n=814 (27%) and ≥ 
11.1mmol/L in n=100 patients (3%). Investigators unclear as to 
whether fasting/non-fasting glucose was measured 
(Koskela, Salonen, 
& Niskanen, 2013) 
 
Of 130 patients without a previous diagnosis of diabetes, 79% showed 
hyperglycaemia, defined as a FPG>6.9mmol/L or post-prandial 
glucose>11.1mmol/L 
 
(Chakrabarti, Angus, 
Agarwal, Lane, & 
Calverley, 2009) 
 
Hyperglycaemia (defined as RPG>7.0mmol/L) was present in 50% 
(44/88) of patients whilst 28 (32%) did not have a pre-existing 
diagnosis of diabetes mellitus. 
 
Table	  86:	  Studies	  reporting	  hyperglycaemia	  in	  non-­‐diabetic	  patients	  hospitalised	  with	  COPD	  exacerbations 
 
A number of factors associated with increased peripheral insulin resistance, including 
hypoxia, acidosis, inflammation and corticosteroid treatment have been linked to the 
development of hyperglycaemia in COPD. (Adrogué et al., 1988; Blackburn, Hux, & 
Mamdani, 2002; Gläser, Krüger, Merkel, Bramlage, & Herth, 2015; Louis & Punjabi, 2009; 
Slatore, Bryson, & Au, 2009; Van Cromphaut, 2009) 
 
Metformin is known to improve insulin sensitivity (Bailey & Turner, 1996) and has 
additional anti-inflammatory (Huang et al., 2009; Isoda et al., 2006) and anti-oxidant effects 
(Faure et al., 1999). As a treatment, it is easy to administer and is rarely associated with 
hypoglycaemia when used as monotherapy. (Wright, Cull, Macleod, & Holman, 2006). 
Additionally, it has been used in the COPD population without leading to lactic acidosis 
(Hitchings, Archer, Srivastava, & Baker, 2014). 
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The Metformin study therefore provided a safe opportunity to examine the practical aspects 
of treating IR (and SH) in the acute care setting. Whilst there are many studies reporting on 
insulin treatment in SH, only a few have used metformin to treat SH (Gore, Wolf, Herndon, 
& Wolfe, 2003; Gore, Wolf, Sanford, Herndon, & Wolfe, 2005; Panahi et al., 2011) and none 
of these have been in an acute medical population, making this novel work. This study also 
provided the opportunity to comment on the metabolic characteristics of patients hospitalised 
with COPD as well as their circadian CBG patterns -to our knowledge, the first time that this 
has been done. 
It is also of interest to compare relevant metformin study findings with that of the prospective 
study - there were some similarities between the populations in terms of demographic data 
(see section 4.10) and so it was considered reasonable to provide descriptive statistics for 
interest. However, the populations were not case matched and so inferential statistics (section 
4.7) should be interpreted with caution.  
Several interesting observations were made. Firstly, consistent with existing literature, (Table	  
86) the prevalence of hyperglycaemia was relatively high in the COPD group. Mean RPG in 
the metformin study was 8.0mmol/L (Table	  68) compared to 6.7mmol/L in the prospective 
group (section 3.4) and 39% of participants had stress hyperglycaemia by the prospective 
study definition (Table	   69). As observed in the prospective study, there was evidence of 
otherwise clinically occult hyperglycaemia (Table	  73).  There were no differences in baseline 
variables (including age, weight, CAT score) between people with and without SH (Table	  70). 
In terms of metabolic abnormalities (section 3.10.2), the mean HbA1c for all metformin 
study participants was in the ‘high risk’ category at baseline (Table	  68). Higher proportions of 
participants had an HbA1c in the high-risk category (35%, total n=18) compared to 19% in 
the prospective study (Table	   36). A relatively high proportion of participants (15%) were 
	  	  	  	  	  	  	  202	  
	  
found to have biochemical features of DM (see section 3.10.2) in comparison to 6.4% of 
participants in the prospective study.  These differences may, in part, be related to preceding 
steroid therapy in the COPD population (Panthakalam, Bhatnagar, & Klimiuk, 2004). It was 
not possible to compare proportions of participants with IGR (including IFG, IGT and high 
risk HbA1c -see section 5.3) as an OGTT and FPG were not included in the protocol of the 
metformin study. 
Results from published studies are conflicting. A high prevalence of metabolic syndrome has 
been reported in COPD (ranging from 43-57%), observed more frequently in overweight or 
obese COPD patients than in BMI matched healthy subjects (Breyer et al., 2014; Díez-
Manglano et al., 2013).  Meanwhile, a large, (n=16 088) longitudinal study which corrected 
for confounding factors, reported a higher risk of T2DM in COPD patients compared to those 
without COPD (C. T. Lee, Mao, Lin, Lin, & Hsieh, 2013). 
When looking at the risk of T2DM in our COPD group (section 4.5), the GUARD risk 
calculator (http://www.cphs.mvm.ed.ac.uk/diabetes-­‐risk/)	   predicted a 4.9% 3 year risk of 
developing DM in the metformin group overall (3.1% in prospective group overall) and 6.8% 
in the metformin SH group compared to 5.4% in the prospective SH group (baseline RPG 
only). A value of 5% corresponds to ‘high risk’ as defined by NICE (McAllister et al., 2014; 
NICE 2012).  
The GUARD calculator does not require information on diagnosis (only age, gender and 
admission glucose) but data from the original study (McAllister et al., 2014) predicted the 3-
year risk of T2DM in people with COPD (Figure	  78).  Further work is needed to establish 
these findings as well as to develop appropriate interventions for this group of patients 
following their discharge from the acute setting. 
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Figure	  78:	  	  Three	  year	  risk	  of	  Type	  2	  Diabetes	  by	  glucose	  for	  patients	  in	  subgroups	  (including	  COPD)	  predicted	  by	  glucose	  
level	  obtained	  from	  logistic	  regression	  models.	  ‘All	  models	  adjust	  for	  age,	  sex	  and	  a	  main	  term	  and	  interaction	  term	  with	  
glucose	  for	  the	  relevant	  grouping	  variable	  (eg	  admission	  to	  ICU).	  Lines	  represent	  estimates	  and	  ribbons	  indicate	  95%	  CIs	  
with	   blue	   used	   to	   indicate	   membership	   of	   the	   relevant	   sub-­‐group	   and	   red	   used	   to	   describe	   the	   remainder	   of	   the	  
population’.	  	  
Figure	  and	  description	  reprinted	  from	  PLOS	  Medicine,	  August	  2014;11(8).	  McAlister	  DA	  et	  al.	  ‘Stress	  hyperglycaemia	  in	  
hospitalised	   patients	   and	   their	   3-­‐year	   risk	   of	   diabetes:	   a	   Scottish	   retrospective	   cohort	   study’	   Figure	   	   4,	   page	   9.	  
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138030/)	   Open	   access	   article,	   reprinted	   under	   Creative	   Commons	  
Attribution	  License.	  Material	  not	  modified.	  
 
With regards the management of SH in the acute setting (question 5, section 1.4), metformin 
appeared to be largely well tolerated at the local centre. Treatment did not, however, appear 
to have a statistically significant lowering effect on in-patient CBG (Figure	  75), follow-up 
RPG and HbA1c values (Table	  79) or length of stay (Table	  81).  
It is of interest that there was a discrepancy in RPG and CBG values (Table	   73). This is 
perhaps not surprising given the fact that the COPD participants were all steroid-treated 
(Figure	   10). It is well recognised that blood glucose levels may peak later in the day in 
individuals prescribed morning corticosteroids (Burt et al., 2011) and, as such, a single RPG 
may not be the best measure to assess hyperglycaemia.  Scheduled CBG measurements, 
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whilst labour intensive, undoubtedly provide a rounder view.  This is illustrated by the earlier 
example of a participant with marked hyperglycaemia identified through CBG measurement 
(CBG of 23.2mmol/L) who based on a RPG of <7.1mmol/L, may otherwise have been passed 
as ‘normoglycaemic’ (Table	  73).  Only a handful of studies have reported frequent (capillary 
or continuous) glucose values in people hospitalised with COPD (Archer et al., 2011; Burt et 
al., 2011). Further work to establish the feasibility of such measurements in the AMU setting 
would be beneficial. 
It is also recognised that 2 individuals may have a similar mean glucose level but markedly 
different glycaemic variability (Moritoki Egi & Bellomo, 2009) (Figure	  79). The importance 
of GV has been highlighted in a number of studies which report that the measure is a better 
predictor of adverse outcomes than mean glucose level (Ali et al., 2008; Donati et al., 2014; 
Dungan et al., 2011; M Egi et al., 2006; Wintergerst et al., 2006). Pathological mechanisms 
linking increased GV to adverse outcomes are outlined in 4.1.1.  
 
Figure	  79:	  Graphic	  representation	  of	  glycaemic	  control	  with	  a	  high	  mean	  glucose	  level	  and	  high	  variability	  (left)	  and	  a	  
high	  mean	  glucose	  level	  and	  low	  variability	  (right).	  
Figure	  and	  description	  reprinted	  from	  the	  Journal	  of	  Diabetes,	  Science	  and	  Technology	  2009;3:6.	  Egi	  M	  and	  Bellomo	  R.	  
‘Reducing	  glycaemic	  variability	  in	  intensive	  care	  unit	  patients:	  a	  new	  therapeutic	  target?’	  Figure	  1,	  p1304.	  Reprinted	  
with	  permission	  from	  Rightslink®	  and	  UMI’s	  ‘Books	  on	  Demand’	  program.	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Notably, GV was positively correlated with RPG and HbA1c in the metformin study (Table	  
82) and appeared to be highest in the group with the highest baseline RPG (Table	  73). There is 
a scarcity of similar work available to draw comparison with as the measure has only rarely 
been studied in COPD patients outside of the ITU setting. One study of GV in T2DM (n=63) 
found that in participants with similar HbA1c levels <7.5% (<59 mmol/mol), almost all 
glycaemic markers and GV parameters were significantly correlated. These correlations were 
not observed in those with HbA1c levels ≥ 7.5% (≥ 59 mmol/mol). (Suh et al., 2014). 
Authors of a similar study conclude that, ‘ambient hyperglycaemia and glycaemic variability 
coexist…although it is difficult to know whether glycaemic variability is the chicken or the 
egg’ (L Monnier & Colette, 2014).  
In any case, given the adverse outcomes described with increased GV, careful consideration 
should be given to the most appropriate tools for assessment/management of glycaemic 
variability in COPD. Tight glycaemic control with insulin has been shown to be feasible and 
acceptable to patients with COPD in a general ward setting (Archer et al., 2011) but was 
associated with ‘considerable glycaemic variability’. 
Metformin shows promise in this context. Although participants treated with metformin did 
not have a lower GV compared to those treated with placebo, they were noted to have lower 
GV (2.15 mmol/L) when compared to a separate COPD population treated with insulin 
(2.9mmol/L). (Archer et al., 2011). Once again, given the novelty of this work, there were 
very little further data to consider. A comparison is therefore made with a study in people 
with T2DM. In n=75 drug-naïve patients with early T2DM and good glycaemic control 
(HbA1c 6.5-8.0%), metformin 1g bd was associated with a lower GV when compared to 
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insulin glargine after 36 weeks of treatment (SD of interstitial glucose 1.3 versus 1.6 
respectively p=0.001) (Pistrosch et al., 2013). 
Of note, the standard deviation of CBG was used to express GV in the metformin study. This 
measure is widely recognised and simple to use but it is accepted that it has some limitations 
(Kohnert et al., 2010). 
Another important aspect in the treatment of SH and one which has plagued a number of 
insulin-treated studies is hypoglycaemia (Finfer et al., 2012). Despite the fact that metformin 
monotherapy is not normally associated with hypoglycaemia, a greater number of episodes 
were recorded in group A compared to group B participants. (section 5.7) 
When examined in more detail, the majority of episodes in group A (19/25 or 76%) actually 
occurred in 2 patients. This secondary analysis did not investigate the multifactorial causes of 
hypoglycaemia but, notably, both of these participants were over the age of 60 years. 
Following a number of high profile cases, (Panorama, 2011, A Jury in the Dark, BBC), it is 
increasingly recognised that spontaneous hypoglycaemia may occur in a relatively high 
proportion of elderly, hospitalised patients (Mannucci et al., 2006) . With this in mind, it is 
difficult to draw any robust conclusions as to the link between metformin therapy and 
hypoglycaemia.  
To conclude, this novel work presents a number of findings which merit further investigation. 
Adding to the body of existing literature, a relatively high prevalence of SH was found in 
people hospitalised with an exacerbation of COPD. Although the study was not specifically 
designed to investigate metabolic disorders, a strikingly high proportion of people with 
COPD were also found to be at ‘high risk’ of DM. Steroid prescription was equivalent in the 
active and placebo metformin groups but may of course have varied before admission. 
Further work could investigate this in more detail. 
	  	  	  	  	  	  	  207	  
	  
CBG readings illustrated (otherwise clinically occult) episodes of hypo- and hyperglycaemia 
as well as glycaemic variability and demonstrated that a random plasma glucose 
measurement is often inadequate to provide the full picture. Whether more detailed 
glycaemic profiles are practical in the AMU setting is a matter for further consideration.  
Finally, this is the first randomised controlled trial to bear on metformin as a treatment option 
for SH in the acute care setting. Metformin is a highly attractive therapy in this context for a 
number of reasons. In contrast to insulin therapy, which is costly, cumbersome and may be 
associated with increased mortality (Finfer et al., 2009), metformin is cheap and well-
tolerated. Furthermore, metformin has also been shown to reduce the risk of progression to 
T2DM in certain high-risk populations of which COPD may be considered one (Aroda et al., 
2015; A. Ramachandran et al., 2006).	  
 
6.10 Biomarkers in Stress Hyperglycaemia 
Selected biomarkers were examined to see whether they may offer prognostic utility in SH 
and aid management. (see section 3.1.1)  Study findings are discussed in the context of 
existing literature in the sections below (6.10.1-6.10.11). 
 
6.10.1	  Cortisol	  in	  Stress	  Hyperglycaemia	  
All prospective study participants were found to have an objectively low illness severity 
(CEWS score was ‘0’ in all but 3 group 1 participants who had a score of ‘1’, section 3.8). 
Therefore, it was not possible to examine whether lower cortisol levels were associated with 
lower illness severity scores and persistent glucose intolerance as previously reported 
(Carmen Wong et al., 2010). In contrast to earlier data, (Lehrke et al., 2008) cortisol was not 
associated with IR in the prospective study.  
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Notably, despite a commonly held view that cortisol levels are elevated during acute illness, 
there are very little data in favour of this. There was no significant difference in cortisol 
values between group 1 ‘stressed’ participants and group 2 participants with ‘normal glucose 
tolerance’. Additionally, the mean cortisol value, (taken between 07:30 and 09:00 on the 
morning after study entry) for prospective study participants) was modest at 406 nmol/L (see 
section 3.9). 
	  
6.10.2	  Troponin	  I	  in	  Stress	  Hyperglycaemia	  
Cardiac troponin I is a sensitive marker of acute cardiac damage but also has a role in 
predicting mortality in many other contexts.   For example, a high incidental rise in troponin I 
in older patients carries a higher mortality risk than a rise associated with a diagnosis of acute 
coronary syndrome (Myint et al., 2008). Similarly, a mildly elevated Troponin measured in 
patients with COPD during an acute exacerbation is a strong independent predictor of 
mortality following discharge (Martins et al., 2009). The association between elevated 
troponin levels and mortality has also been demonstrated in patients with sepsis (John et al., 
2010), pulmonary emboli (Becattini, Vedovati, & Agnelli, 2007) and a variety of other 
conditions. Troponin I levels have not yet been studied in patients with SH. 
In all participants apart from 3, the Troponin I value was  <0.05 ng/mL. Therefore, no further 
analyses were performed. Despite the wide number of presenting diagnoses in the prospective 
study and the fact that Troponin I is known to be elevated in a variety of non-ischaemic 
causes of myocardial injury as well as non-cardiac pathologies including renal failure, COPD 
and sepsis (Tanindi & Cemri, 2011), this novel work only found elevated Troponin I levels in 
three patients in the acute care setting. This implies a limited utility for Troponin I as a 
prognostic marker in SH. 
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6.10.3	  BNP	  in	  Stress	  Hyperglycaemia	  
In view of established associations between heart failure, DM and IGT (Turfan et al., 2012), 
links between BNP and glucose values were explored. Although the mean BNP value 
appeared higher in those with metabolic abnormalities (176, n=21), compared to those 
without (97.7, n=34), this difference was not statistically significant (section 3.10.2). No 
statistical difference was found in BNP values between group 1 and 2 participants.  
B-type natriuretic peptide (BNP) is secreted from the left and right ventricle in response to 
ventricular stretch and is elevated in both systolic and diastolic dysfunction (Epshteyn et al., 
2003). Many studies have found elevated BNP levels in patients with asymptomatic left 
ventricular dysfunction (Macabasco-O’Connell, Meymandi, & Bryg, 2010) and coronary 
artery disease. (Rana et al., 2006)  This has led to its proposal as a screening tool to exclude 
LVD in high-risk patients, such as those with diabetes (Romano et al., 2010). Combined 
analysis of BNP and glucose have also been shown to be helpful in the risk stratification of 
patients with ACS (Wei, Wang, Fu, Bai, & Zhu, 2014).  
Although a small study exploring the effect of BNP on glucose metabolism found no 
diabetogenic properties (Heinisch et al., 2012), other work suggests a close relationship 
between glucose metabolism and the natriuretic peptide axis. An increase in BNP values has 
been seen with poor glycaemic control in DM (Dal et al., 2014) and dual angiotensin-II 
suppression therapy has been shown to decrease blood glucose levels (White et al., 2007).  
There are also conflicting data on the relationship between BNP and insulin resistance with 
some studies showing an association (Hamasaki, Yanai, Kakei, Noda, & Ezaki, 2015; 
Mizuno et al., 2013; Tassone et al., 2009) and some not.  The prospective study showed that 
BNP levels were correlated with HOMA2 %S (p<0.05).  
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6.10.4	  CRP	  in	  Stress	  Hyperglycaemia	  
Inflammation is known to play a pathogenic role in the development of T2DM and a number 
of studies have linked higher levels of the acute-phase protein CRP to IGT, the metabolic 
syndrome and T2DM. (Choi et al., 2004; Knudsen et al., 2010; Luna et al., 2012; Yuan et al., 
2006). Our findings were not in keeping with this as CRP levels were not significantly higher 
in those with metabolic abnormalities (section 3.10.2).  Of course, numbers analysed in the 
prospective study were relatively small and CRP levels will have been affected by differences 
in presenting diagnoses. It is also worth considering that the relatively short duration of study 
follow-up, in contrast to other studies (Doi et al., 2005) did not capture all MAs which may 
have been associated with a higher CRP.  
Of interest, CRP was positively correlated with fasting insulin  (p<0.05) for all participants in 
the prospective study (Table	   26).  This has been observed previously and linked to the 
development of insulin resistance. (Yuan et al., 2006).  
 
6.10.5	  Lactate	  in	  Stress	  Hyperglycaemia	  
A number of studies have linked elevated lactate levels to the development of T2DM. 
(Crawford et al., 2010; Juraschek, Selvin, Miller, Brancati, & Young, 2013; Juraschek, 
Shantha, et al., 2013) Both an insufficient oxidative capacity (Juraschek, Selvin, et al., 2013) 
and increased insulin resistance (Juraschek, Shantha, et al., 2013)  have been proposed as 
potential mechanisms.  Lactate values in the prospective study were not significantly 
different between participants with and without metabolic abnormalities  (section 3.10.2). 
Again, this may have been related to the relatively short follow-up.  
Lactate has also been shown to have value in predicting mortality (Husain, Martin, Mullenix, 
Steele, & Elliott, 2003; Kruse, Grunnet, & Barfod, 2011; McNelis et al., 2001; Mikkelsen et 
al., 2009) and length of ICU stay (H. M. Soliman & Vincent, 2010) in critically ill patients. 
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There is a paucity of evidence examining lactate values in the AMU setting.  Notably, the 
mean (baseline) lactate value appeared higher in COPD compared to prospective study 
participants  (1.96 mmol/L and 1.34 mmol/L respectively), an expected finding given that 
blood lactate is a sensitive marker of anaerobic metabolism, reflecting oxygenation. There 
was no association between lactate and length of stay in the prospective study. 
	  
6.10.6	  	  Vitamin	  D	  in	  Stress	  Hyperglycaemia	  
An independent samples t-test demonstrated a statistically significant difference (p <0.05) 
between the 25-OH-Vitamin D values of group 1 and 2 participants (means 23.4 and 52.8 
nmol/L respectively, section 3.9).  Results were only available for a few participants  (n=13) 
so no further analyses were performed. In view of work linking 25-hydroxyvitamin D levels 
to insulin sensitivity and beta cell dysfunction (Gao et al., 2015; Kayaniyil et al., 2010), 
further research in this context would be of benefit. 
	  
6.10.7	  Blood	  Ketone	  Levels	  in	  Stress	  Hyperglycaemia	  
Blood ketones were predominantly checked as a safety measure to ensure that ketosis in 
newly hyperglycaemic patients was identified and appropriately managed.  Before the advent 
of blood ketone testing, urine dispticks were used for this purpose. Urine testing did not, 
however, capture the predominant ketone body responsible for acidosis in Diabetic 
Ketoacidosis (DKA) -beta-hydroxybutyrate (β-OHB).  
Blood ketone testing is now part of standard clinical care for DKA, providing rapid, accurate 
results (Byrne, Tieszen, Hollis, Dornan, & New, 2000) and endorsed by the American 
Diabetes Association (T. M. Wallace & Matthews, 2004), and the Joint British Diabetes 
Societies. (Savage et al., 2011).  
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DKA and SH share some similarities - increased levels of stress hormones, a catabolic state 
with lipolysis and increased gluconeogenesis are features of both conditions. (Dungan et al., 
2009; T. M. Wallace & Matthews, 2004)  In this context, it is interesting to note that group 1 
participants had lower mean ketone values (p ≤0.05) as well as lower variance in ketone 
values (p≤0.01) compared to group 2 (n=58 overall). This adds to the body of work which 
suggests that insulin may not be the best treatment for SH (Finfer et al., 2009). It is also 
interesting to note that a higher proportion of participants within group 2 had a cachectic 
body type (table 20). This may explain the higher ketone values in group 2. Further work 
could explore whether this may, in fact, be protective for the development of SH.  
The mean ketone value for all prospective study participants was 0.3mmol/L. Ketonaemia of 
≥3mmol/L forms part of the diagnosis criteria for DKA whilst levels <0.6mmol/L are 
considered normal (Wiggam et al., 1997). There are no studies examining ketone values in 
the acute medical population or in people with SH. This novel work adds to knowledge on 
the pathophysiology of SH - further work in this area may help to guide treatment decisions 
in the future.  
. 
6.10.8	  eGFR	  in	  Stress	  Hyperglycaemia	  
Links between a reduced estimated glomerular filtration rate (eGFR) and features of the 
metabolic syndrome have been proposed.  (Miyatake, Shikata, Makino, & Numata, 2010). In 
addition, a large study including 99 140 people of varying ages (Okada et al., 2012) found 
that glomerular hyper-filtration (increased eGFR), a well-recognised and reversible feature of 
early renal dysfunction in DM (S. L. Jones, Wiseman, & Viberti, 1991; Neuringer & Brenner, 
1992), was also a feature of pre-diabetes (defined as FPG 5.6-6.9mmol/L). This was 
corroborated by a separate smaller study (Melsom et al., 2011). 
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To our knowledge, glomerular filtration rates have not previously been described in stress 
hyperglycaemia. No differences were observed in the prospective study and proportions of 
participants with an eGFR <60 ml/min/1.73 m2 were similar in the group with and without 
metabolic abnormalities (13% and 10% respectively). When the prospective study 
participants were divided into group 1 (stress hyperglycaemia) and group 2 (normal glucose 
tolerance), no statistical difference was found in eGFR values and there were equal 
proportions of participants with an eGFR <60 ml/min/1.73 m2  (14%).  
  
6.10.9	  Pro-­‐Adrenomedullin	  in	  Stress	  Hyperglycaemia	  
Mid-regional pro-adrenomedullin (MR-proADM) is a stable, surrogate marker of 
adrenomedullin, a potent vasoactive peptide linked to endothelial cell function and glucose 
metabolism. (Tesauro & Cardillo, 2011).   Elevated levels of MR-proADM have been 
demonstrated in the metabolic syndrome and T2DM (Lim et al., 2007; Seissler et al., 2012; 
Vila et al., 2009) and shown to fall with bariatric surgery and weight loss. (Vila et al., 2009).  
MR-proADM offers prognostic utility in a range of acute diagnoses, particularly 
cardiovascular disease (Nishida et al., 2008; Peacock et al., 2011; Potocki et al., 2009; Stolz 
et al., 2008) as well as stress hyperglycaemia (Schuetz et al., 2014). 
Although the prospective study did not offer the opportunity to study the association between 
MR-proADM and outcomes in any great detail, there was no statistical difference between 
MR-proADM values of group 1 and 2 participants, adding support to the premise that people 
with SH are not metabolically different to people with normal glucose tolerance.  
Interestingly, our study did demonstrate a highly significant correlation between MR-
proADM and Copeptin for all participants (Table	  26). This is a novel finding worthy of further 
investigation.  
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6.10.10	  Copeptin	  in	  Stress	  Hyperglycaemia	  
Copeptin is the stable C-terminal fragment of AVP prohormone with links to DM, 
(Enhörning et al., 2010), metabolic syndrome (Enhörning et al., 2011) and stress (Katan & 
Christ-Crain, 2010). A central hypothesis of this study (hypothesis 5) investigated whether 
people with SH would have significantly different copeptin values compared to people 
without Stress Hyperglycaemia.  
In fact, no statistically significant difference was observed between mean copeptin values for 
group 1 and 2 participants and there was insufficient evidence to reject the null hypothesis 
(see section 6.1). Group 1 participants were, however, noted to have a lower variance in 
copeptin values compared to group 2 participants (p≤0.01). Copeptin values were also not 
significantly different in participants with metabolic abnormalities compared to those without 
(see section 3.10.2).  
In all participants (group 1 and 2 combined) a statistically significant correlation was noted 
between fasting insulin and Copeptin (p<0.05). This is consistent with the findings of 
(Enhörning et al., 2010) who demonstrated that copeptin levels are independently associated 
with hyperinsulinaemia and future development of diabetes mellitus. A longer follow-up 
would be of benefit for future work of this nature. 
With regards the pro-ADM correlation mentioned in section 3.9, both markers have been 
shown to be independently elevated in IGT and previously unknown DM (S. et al., 2012) but 
to our knowledge, a strong correlation between them both has not been described before. This 
novel finding could shed further light on the early pathogenesis of metabolic syndrome. 
Copeptin was also noted to be correlated with length of stay in group 1 but not group 2 
participants (p<0.05). This is another interesting finding which could be of practical use in 
the future if supported by further work. 
	  	  	  	  	  	  	  215	  
	  
	  
6.10.11	  Biomarkers	  in	  Stress	  Hyperglycaemia-­‐Conclusion	  
In view of budget and time constraints, biomarker values were not available for all 
participants and it was not possible to examine associations between biomarkers and long-
term outcomes. Nonetheless, the data presented is novel, fleshes out the profile of people 
with SH, and highlights some interesting trends which merit further study.  
A number of biomarkers linked to the metabolic syndrome and IGR were not significantly 
different between group 1 and 2 participants (e.g. CRP, eGFR, MR-proADM), supporting the 
theory that people with SH are not as a group, metabolically different and destined to develop 
MA. There were also no significant differences in these biomarker values between 
participants with and without MA (section 3.10.2), although, notably, numbers were small. 
A number of other interesting findings including low ketone levels in SH, and links between 
copeptin and proADM emerged through this work and may be worthy of further exploration. 
It should of course be considered that there are challenges to translating biomarker evidence 
into clinical practice (Tang, 2010) with they may offer little in the way of support for the 
practising physician unless a number of criteria are fulfilled (D. S. Lee & Tu, 2009; 
University of Leicester and UK National Screening Committee, 2012). With this in mind, 
perhaps the best role for biomarkers is not at the front door but rather behind the scenes 
further to address research questions 3 and 5 (section 1.4) through greater knowledge on the 
pathophysiology of SH.   
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6.11 Stress Hyperglycaemia –The Phenotype 
	  
As described in section 1.5, the main research objective relates to the metabolic profile of 
people with stress hyperglycaemia and differences between individuals with and without the 
condition. The results are presented in section 3.3 and discussed in sections 6.2 and 6.10.10. 
In addition to the central hypotheses, a number of measures were carefully selected for their 
novelty, potential ability to flesh out the profile of the individual with stress hyperglycaemia 
and relevance to research questions 3 and 5 (see section 1.4).  
Some of these measures including biomarkers, glycaemic variability and insulin resistance 
are discussed in separate sections (see 6.10, 6.6 and 6.7 respectively). This section focuses on 
the remaining measures, namely those presented in result sections 3.2, 3.4-3.8 and 3.10. It is 
hoped that these descriptions as well as comparisons between people with and without SH 
will provide the basis for future work in this field. Because of the novelty of the data, there is 
little comparative work. 
Firstly, people with SH did not appear to fall within a particular age or gender demographic. 
(section 3.2). Effects of ethnicity could not be well studied as there was limited variation 
within the study population. A similar study used a retrospective methodology to examine the 
records of n=2030 all-comers admitted to a US hospital. The investigators also found no 
difference in mean age, gender and racial distribution between n=223 people with new 
hyperglycaemia but no history of DM and other groups (Umpierrez et al., 2002).  
Metabolic profiling is discussed in section 6.2.  BIVA was selected to compliment this and 
provide more detailed characterisation. In support of the results displayed in section 3.3, no 
statistically significant differences were found in the BIVA-derived nutrition scores of group 
1 and 2 participants (section 3.6). Reassuringly, stress hyperglycaemia was not associated 
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with marked dehydration as supported by clinical assessment and BIVA-derived hydration 
scores. 
In terms of diagnosis associated with SH, a large body of work (see Chapter 1) focuses on 
selected, single disease groups rather than an undifferentiated patient cohort.  The US study 
of all-comers described above (Umpierrez et al., 2002) did not report on individual diagnoses 
but rather admitting specialities. The prospective study showed that the most frequent 
primary diagnosis category within both study groups was respiratory disease, with COPD 
accounting for 31% of cases (Appendix 1).  
Although mean RPG values were not statistically significantly different across different 
diagnostic categories of group 1 participants (Table	   17), the metformin study (Chapter 5) 
demonstrated a high prevalence of metabolic abnormalities and stress hyperglycaemia within 
the COPD group. This is discussed in more detail in section 6.9 and merits further work. For 
example, the feasibility of RPG inclusion into COPD assessment tools could be investigated. 
This would be particularly pertinent in view of frequent corticosteroid therapy in this group 
of patients. This approach would, of course, only be helpful if clear evidence-based 
management goals were established. 
All participants in the metformin study were steroid-treated. In the prospective study, similar 
proportions of participants in group 1 and 2 as well as similar proportions of participants who 
did/didn’t develop metabolic abnormalities were steroid-treated (Figure	  21, section 3.10.2). 
Elucidating the contribution of steroid therapy to stress hyperglycaemia and metabolic 
abnormalities (Clore & Thurby-Hay, 2009) is a substantial body of work which follows on 
from this thesis. 
There were a number of other notable similarities between groups 1 and 2, namely illness 
severity, anxiety scores and family history of DM (sections 3.3, 3.7 and 3.8). Perhaps the 
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most interesting similarities, however, relate to HbA1c and fasting plasma glucose levels 
(Table	   24 and Table	   18). The latter suggests that SH is short-lived in this cohort. CGM 
provided another illustration as to the importance of more than one glucose reading in this 
context: SG values were often incongruous with the relatively modest RPG values recorded 
and marked glycaemic excursions were seen in both study groups (section 4.3). Ideally, this 
study would have had a more substantial follow-up to examine the effect of this variability in 
more detail across both study groups. 
In terms of outcomes, a surprisingly high proportion of all study participants (40%) were 
found to have metabolic abnormalities during the course of this study.. Other studies 
incorporating a return visit have reported similar figures of up to 42% for IGT and 46% for 
DM (Vancheri et al., 2005; Wallander, Malmberg, Norhammar, Rydén, & Tenerz, 2008). 
Post discharge follow-up incorporating people with and without SH would be of interest to 
take this work forward. 
Variables including HbA1c were not significantly different from baseline in group 1 
participants attending study follow-up. Although fasting insulin and HOMA2-IR values 
appeared higher at study follow-up, these findings were not statistically significant (Table	  39 
and Table	  40). These measures are discussed in more detail in sections 6.7 and 6.8. 
Length of stay was the other outcome of interest. Again, there was no statistically significant 
difference between group 1 and 2 participants (section 3.10.1). This is not in keeping with 
existing literature (Campbell, 2007) and could, perhaps, be explained by the AAU 
recruitment environment which supports early discharge.  
In conclusion, detailed profiling of people with stress hyperglycaemia did not reveal any 
significant differences in the measures discussed (see section 6.7 and 6.8 for discussion of 
	  	  	  	  	  	  	  219	  
	  
fasting insulin). The similarities are, however, of significant interest and will be discussed in 
the final study conclusions (section 6.13).  
6.12 Stress Hyperglycaemia in the Acute Care Setting, The Practical Aspects 
	  
6.12.1 The Acute Care Setting 
	  
Participants for the prospective and metformin study were recruited from the acute care 
setting. The research challenges and questions posed -particularly question 5 (‘what is the 
best management for stress hyperglycaemia in the acute care setting?) -require consideration 
of context. 
Substantial evidence demonstrates that early recognition and management of acutely unwell 
patients contributes towards optimal clinical outcomes. This evidence, along with an 
increasing number of medical admissions as well as other drivers led to the development of 
acute medicine. As a speciality, it has been pivotal in improving care (National Patient Safety 
Agency, 2007; B. Williams et al., 2007) and Acute Medical Units (AMUs) are now integral 
to the vast majority of acute hospitals in the UK (Jayawarna, Atkinson, Ahmed, & Leong, 
2010).  
 
The workforce within the acute setting faces unique challenges in caring for a diverse and 
often clinically complex population at the point of admission to hospital. Timely 
communication with a broad range of stakeholders is required in order to ensure rapid, 
effective treatment and safe discharge/transfer of care. A broad range of guidelines and care 
pathways have been developed to support and enhance clinical decision-making in this 
dynamic environment (National Institute for Health and Care Excellence, 2007).  
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Acute medicine is one of the fastest growing specialties in the UK with an 81.4% expansion 
in acute medicine consultants between 2010 and 2011 (n=295) (Federation of the Royal 
Colleges of Physicians of the UK, 2013). Whilst dedicated consultant cover seven days a 
week has been shown to be associated with reductions in readmissions and mortality, junior 
doctors, nurses, allied health professionals and pharmacists also play an essential role in 
delivering high quality acute care in the AMU setting (Royal College of Physicians, 2012).  
 
	  
6.12.2	  Challenges	  of	  Conducting	  Research	  in	  the	  Acute	  Care	  Setting	  
	  
Whilst patients were very accommodating towards research and willing to give their time, 
there were a number of challenges encountered in conducting research in this setting: 
• Rapid turnover of patients and staff 
• Difficulty with labour-intensive research procedures especially CGM 
• Buy-in to research from busy staff 
• Difficulty in obtaining fasting blood samples 
• Poor attendance at study-follow, perhaps due to the absence of an on-going condition 
• Difficulty in effectively monitoring new treatments and devices 
 
A number of these challenges could be overcome through greater engagement of all relevant 
stakeholders. It is of interest to consider other models of research which have worked well in 
the acute care setting. The Investigator was also involved in the design and distribution of a 
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Society of Acute Medicine survey which was sent out electronically and received rapid 
responses from units across the United Kingdom (Soong, Balasanthiran, MacLeod, & Bell, 
2013).  
A questionnaire survey was also conducted in the acute care setting examining doctors’ views 
towards SH and its management. This obtained a good response rate and was easy to conduct.  
It illustrated that doctors vary considerably in their perceptions of and approaches to stress 
hyperglycaemia (Appendix 6). 
 
6.13 Final Study Conclusions 
Stress Hyperglycaemia is a field which has gradually gained more interest over the years as 
researchers and clinicians have established the association with poor outcomes. There are still 
a number of barriers to conducting research in this field including a lack of a consensus 
definition for SH. 
This novel work profiled people with SH in a setting and to a level not reported previously. 
The headline findings may be summarised as: 
1. Similar metabolic profiles, HbA1c, cortisol values and phenotype in people with and 
without stress hyperglycaemia 
2. Lower fasting insulin values in people with stress hyperglycaemia compared to those 
without 
3. Lower HOMA2 reported insulin resistance in people with stress hyperglycaemia 
compared to those without 
4. Normal FPG in people with stress hyperglycaemia the morning after recruitment (and 
similar FPG in people with and without SH the morning after recruitment) 
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5. High prevalence of occult and stress hyperglycaemia in the acute care setting 
6. High prevalence of metabolic abnormalities in the acute care setting: 52% in 
participants with stress hyperglycaemia  
7. 35% of participants in the metformin study presenting with an HbA1c value in the 
‘high risk for DM’ category 
8. High predicted 3 year risk of DM in metformin (6.8%) and prospective SH (5.4%) 
groups 
9. Associations between copeptin, proADM and insulin  
10. Association between GV and IR 
11. No difference in glycaemic variability between people with/without stress 
hyperglycaemia or any obvious effect of metformin on GV  
 
The similarities between people with and without stress hyperglycaemia are of significant 
interest. Whilst a number of studies have shown that SH is often a precursor to glucose 
intolerance, few have compared the SH population to a normoglycaemic group. Despite a 
relatively short follow-up period, this work has shown that occult hyperglycaemia, as 
illustrated by CGM, and metabolic abnormalities occur frequently in both SH and 
(seemingly) normoglycaemic populations. An important conclusion from this is that, as 
already recognised in the diagnosis of DM, a single RPG is insufficient to provide a relevant 
insight into an individual’s glycaemic excursions during hospitalisation. 
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Along the same lines, it could also be argued that a single RPG is insufficient to classify an 
individual as having SH or not. The difference in insulin levels between the study groups, 
however, seems to suggest a distinction between the groups.  
Despite this, people with SH do not appear to be phenotypically different from people 
without the condition and marked hyper and hypoglycaemia were common in both groups of 
patients despite modest RPG levels.  
 
The phenotypic similarities between people with and without SH also supports the argument 
made by some researchers that SH is, in fact, an ‘evolutionarily conserved adaptive response’ 
which allows a higher blood ‘glucose diffusion gradient’ and thus maximises cellular glucose 
uptake during times of stress. This is supported by a lack of data demonstrating causation of 
harm by SH (as opposed to association with harm) as well as the studies showing a lack of 
benefit to intensive insulin therapy (Marik & Bellomo, 2013). This hypothesis ideally 
requires more detailed consideration by future investigators. 
 
In conclusion of this thesis, the acute care setting provides an excellent opportunity for the 
opportunistic pick-up of metabolic abnormalities. Significant morbidity could then be 
prevented with timely and appropriate intervention. The practicalities of this approach are 
subjects for further research and debate.  
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6.14 Study Limitations & Future Work 
	  
• Given time constraints, only approximately half of the patients that were found to be 
eligible for study could be approached by a solo investigator for inclusion (n=93 out 
of a possible n=196). Attempts were made to make the approach process as random as 
possible although it is recognised that this step may have introduced an element of 
selection bias.  
 
• Episodes of marked hypo and hyperglycaemia were only evident to the investigator 
following removal of the CGM and sometimes after the participant had been 
discharged from the acute setting. It is therefore not possible to fully comment on the 
causes and implications of glycaemic variability in the prospective study. Future work 
could address this in more detail and, in particular, why participants from group 2 had 
more hyperglycaemic readings on CGM. 
 
• Notably, only 32 out of 52 metformin study participants had an HbA1c value 
available for analysis. As this data was received for secondary analysis from the main 
investigators and included data from 9 UK study centres, the reasons for missing data 
were not always clear to the investigator.  
 
• 50% of group 1 subjects were lost to follow-up and this is clearly not optimal. Table 6 
in section 3.1.2 lists the various reasons that participants were lost to follow-up 
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despite the best efforts of the investigator. A number of these reasons are discussed in 
section 6.12.2 and include the absence of an ongoing condition/relationship with the 
clinical team in the AMU environment.  
 
• In addition, there was a variation in visit 1 follow-up time period ranging from 94-190 
days (see section 3.10.3). It is recognised that this may have had an impact on visit 1 
findings. This variation occurred for a number of reasons, mostly practical (see 
section 2.1.2).  Notably, the follow up aspect is, however, only a small part of the 
study and does not form part of the central study hypothesis. Future work could look 
at less complex follow-up arrangements (perhaps using relevant databases/telephone 
appointments) to increase timely uptake.   Future work with more resource could also  
incorporate a visit 1 assessment for group 2 in order to provide a comparison (deemed 
too challenging within the available timescale of this project)  
 
• Future work could look at correlation of RPG overall with other indices (rather than a 
cut-off value) 
 
• Future work could also examine whether higher ketone values may be protective for 
the development of SH 
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Appendix	  
Appendix 1:Primary Diagnosis Categories for all Prospective Study Participants 
	  
ICD-­‐10	  code	   Number	  of	  Participants	  
Bacterial,	  viral	  and	  unspecified	  respiratory	  disease	   11	  
COPD	   9	  
Asthma	   4	  
Bronchiectasis	   2	  
Pleural	  Effusion	   1	  
Pulmonary	  Embolism	   2	  
TOTAL	   29	  
Table	  87:	  Conditions	  included	  in	  category	  ‘Respiratory	  disease’,prospective	  study	  	  
	  
ICD-­‐10	  code	   Number	  of	  Participants	  
Unstable	  angina/AMI/IHD	   4	  
AF	  and	  Flutter	   1	  
Cardiovascular	  disease	  unspecified	   1	  
TOTAL	   6	  
Table	  88:	  Conditions	  included	  in	  category	  ‘Cardiovascular	  Disease’,	  prospective	  study	  	  
	  
ICD-­‐10	  code	   Number	  of	  Participants	  
Anaemia	   1	  
Disorders	  of	  mineral	  metabolism	   1	  
TOTAL	   2	  
Table	  89:	  Conditions	  included	  in	  category	  ‘Metabolic/Haematological’,	  prospective	  study	  
	  
ICD-­‐10	  code	   Number	  of	  Participants	  
Cellulitis	   6	  
Polyneuropathy	   1	  
Monoarthritis	   1	  
Back	  pain	   1	  
Other	  muscle	  disorder	   1	  
Injury	  of	  Achilles	  tendon	   1	  
TOTAL	   11	  
Table	  90:	  Conditions	  included	  in	  category	  ‘Skin/Rheum’,	  prospective	  study	  
	  
(Additional	  diagnoses	  not	  included	  above:	  Falls/syncope	  n=9,	  chronic	  pain	  n=1,	  unclear	  n=1,	  Reflux,	  constipation,	  abdominal	  
pain,	  acute	  nephritis,	  other	  urinary	  disorders	  all	  n=1	  each)	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Appendix 2: Descriptive statistics for all CGMS participants 
 
	  
 Particpant ID 
Sensor Glucose Values (mmol/L) 
N Min Max Mean SD 
(1) 40  275 5.4 12.8 7.7 1.69 
      
41  150 4.3 11.8 7.0 2.14 
      
55  212 4.3 8.1 6.0 1.01 
      
57  137 4.7 6.2 5.3 0.32 
      
60  277 3.9 11.0 6.5 1.93 
      
(2) 54  255 2.7 9.1 5.4 1.89 
      
56  132 3.4 8.1 5.3 1.47 
      
58  47 6.1 15.7 11.0 2.39 
      
59  220 4.4 11.2 7.2 1.78 
      
61  245 5.4 22.2 10.7 4.17 
      
63  237 3.3 12.6 6.8 2.15 
      
64  209 2.2 8.9 5.9 1.36 
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Appendix 3: ANOVA for CGM Participants 
	  
Sensor Glucose (mmol/L) 
 
ID & Study Group N 
Subset for alpha = 0.05 
1 2 3 4 5 6 
Student-
Newman-
Keulsa,b 
56.2 132 5.289      
57.1 137 5.293      
54.2 255 5.384      
64.2 209 5.898 5.898     
55.1 212  5.968     
60.1 277   6.545    
63.2 237   6.840 6.840   
41.1 150   7.013 7.013   
59.2 220    7.199   
40.1 275     7.700  
61.2 245      10.690 
58.2 47      10.998 
Sig.  0.051 0.766 0.120 0.286 1.000 0.195 
Tukey HSDa,b 56.2 132 5.289      
57.1 137 5.293      
54.2 255 5.384      
64.2 209 5.898 5.898     
55.1 212 5.968 5.968     
60.1 277  6.545 6.545    
63.2 237   6.840    
41.1 150   7.013 7.013   
59.2 220   7.199 7.199   
40.1 275    7.700   
61.2 245     10.690  
58.2 47     10.998  
Sigc.  0.155 0.213 0.202 0.145 0.980  
Means for groups in homogeneous subsets are displayed. 
a. Uses Harmonic Mean Sample Size = 157.203. 
b. The group sizes are unequal. The harmonic mean of the group sizes is used. Type I error levels are not 
guaranteed. 
c. This p value refers to all variables within the same column, demonstrating no difference between the values 
in the homogenous subset 
Table	  91:	  One-way Analysis of Variance (one-way ANOVA) post-hoc tests to examine differences in mean SG values 
between individual (group 1 and 2) CGM participants. 
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Appendix 4: Group 1 Follow-Up Variables, Prospective Study 
 
Participant ID Baseline weight (kg) F/up Weight (kg) 
002R 74.1 
 
70.6 
 
041 74.3 
 
73.3 
 
065 73.0 
 
91.5 
 
011 84.9 
 
94.7 
 
018 82.5 
 
77.3 
 
019 112.5 
 
116.5 
 
057 89.5 
 
86.3 
 
028 98.0 
 
98.5 
 
055 86.0 
 
80.9 
 
060 70.9 71.7 
Table	  92:	  Baseline	  and	  follow-­‐up	  (visit	  1)	  weight	  for	  n=10	  group	  1	  prospective	  study	  participants	  
	  
Participant ID Baseline FPG 
(mmol/L) 
F/up FPG 
(mmol/L 
Baseline Insulin 
(mIU/L) 
F/up Insulin 
(mIU/L) 
002R 5.9 
 
10.2 
 
9.3 
 
10.1 
 
041 8.0 
 
6.1 
 
7.2 
 
6.9 
 
065 5.2 
 
6.1 
 
5.9 
 
10.8 
 
011 
 
4.9 
 
5.4 
 
8.0 
 
34.9 
 
018 
 
5.5 
 
5.2 
 
8.8 
 
6.8 
 
019 5.6 
 
5.1 
 
6.9 
 
10.9 
 
028 
 
5.5 
 
4.6 
 
5.4 
 
3.2 
 
055 
 
5.0 
 
4.3 
 
3.6 
 
4.0 
 
Table	  93:	  Baseline	  and	  follow-­‐up	  (visit	  1)	  fasting	  plasma	  glucose	  and	  insulin	  for	  n=8	  group	  1	  participants	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Participant ID Baseline HbA1c 
(mmol/mol) 
F/up HbA1c 
(mmol/mol) 
002R 44 42 
041 52 
 
36 
 
065 38 
 
36 
011 40 
 
39 
 
018 43 
 
43 
 
019 37 37 
 
057 42 
 
38 
 
028 42 
 
41 
055 36 
 
33 
 
060 36 34 
	  	  	  	  	  	  Table	  94:	  Baseline	  and	  follow-­‐up	  (visit	  1)	  HbA1c	  for	  n=10	  group	  1	  participants	  
	  
	  
Participant ID Baseline HOMA2-IR F/up HOMA2-IR 
002R 1.3	  
 
1.50	  
 
041 1.0	  
 
0.90	  
 
011 1.0	  
 
4.40	  
 
018 1.2	  
 
0.90	  
 
019 0.9	  
 
1.40	  
 
028 0.7	  
 
0.40	  
 
055 0.5	   0.50	  
 
Table	  95:	  Baseline	  and	  follow-­‐up	  (visit	  1)	  HOMA2	  for	  n=7	  group	  1	  participants	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Participant ID Baseline 
Copeptin 
(pmol/L) 
F/up Copeptin 
(pmol/L) 
002R 3.4 1.8	  
 
041 8.7	  
 
10.5	  
 
065 2.3	  
 
6.09 
011 24.5	  
 
15.8	  
 
018 11.5	  
 
6.3 
019 13.0	  
 
15.5 
057 3.4 4.9 
028 5.2	  
 
4.5 
055 14.7	   4.8 
060 6.1 5.4 
Table	  96:	  Baseline	  and	  follow-­‐up	  (visit	  1)	  Copeptin	  for	  n=10	  group	  1	  participants	  
	  
Participant ID Baseline proADM 
(nmol/L) 
F/up proADM 
(nmol/L) 
002R 0.75 0.27	  
 
041 0.69	  
 
0.84 
065 0.63	  
 
0.58 
011 1.44	  
 
0.91	  
 
018 1.55	  
 
1.40 
019 1.52	  
 
0.99 
057 0.48 0.47 
 
028 0.80	  
 
0.64 
055 1.81	   0.75 
060 0.86 1.07 
Table	  97:	  Baseline	  and	  follow-­‐up	  (visit	  1)	  proADM	  for	  n=10	  group	  1	  participants	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Appendix 5: Mann-Whitney Test for GV in Metabolic Abnormalities  
 
 
	  
Figure	  80:	  Mann-­‐Whitney	  test	  to	  examine	  Glycaemic	  Variability	  in	  CGM	  participants	  with	  and	  without	  metabolic	  
abnormalities	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Appendix 6: AAU Questionnaire Study  
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Appendix 7: Permissions to Reproduce Third Party Works 
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